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Abstract 
 
Benign prostatic hyperplasia (BPH) is a common condition that occurs in over 25% of men aged 
50+, increasing to 50% amongst those over 80. Although the aetiology of the condition has not 
been ascertained, the majority of BPH specimens contain inflammatory infiltrates indicating 
inflammation plays an important role in the progression of the disease. Furthermore, a role for 
inflammation has also been suggested in prostate cancer (PCa). BPH is not a pre-cursor of PCa, 
but using BPH as a model of inflammation could result in findings that may apply and add to 
our understanding of PCa. Previous work has demonstrated that the consumption of broccoli 
can alter inflammatory pathways in the human prostate, and this may be due to the action of 
the isothiocyanate sulforaphane (SF), a phytochemical derived from broccoli. This dietary 
compound has a range of biological activities, including reducing inflammation, which has been 
demonstrated primarily by using in vitro models.  
 
In this study, BPH tissue is cultured ex vivo as a model of prostate inflammation to more 
closely replicate in vivo conditions than established cell lines. Both targeted and untargeted 
approaches were employed to test the hypothesis that sulforaphane reduces inflammatory 
pathways, and beneficially alters protein expression in BPH tissue. 
 
Analysis of the effect of SF on inflammatory markers revealed that SF significantly reduced 
levels of secreted IL-6 and IL-8, and to a lesser extent FGF-2. Global proteomic analysis 
demonstrated that there was, as expected, considerable variation between individuals, and 
that SF altered expression of several proteins in BPH tissue.  From these, HSP90β1 was 
identified as a novel target for SF activity, a reduction of which was further verified in 
independent BPH patients. The biological relevance of the reduction of HSP90β1 by SF was 
investigated but not determined.  
 
This work highlights the natural variation present within humans and the need to use a larger 
sample number in order to understand the complex effects of SF on prostate tissue. The 
results suggest that SF can reduce inflammatory markers and alter proteins within the human 
prostate, indicating a possible protective role for SF in pathogenesis of the prostate.  
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Chapter 1. Introduction 
1.1 The Prostate 
The prostate is an exocrine gland of the male reproductive system that is located at the neck of 
the bladder surrounding the urethra. In the embryo, the prostate starts developing at week 11 
and by week 22 is well developed, continuing to grow progressively until at birth it weighs a 
few grams. After birth the prostate enters a regression period followed by a period of 
quiescence until 12 - 14 years old and a maturation period between 14 – 18 years old. During 
this time it increases in weight to approximately 20g by the age of 20 at which point the weight 
stabilises until later life [1].  
 
 
1.1.1 Structure 
The prostate is surrounded by a capsule of thin fibroblastic tissue and can be divided into 
either zones (most common in pathology) or lobes (more often used in anatomy) (Figure 1.1). 
There are four histologically distinct zones: central, which accounts for approximately 25% of 
the gland, peripheral, which accounts for up to 70%, transition, and anterior fibro-muscular (or 
stroma), which together account for approximately 5% [2]. Anatomically the prostate can be 
divided into five lobes; anterior, posterior and median, which roughly correspond to the 
transitional, peripheral and central zones respectively, and two lateral lobes, which span all 
zones, although the lobes are not easily identifiable in the healthy prostate. The prostate is 
composed of 30-50 glands, 16-32 excretory ducts, stroma, blood vessels, lymphatics, and 
nerves, and contains a number of different cell types including basal, stem, neuroendocrine 
and five types of acinar cells which line the ducts; microvillar, secretory, holey, crater and bare 
cells [3]. 
  
 Figure 1.1. Prostate structure: zones and lobes.
Adapted from the National Cancer Institute SEER Training web
.gov/. 
 
 
1.1.2 Function 
The primary function of the prostate is to produce a slightly acidic (pH
constitutes approximately 15% of the volume of semen. This secretion contains a mixture of 
enzymes, lipids, metal ions and amines which facilitate ferti
[4]. The pH of the secretion is essential to reduce the acidity of the urethra increasing sperm 
viability, whilst albumin helps stimulate
[5]. Acting as an endocrine gland, the prostate helps convert testosterone
synthesized by the testes,
Dihydrotestosterone is key in the development of male reproductive tissues and in secondary 
sexual characteristics such as the growth of 
muscle development [6]
is also involved in the control of urination and ejaculation 
 
 
1.1.3 Regulation 
1.1.3.1 Hormones 
Key in the regulation of the prostate 
progesterone. The two main a
control male characteristics by 
the structure and function of the prostate.
synthesis and play a key role in the maintenance of 
 
site, http://training.seer.cancer
lity and are involved in coagulation
 sperm motility, and zinc acts as an antibacterial agent
 to its more potent form, dihydrotestosterone (DHT). 
body and facial hair, deepening of the voice and 
. Further to this, due to its physical mass and musculature the prostate 
[3]. 
are steroid hormones including androgens
ndrogens found in the prostate are testosterone and DHT which 
signalling via the androgen receptor and are essential for both 
 Androgens can alter DNA, RNA and protein 
cellular structures
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 6.6) milky fluid that 
 
 
, the main androgen 
, oestrogen and 
, such as the 
General Introduction 
 
3 
 
endoplasmic reticulum and nuclei, as well as being involved in the control of stromal growth 
and secretory activity.  
 
Loss of androgen stimulation, such as the result of castration, leads to a reduction in protein 
content of the prostate both by increasing protein degradation and by decreasing protein 
synthesis. Such a loss also causes metabolic changes resulting in a reduction in size of the 
prostate [3]. Despite their essential nature in homoeostasis of the normal prostate, androgens 
have also been implicated as crucial in the development of both benign prostatic hyperplasia 
(BPH) and prostate cancer (PCa) [7]. It is interesting though that androgen levels naturally 
decrease with age, whilst the levels of oestrogens remain stable or increase with age, and it 
may well be the ratio of androgens to oestrogens that is related to disease onset.  
 
The function of oestrogens in prostate regulation is still being investigated but research 
suggests a complex role. Firstly, oestrogens are able to suppress pituitary gonadotrophin 
secretion subsequently reducing testosterone production by the testes. They are also capable 
of promoting proliferation of the prostatic basal epithelial cells and altering the inflammatory 
state of the prostate. Oestrogens signal through both oestrogen receptors (OR)-α and –β and it 
appears that whether they mediate adverse or beneficial effects depends on which receptor is 
activated [8].  
 
Other hormones involved in the control of the prostate include prolactin, which works 
synergistically with androgens, progesterone, which is able to stimulate or maintain the weight 
and activity of the gland, and insulin, which is required for normal growth of the prostate [3].  
 
 
1.1.3.2 Growth Factors 
The prostate is also under the regulation of growth factors (GFs) including fibroblast growth 
factors (FGFs), insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), and 
transforming growth factor-beta (TGFβ) [3].  
 
There are nine different FGF genes but it is FGF7 followed by FGF2 (or bFGF) and FGF1 (aFGF) 
that are the main FGFs expressed in the prostate. Fibroblast growth factors are produced by 
the stromal cells in response to androgen stimulation and their receptors are expressed by 
both epithelial cells, which express FGFR-3 IIIc isoform and FGFR-2 IIIc which bind FGF2 and 
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FGF7, and stromal cells, which express FGFR-1 IIIc and FGFR-2 IIIc which bind FGF1 and FGF2. 
They are involved in the growth of both epithelial and stromal cells and can stimulate 
angiogenesis.  
 
Insulin-like growth factor 1 promotes the transition of cells from G1 to S phase of the cell cycle 
having a mitogenic effect and both IGF-1 and the homologous IGF-2 are required for normal 
epithelial cells. Insulin-like growth factor 2 is produced by fibroblast cells in the prostate but it 
is unknown which cells produce IGF-1. Prostatic epithelium produces EGF, which is mitogenic 
to epithelial cells, in response to androgens and is also found in prostatic secretion suggesting 
it may also have a post-ejaculatory role. Transforming growth factor-beta suppresses epithelial 
cell growth but increases stromal growth and also controls angiogenesis. Both TGFβ protein 
and receptor expression are negatively regulated by androgens [9]. 
 
 
1.1.4 Inflammatory System 
The prostate is one of the few organs that has contact with the outside world and therefore is 
regularly exposed to a range of antigens. In the healthy prostate there are very low levels of T 
cells, B cells & macrophages (Figure 1.2) which are found throughout the interstitium and in 
between the epithelial cells (ECs) [10].  
 
The T cells can be divided into two classes with CD8
+
 cytotoxic T cells (TC) being more prevalent 
than CD4
+
 helper T cells (TH). In the healthy prostate the TC cells are believed to prevent an 
autoimmune response to sperm and other prostatic antigens. Both ECs and stromal cells 
express toll-like receptors (TLRs) which can activate immune responses via the TLR-dependent 
signalling pathway as a result of exposure to microbes resulting in the induction of interleukin-
1 and -15 (IL-1 and IL-15) expression. [10]. 
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Figure 1.2. Haematopoiesis and inflammatory cell development.  
Simplified diagram demonstrating the development of and relationship between blood cells 
and cells involved in the inflammatory process. Adapted from Vander, Sherman & Luciano’s 
Human Physiology 9
th
 edition [11]. 
 
 
1.2 Diseased Prostate 
There are three main conditions that may affect the prostate; prostatitis, benign prostatic 
hyperplasia (BPH) and cancer (PCa). Unlike prostatitis which can occur at any age the incidence 
of both BPH and PCa increases with age. With an aging population the incidence of these 
diseases is increasing, putting a greater burden on the National Health Service (NHS). 
Therefore, now more than ever, it is important we understand the aetiology and development 
of these diseases to try and reduce their occurrence thereby easing the strain on healthcare 
budgets. In both BPH and PCa it has been hypothesised that inflammation may play an 
important role so along with a summary of how the diseases develop and progress the possible 
role of inflammation in both conditions is discussed. 
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1.2.1 Benign Prostatic Hyperplasia 
Benign prostatic hyperplasia (BPH) is a highly common disease that occurs in a quarter of men 
over 50, a third of men over 60 and half of all men over 80 [12] although the initial 
development may start before the age of 30 [13]. It is a condition in which the prostate 
becomes enlarged due to over proliferation of cells in the tissue surrounding the urethra 
ultimately leading to lower urinary tract symptoms (LUTS) such as urinary frequency and 
urgency, nocturia, incomplete bladder emptying and weak urine stream [12]. Although BPH is 
not a life-threatening condition it can still have a large impact on the quality of life as patients 
report problems with mobility, self-care, pain and anxiety [14]. 
 
 
1.2.1.1 Development 
In BPH, the areas of enlargement in the prostate are termed nodules and most commonly arise 
in the internal transition and peripheral zones (Figure 1.1) adjacent to the proximal urethra in 
an area that normally accounts for 2% of the healthy prostate [15]. The majority of the mass of 
BPH tissue is composed of nodules from the transition zone which are believed to develop first 
and mainly consist of epithelium.  
 
Nodules from the peripheral zone develop later and are smaller, fewer in number and mainly 
consist of fibroblastic tissue. As a result, in the initial stages of BPH, prior to clinical 
manifestation, the transition zone becomes enlarged due to microscopic nodule formation as a 
result of glandular budding and branching [15]. As the condition develops the nodules further 
increase in size and more ducts become involved in the process so the prostate becomes much 
enlarged, although at this stage it is not necessarily clinically apparent.  
 
The final stage of BPH is the development of clinical symptoms, although prostatic 
enlargement alone is not enough to cause this, other factors such as prostatic infarction, the 
response of the prostatic capsule or incidental adenocarcinomas may determine the point at 
which BPH becomes clinically evident [12, 15]. It is estimated that approximately 50% of 
pathological BPH develops into clinical BPH [16].  
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The cause of BPH is not clearly defined although advancing age appears to be a major factor in 
its development [16]. Not all patients who develop clinical BPH go on to need treatment as the 
condition may not be severe enough or the individual may be tolerant of the symptoms. If left 
to develop naturally and left untreated BPH may result in urinary tract infection, urinary 
retention, renal failure and bladder stones, so it is important to treat it before it progresses to 
this stage [16].  Current treatments include drugs, such as α1-AR antagonists and 5-α-reductase 
inhibitors, as well as surgery [12].  
 
 
1.2.1.2 Inflammation 
Although increasing age is associated with the development of BPH other factors such as 
androgen levels, in particular DHT, oestrogen levels, growth factors, and lifestyle have been 
implicated in the aetiology of the disease [17]. Historically the idea that inflammation may be 
the cause of BPH was first proposed in the first half of the 20
th
 century although this was 
superseded by the embryonal reawakening theory for the majority of the century. It was only 
in the latter half of the century that interest shifted back to relevance of inflammation in BPH 
progression [10]. Since then research has identified inflammatory markers commonly found in 
BPH tissue leading to the hypothesis that BPH many be an immune-mediated inflammatory 
disease as the majority of BPH samples exhibit inflammatory infiltrates, despite a lack of 
infection or correlation with foreign antigens in the patient.  
 
The type of immune response seen in BPH tissue is determined by the cytokines produced by 
the TH cells. These cells can be either of the TH1 lineage, which control the cell-mediated 
immune response and are characterised by the secretion of IFN-γ and IL-2, the TH2 lineage, 
which control the humoral immune response and secrete IL-4 and IL-13, or the TH0 lineage 
which produce both responses. It is thought in the initial phase of BPH the response is TH1 as 
illustrated by the increased mRNA expression of IL-2 and IFN-γ 10- and 3-fold respectively. As 
BPH progresses a shift towards a TH0 response is seen with IFN-γ and IL-4 mRNA both 
increasing by 10-fold and IL-13 increasing 3-fold. A progression towards TH2 response is 
observed in fully developed BPH with IL-4 and IL-13 increasing 3- and 2-fold respectively with 
lower levels of IFN-γ and much reduced levels of IL-2 mRNA (Figure 1.3) [18].    
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Figure 1.3. Immune response and cytokine expression in BPH progression. 
 As BPH progresses the immune response changes as shown by the changing cytokine 
expression profile of CD4
+
 T helper cells. The cytokine expression alters from baseline 
expression in normal tissue to a TH1 response at BPH initiation developing to a TH2 response in 
established BPH. IFN-γ and IL-2 (purple plots) are associated with the TH1 response whilst IL-4 
and IL-13 (blue plots) are associated with Th2. Data taken from Steiner et al 2003 [18].  
 
 
The inflammatory infiltrates found within BPH tissue contain approximately 70% T cells, 15% B 
cells and 15% macrophages as well as mast cells (Figure 1.2). T cell infiltrates naturally increase 
with age but in BPH the level of T cells increases 28-fold. In comparison to the healthy prostate 
the ratio of TC cells to TH cells is reversed with 55% of T cells being TH cells, a 60-fold increase, 
and 28% TC cells.  
 
The remaining T cells found in BPH are approximately 8% CD4
+
/CD8
+
 and 10% CD4
-
/CD8
-
 T cells 
[18]. Increased levels of macrophages may be a result of reduced levels of macrophage 
inhibitory cytokine 1 (MIC-1). The inflammatory process may be initiated by de novo 
expression of MHC class II antigen human leukocyte antigen (HLA)-DR and heat shock proteins 
72 and 73, up-regulation of which can be measured in 1 - 5% of glands analysed in prostates of 
men aged 25 and over [10].  
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As well as an increase in inflammatory cells there are a number of changes to the cytokines 
expressed in the prostate in BPH. These can be divided into two main functions; those involved 
in recruiting leukocytes and those involved in prostate cell growth [10].  
 
Proliferation of normal prostate-derived stromal cells is inhibited by IL-4 and not effected by 
IFN-γ, IL-2 or IL-7, but BPH-derived stromal cells barely respond to IL-4 and instead proliferate 
in response to IFN-γ, IL-2 and IL-7. IFN-γ was also shown to increase proliferation of BPH-
derived epithelial cells [19]. Interestingly there is a 3-fold increase in IFN-γ and de novo 
expression of IL-4 and IL-2 in BPH tissue [20]. Furthermore, IFN-γ causes a 2-fold increase in 
the expression of IL-15 by stromal cells which along with an increase in the expression of IL-15 
by smooth muscle cells can cause a 100-fold increase in the growth of memory T cells and 
increase in recruitment of more T lymphocytes [21].  
 
Another cytokine that is increased in BPH is IL-17 which is produced by activated T cells and 
some epithelial and smooth muscle cells. IL-17 stimulates the expression of pro-inflammatory 
molecules by epithelial, endothelial and fibroblast cells including increasing IL-6 expression by 
stromal cells by 9-fold and IL-8 by 26-fold [22]. Both IL-6 and IL-8 stimulate stromal growth 
(Figure 1.4). 
 
General Introduction 
 
10 
 
 
 
Figure 1.4. Inflammatory pathways in BPH. 
Simplified drawing illustrating some of the inflammatory cytokines expressed in BPH and their 
relationships with cells. Cytokines can stimulate cells to modulate cytokine expression and/or 
promote proliferation (green arrows). Different cell types express varying inflammatory 
cytokines (blue arrows). Stromal cells encompasses endothelial, smooth muscle and fibroblast 
cells.  
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1.2.2 Prostate Cancer 
Prostate cancer (PCa) is the fourth most common cancer in the UK after breast, lung and 
colorectal cancer. In 2007 there were 36,101 new cases and 10,168 deaths, accounting for 12% 
of all new cases of cancer and 6% of all cancer deaths.  From the mid 1980s to the early 1990s 
there was a sharp increase in the incidence of prostate cancer in the UK which can partly be 
attributed to new methods of diagnosis leading to increased detection. These rates started to 
fall in the mid 1990s but have recently started to increase again, which has been partially 
attributed to a rise in the aging population.  
 
Thankfully despite this increase in incidence the death rate is decreasing, in the 1970s only 
20% survived for more than ten years past diagnosis but this has now increased to nearly 70% 
[23]. Although cure rates for cancers localised to the prostate are relatively high most cases 
are not diagnosed until a later stage when metastasis has already occurred. With current 
treatment, around 80% of these individuals go into remission, but within two years many of 
them relapse, developing a disease resistant to current treatments which is therefore 
incurable [24-25].   
 
 
1.2.2.1 Development 
Cancer is a disease in which a mutation or mutations within a cell alters its response to normal 
control mechanisms causing it to grow unregulated eventually leading to invasion and 
metastasis away from the site of origin. There are six main steps in the development of cancer: 
development of growth signal autonomy; unresponsiveness to growth inhibition; insensitivity 
to apoptotic signals; evasion of senescence; promotion of angiogenesis and the ability to 
invade and metastasise [26].  
 
What makes cancer so difficult to understand and treat is that each cancer behaves differently 
according to the individual mutations it has accumulated. Prostate tumours often arise as a 
result of a pre-cursor condition, such as prostatic intraepithelial neoplasia (PIN) and are often 
diagnosed as a result of a patient exhibiting symptoms similar to those seen in BPH, such as 
problems with urination. Often a blood test will be performed to measure prostate specific 
antigen (PSA) as increased levels are associated with PCa but ultimately the cancer will be 
diagnosed by biopsy and assigned a Gleason score (Figure 1.5).  
 
 The Gleason system was developed in the 1960
grade to the tumour de
eosin (H&E)-stained tissue samples. This grade is correlated to the progression of the disease 
and the likely prognosis for the patient. The lowest Gleason grade (1) is assigned when the 
tumour has well-defined smooth edges but as the cancer progresses and the tumour becomes 
less defined and stromal invasion becomes more e
1.5) [27]. 
 
Figure 1.5. Gleason grades. 
Extensively used standard drawing originally by Dr D. F. Gleason. Gleason grade assigns a value 
according to certain features to the two largest areas of cancer within the 
Metastasis is rarely seen in cancer with a grade of 3 but more commonly so in grades 4 and 5. 
The two grades are added together to produce a Gleason score. The higher the score the more 
advanced the cancer is: a score of 2
 
s – 1970s by Dr Donald F Gleason and assigns a 
pendent on the arrangement of carcinoma cells in 
xtensive the grade increases (<5
 
 
-4 is low grade, 5-7 is intermediate and 8
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One of the main treatments for PCa is androgen ablation as during the early stages the tumour 
is dependent on androgens for growth. This therapy is initially effective for the majority of 
patients however the majority of patients relapse with an aggressive form of the disease that 
is independent of androgenic control known as hormone-refractory PCa [28]. 
 
 
1.2.2.2 Inflammation 
Although many factors have been suggested as possible determinants for PCa the only 
established risk factors are family history, increasing age, and ethnicity. 
 
More recently it has been hypothesised that inflammation may play a role in PCa [29]. An 
established risk factor for many cancers, chronic inflammation has been accepted as playing a 
key role in the aetiology of 20% of all cancers including cancers of the stomach, liver and 
intestine. In normal tissue, after an inflammatory response anti-inflammatory cytokines and 
proteins are produced to end the inflammation but in chronic inflammation this homeostasis 
does not occur and the inflammation persists.  
 
As the prostate ages inflammation naturally increases, due to infections and other factors, and 
it has been suggested this may be linked to the initiation of PCa by causing cellular and 
genomic damage, increasing cell turnover, and producing an environment conducive to 
tumour cell growth and angiogenesis, promoting carcinogenesis [30]. In one study in which 
biopsies were taken at baseline and five years from men with suspected malignancies they 
reported that those with inflammation at baseline had a 20% chance of developing PCa within 
the five years compared with a 6% chance for those who did not [31].  
 
Injury to the prostatic epithelium can often result in proliferative inflammatory atrophy (PIA) 
lesions in which cells do not fully differentiate and are associated with chronic inflammation. 
The majority of PIA lesions arise in the peripheral zone which is where the majority of cancers 
originate [32] and it has been suggested that PIA can transform into prostatic intraepithelial 
neoplasia (PIN), a precursor of cancer (Figure 1.7) [33-34].  
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In PIA, PIN and PCa an over-expression of cyclooxygenase-2 (COX-2) has been reported which 
leads to an increase in prostaglandin expression, an event associated with prostate 
carcinogenesis. Prostaglandins can inhibit apoptosis and promote angiogenesis and metastasis. 
COX-2 expression can be controlled by a number of factors including IL-6 and NFκB [30].  
 
The chronic inflammation observed in the prostate is similar to that seen in BPH with regards 
to the inflammatory cells including lymphocytes, monocytes and macrophages. Macrophages 
have been linked to both tumour progression and suppression as they are involved in killing 
tumour cells by secreting TNFα. However TNFα, and also IL-2, can promote the expression of 
prostate derived factor/macrophage inhibitory cytokine (MIC-1) by monocytes, which in turn 
inhibits TNFα secretion reducing the effectiveness of macrophages in protecting against the 
tumour.  
 
MIC-1 is a member of the TGFβ superfamily and has been implicated as a link between 
inflammation and PCa due to the correlation between MIC-1 levels and tumour grade. 
Although MIC-1 is not normally detectable in the prostate, it has been found in samples from 
patients with no PCa suggesting that MIC-1 may be involved in the initiation rather than 
development of PCa. It is therefore suggested that MIC-1 is an early response to inflammation 
leading to the production of an environment favourable to tumour growth due to its 
proliferative effects [35].  
 
Another member of the TGFβ superfamily, TGFβ1, has also been implicated in PCa although it 
has a very complex relationship with prostate regulation.  TGFβ1 is able to inhibit the growth 
and proliferation of non-malignant cells but conversely promotes survival and proliferation of 
tumour cells and is linked with the metastatic potential of the disease.   
 
Many other alterations in cytokine levels have also been associated with prostate cancer 
including increased IL-1 which has been shown to promote tumour growth and is necessary for 
metastasis of prostate cancer cells. Increased IL-6 levels have also been correlated to 
metastatic PCa and it is known that this cytokine can promote proliferation and inhibit 
apoptosis of many malignant cell types. Furthermore, the activity of IL-6 may be linked to the 
androgen response status of the cell.  
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IL-17, a very potent pro-inflammatory cytokine, is involved in angiogenesis and can promote 
tumour cell growth as well as stimulating the secretion of TNFα and IL-1. It has also been found 
to be increased in many PCa samples and can further stimulate IL-6 and IL-8 expression. IL-17 
may therefore be able to act indirectly by altering the secretion of other proinflammatory 
cytokines implicated in carcinogenesis, and also directly by promoting angiogenesis and 
increasing tumour cell growth. 
 
IL-8 is able to promote tumour cell growth and may also assist in angiogenesis and metastasis 
by increasing the secretion of matrix metalloproteinases (MMPs), including MMP-9, that break 
down the ECM;  elevated levels of IL-8 and MMP-9 have been found to correlate to PCa 
metastasis.   
 
Increased TNF-α is also correlated with disease progression and decreased survival in PCa 
patients and has been found to stimulate MMP-9 expression [36]. Different expression 
patterns of cytokines have been linked to cancer progression. Hepatocyte growth factor (HGF) 
and IL-18 binding protein a (IL-18BPa) are increased in patients with extensive PCa. IL-17, 
glucocorticoid-induced tumour necrosis factor receptor (GITR), intercellular adhesion molecule 
1 (ICAM-1) and IL-18BPa are elevated in PCa specimens with neutrophilic inflammation into 
glands; whilst IL-18BPa, IL-17, GITR and ICAM-1 are higher in samples with lymphocytic 
inflammation in the stroma [37]. All these studies are suggestive of a link between PCa and 
inflammation but do not definitively show that inflammation is essential for PCa initiation 
(Figure 1.6).  
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Figure 1.6. Inflammatory pathways in PCa.  
Simplified drawing illustrating some of the inflammatory cytokines expressed in PCa and their 
relationships with cells. Cytokines and other molecules can stimulate cells to modulate 
cytokine expression and/or promote proliferation, angiogenesis and metastasis (green arrows) 
whilst others can inhibit these processes (red arrows). Different cell types express varying 
inflammatory molecules (blue arrows). The area within the grey dashed line represents all the 
cell types present within the tissue, all of which can secrete cytokines and other molecules.  
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1.2.3 Benign Prostatic Hyperplasia and Prostate Cancer 
The relationship between BPH and PCa (Figure 1.7) has been investigated on a number of 
separate occasions. The first investigations were conducted over 30 years ago in two separate 
studies which resulted in opposing conclusions- one suggesting a link between the two [38], 
the other indicating no increase in risk of PCa as a result of BPH [39]. More recently a further 
study also concluded that the presence of BPH does not increase the risk of PCa [40], and no 
epidemiological evidence has successfully demonstrated a role for BPH in  the aetiology of PCa.  
 
Although both diseases are associated with increasing age, epidemiological evidence suggests 
that BPH develops earlier than PCa. Anatomical evidence highlights that  BPH nodules almost 
exclusively arise in the transitional zone in comparison with PCa where two thirds originate in 
the peripheral zone, a quarter in the transition zone and the rest in the central zone [41].  
 
Research into the aetiology of both diseases has demonstrated that androgens and oestrogens 
are crucial to the development of both diseases although this may just highlight the 
importance of steroid hormones in the prostate rather than suggest a link between BPH and 
PCa.  
 
With the knowledge that the majority of BPH specimens contain inflammatory infiltrates and 
the growing body of evidence to suggest a role of inflammation in PCa it could be that this may 
be a link. Comparison of inflammatory molecules that have been noted as altered in either 
BPH or PCa reveals there are a number that overlap, including the powerful pro-inflammatory 
IL-17 and subsequently IL-6 and IL-8 whose expression it promotes. On the other side of the 
coin the expression of toll-like receptors (TLRs) has been found to be different in the two 
diseases with TLRs 4, 5, 7 and 9 more highly expressed in BPH in contrast to TLRs 1, 2 and 3 in 
PCa.  
 
Other inflammatory markers such as CCR-3, COX-2 and CXCR-4 have also been noted to be 
increased in BPH as opposed to PCa where Rantes, IL-8, MMP-2 and -9, and CCR-5 are found at 
higher levels [42]. Interestingly in samples taken from the normal peripheral and transition 
zones of PCa patients MIC-1 was found to be higher in the peripheral zone, the site of origin of 
most tumours, compared to the transition zone, where the majority of BPH arises [35]. 
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Figure 1.7. Prostatic disease progression.  
PIA = proliferative inflammatory atrophy, BPH = benign prostatic hyperplasia, PIN = prostatic 
intraepithelial neoplasia. Inflammation in the prostate is associated with both BPH and PIA. 
BPH is not considered a pre-cursor of PCa but it has been suggested there could be a link. PIA 
has been shown to develop into PIN, a known pre-cursor of PCa, but this is not an essential 
step in PIN development. Once PCa has developed, as the disease progresses metastasis can 
occur. Adapted from Vasto, 2008 [30]. 
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1.3 Diet and Disease 
It has long been known that what we eat can have a great influence on our health. The exact 
nature of the relationship between foods and human health is extremely complex and is 
subject to a vast amount of research [43]. In particular, the link between major diseases and 
diet are well researched with estimates suggesting 30% of tumours in the Western world are 
caused by diet alone [44]. Dietary agents are both able to increase and decrease our risk of 
disease and how specific foods and nutrients can alter our disease risk depend upon each 
individual disease. Epidemiological studies further support the idea that diet influences 
disease, as the prevalence of many diseases alters due to the diet consumed within a region. 
The evidence for the role diet can play in both BPH and PCa is reviewed.  
 
 
1.3.1 Diet and Benign Prostatic Hyperplasia 
A number of studies have suggested a role for diet in the aetiology of BPH although any 
associations are still under debate. Traditionally BPH occurrence is much higher in the western 
world than Asia where the typical diet is low in fat and high in fibre [45]. However in recent 
years the number of cases of BPH in Asia is starting to rise, an increase associated with the 
Westernisation of the diet including increased consumption of fats and animal proteins 
coupled to reduced vegetable and wholegrain intake [46].  
 
Epidemiological studies, including case-control and prospective cohort studies, have 
investigated the role of diet in BPH risk. Of the studies that examined the effect of total calorie 
intake or BMI on BPH risk neither found an association [47-48].  
 
Examination of the main nutrient groups shows no relationship with BPH risk for total 
carbohydrate [49] or sugar consumption [47] but there is conflicting evidence on the effect of 
protein consumption, with one study finding no effect [47], one finding an increased risk [49] 
and another reporting a decreased risk if a high percentage of total energy came from protein 
[48].  
 
With regards to total fats, Bravi and colleagues [47] and Suzuki and colleagues [49] found no 
change in BPH risk but Bravi and colleagues found a reduced risk due to polyunsaturated fatty 
acids (PUFAs), linoleic and linolenic consumption. In contrast, Suzuki and colleagues found 
PUFAs increased risk which corresponded with two other studies [48, 50], both of which found 
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total fat consumption increased BPH risk. Bravi and colleagues also reported that starch 
increased risk [47] although in further analysis neither pasta, rice or potatoes had any effect 
but both cereals and bread increased risk [51].  
 
Past knowledge suggests that fruit and vegetables should be beneficial which is confirmed by 
these studies although only one found an effect from total fruit and vegetable consumption 
[48]. This study further suggested that the fruits and vegetables that were most beneficial 
contained vitamin D and lycopene. 
 
In a separate study Rohrmann and colleagues found no effect of total fruit and vegetable 
consumption [52] but instead saw an effect from vegetable consumption only, in particular 
naming the rutaceae, legumes and cruciferous vegetable families as most beneficial. They 
further suggested that β-carotene, lutein and vitamin C reduced risk, the last of which 
correlates with the indication that orange juice [52] and citrus fruits [51] reduce risk. Bravi and 
colleagues [51] also suggested that cooked vegetables offered more protection than raw and 
from the same data Galeone and colleagues suggested allium vegetables may also be of 
particular benefit [53].  
 
Further food groups implicated in increasing risk include eggs and meat whilst pulses are 
believed to reduce risk [48, 51]. This data suggests that diet may well influence BPH risk but 
the best diet to protect against BPH is still unclear. 
 
 
1.3.2 Diet and Prostate Cancer 
As with BPH, diet is believed to play a role in prostate cancer risk due in part to the 
observation that Japanese migrants living in the US and who had adopted a Western diet 
increased their risk of developing Western cancers, including prostate cancer, to a level 
comparable to that of native US citizens [54-55], an observation that cannot be attributed 
entirely to genetics.  
 
Examination of total energy intake showed no correlation with PCa risk in a study in the 
Netherlands [56] but was found to be correlated to increased risk in other studies [57-58]. The 
correlation of fats appears complex with some reporting no effect [56, 59-60] and other 
reporting an increase in risk [57-58, 61], although Slattery and colleagues noted this increase in 
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risk only applied if a high fat diet was consumed as an adult compared to as an adolescent [61]. 
Further analysis of fat consumption suggested that animal fats [62-63] and oleic acid [56] were 
responsible for increased risk whereas linoleic and leniolenic acids [56] and marine fats reduce 
risk [64].  
 
The other major nutrient groups, proteins and carbohydrates are less extensively studied with 
only one study reporting any findings which was that there was no correlation with PCa risk 
[59, 65]. Hsing and Chokkalingam reported no correlation between meat consumption and PCa 
risk [66] but Schuurman and colleagues suggested this was true for fresh meat but that cured 
meat increased risk [65]. It has further been reported that red meat is associated with higher 
risk [58]. Augustsson and colleagues reported that fish reduced risk significantly [64] but 
others have found no effect [65].  
 
Dairy products have been reported both as having no correlation [66-67] and as increasing risk 
[68] although Schuurman and colleagues reported milk had a detrimental effect  on prostate 
health whereas eggs and cheese had no effect [65]. Dairy products are the main source of 
calcium in the diet and this has been correlated with increased risk by many studies [57, 67-69] 
although just as many found no relationship [59, 62, 65].  
 
The major body of research with regards to PCa and diet surrounds fruit and vegetables and 
their associated phytochemicals. Total fruit [70] and vegetable consumption was found to have 
no effect in one study [66] but they are often implicated in reducing risk [69, 71], especially 
vegetables  [70] and most notably those of the cruciferous family [70, 72-78].  In a number of 
these studies they suggested that cruciferous vegetables may offer protection at different 
stages of the disease, including during initiation [74] and progression [76] of PCa, or 
development of an extra-prostatic tumour [77]. Tomatoes and lycopene have been linked to a 
reduction in PCa risk [79-81] but not all studies support this suggestion [60, 62, 70]. Likewise β-
carotene and other carotenoids have also been suggested as offering protective effects [59-60, 
80]. α- and γ-tocopherol, the major forms of vitamin E found in supplements, and selenium 
have also been observed to reduce risk [58, 82].  
 
Further suggested to reduce risk are vitamin A [59, 83], vitamin C [58, 84], soy foods and 
isoflavones [85], vitamin B6, garlic, beans and peas [60].  
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1.3.3 Cruciferous Vegetables 
As previously discussed a link between vegetable consumption and health has long been 
established. Furthermore, recent evidence has shown that cruciferous vegetables in particular 
are more strongly associated with the reduction of cancer risk than vegetable consumption in 
general [72, 75] and have been suggested as protective against both BPH and PCa. In 
particular, consumption of cruciferous vegetables has been reported to reduce the risk of PCa 
by 39, 40 and 32% [70, 73, 78], reduce the risk of extra-prostatic PCa by up to 40% [77], and 
reduce the risk of progression by 59% in men diagnosed with non-metastatic disease [76]. 
 
Crucifers or alternatively brassicas are members of the Cruciferae or Brassicaceae family that 
consist of some of the most commonly consumed vegetables in Asian and European diets. 
Members of this family include cabbage, turnips, cauliflower, watercress, rocket, mustard, 
Chinese cabbage and broccoli among others [86]. The Cruciferae family are so-called as they 
produce flowers which have four petals in the shape of a cross otherwise known as a ‘crucifer’ 
and the term ‘brassica’ is the Latin word for cabbage. They are known to contain a number of 
nutrients and bioactive compounds such as fibre, flavonoids, minerals, vitamins and 
glucosinolates (GLS), many of which are known to have chemopreventive properties.  
 
 
1.3.4 Glucosinolates 
It is the latter group of phytochemicals, GLS, which are highly characteristic of this group of 
vegetables and are responsible for their distinctive aromas and taste [87]. Glucosinolates are a 
group of approximately 120 sulphur-rich phytochemicals that share a common structure 
consisting of a β-D-thioglucose group, a sulfonated oxime group and a variable side chain, 
derived from one of eight amino acids (Figure 1.8a) [88]. They are not biologically active 
compounds but under the correct conditions and in the presence of certain enzymes they can 
undergo reactions to produce a number of chemically related bioactive compounds such as 
cyanaoepithioalkanes, nitriles, indole-3-carbinol and isothiocyanates (ITC).  
 
 
1.3.5 Isothiocyanates 
Isothiocyanates are a group of bioactive compounds derived from GLS which are found in 
cruciferous vegetables. The hydrolysis of GLS to ITC occurs upon release of endogenous 
myrosinase, a native β-thioglucosidase, from the plant cell due to disruption of the structure 
caused by harvesting, processing or chewing [89]. The reaction yields glucose and a 
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thiohydroxamate-0-sulfonate as myrosinase catalyzes the hydrolysis of the glucosidic bond in 
the GLS. The thiohydroxamate-0-sulfonate is highly unstable and depending on the reaction 
conditions, for example the presence of co-reactors and the temperature, the side chain 
structure spontaneously rearranges to form a number of possible structures. If the reaction 
occurs at a relatively neutral pH (6-7) the most common products are stable ITC although other 
outcomes can occur (Figure 1.8b) [90].  
 
 
                  
 
Figure 1.8. Glucosinolate and isothiocyanate structure.  
R represents a variable amino acid side chain specific to the (a) glucosinolate or (b) 
isothiocyanate. There are approximately 120 known side chain structures.  
 
 
1.4 Sulforaphane 
Of the ITCs one of the most studied compound with respect to cancer prevention is 
sulforaphane (SF) which is derived primarily from broccoli and produced from glucoraphanin, 
its chemically related GLS (Figure 1. 9). Glucoraphanin is either converted to SF by the 
endogenous myrosinase, as previously described, or once consumed, if the myrosinase has 
been denatured by cooking [91], by microbial thioglucosidases in the gut [89, 92]. 
Sulforaphane is then absorbed and conjugated with glutathione before being metabolized via 
the mercapturic acid pathway prior to excretion from the body in the urine.  
 
(a) (b) 
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Myrosinase
Sulforaphane
 
 
Figure 1.9. Conversion of glucoraphanin to sulforaphane.  
Myrosinase cleaves the thio-glucose bond of glucoraphanin to give rise to an aglycone which is 
unstable and undergoes a Lossen rearrangement to produce sulforaphane. 
 
 
The conjugation of SF and glutathione is catalyzed by glutathione S-transferases (GSTs) 
although it can occur non-enzymatically. Glutathione S-transferases are categorized into three 
different families: cytosolic, mitochondrial and microsomal. The cytosolic GSTs are dimers 
formed from approximately 17 subunits divided between 7 different classes [93]. The two 
members of this family that have been  shown to have the greatest catalytic activity on SF and 
glutathione conjugation are GSTM1 and GSTP1, although even in the presence of these GSTs 
SF conjugation occurs much slower than that of other ITCs. Glutathione S-transferases also 
assist the disassociation of ITCs from glutathione, although this occurs at a significantly lower 
rate than the association [94].  
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Polymorphisms in many of the GST genes have been recorded including a null mutation in 
GSTM1 which results in the absence of a functional gene product. This polymorphism is 
thought to be so common that it can be found in 50% of the population [95]. 
 
A number of epidemiological studies conducted on Western subjects have gathered evidence 
that suggests GSTM1 +ve individuals gain greater cancer protection from the consumption of 
crucifers, in particular broccoli, than their GSTM1 -ve counterparts [75, 96-97]. One of these 
studies even goes as far as to suggest that consuming just one portion of broccoli a week can 
decrease prostate cancer risk by 50% [75]. However in contrast, studies from Asia suggest that 
GSTM1-ve individuals gain the most benefit although this may be due to the identity of the 
major crucifer being consumed, which in these studies was Chinese cabbage, not broccoli [98-
99].  
 
Despite accumulating evidence for the protective effects of broccoli it is unknown by what 
mechanism it occurs as after absorption SF is found in relatively low concentrations in the 
plasma before being quickly excreted. A study by Gasper and colleagues observed faster 
excretion of SF metabolites in the 6 hours immediately proceeding consumption of broccoli as 
well as a higher percentage of total SF excretion during the first 24 hours in GSTM1 -ve 
subjects compared to GSTM1 +ve individuals. The difference between the two is statistically 
significant as GSTM1 +ve individuals only excrete approximately 60% of SF within 24hrs of 
consumption compared to 100% for those who are GSTM1 -ve. Despite this, genotype appears 
to have no significant effect on the levels of SF conjugates found in plasma [100].  
 
The same paper posits three possible hypotheses to explain these results which include GSTM1 
+ve individuals absorbing less SF from the gut, metabolizing and excreting it via an alternative 
pathway, or retaining the SF in certain tissues. Although there is no experimental evidence to 
support any of these hypotheses there are some epidemiological observations to back up all 
three ideas, none of which is conclusive [100].   
 
Although GSTM1 is the GST with the greatest catalytic activity with regards to SF conjugation 
there are other enzymes, such as GSTP1, that can also catalyze the reaction. Similarly these 
enzymes have common polymorphisms and are often deleted so it may be that whether an 
individual gains the greatest possible protective benefit from cruciferous vegetables may be 
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due to the combination of genetic polymorphisms. Or in other words just being GSTM1 +ve or 
-ve may not be enough to determine the benefit a person receives from cruciferous 
vegetables, but whether a person is +ve or -ve for a number of different enzymes may be the 
determinant, as other enzymes may be able to fulfill the role of a single missing enzyme but 
not of multiple deletions. This idea was investigated by Steinbrecher et al who evaluated the 
risk of PCa and GLS with regards to polymorphisms in a number of enzymes including GSTM1. 
They reported that polymorphisms in these genes modulated the risk of PCa in response to 
GLS intake, in particular noting that deletion of GSTM1 and GSTT1 combined had a greater 
protective effect than either deletion alone [101]. Therefore supporting the hypothesis it is the 
combination of polymorphisms that determines the benefit derived from cruciferous 
vegetables, so measuring the effect in terms of a single polymorphism may give misleading 
results. As such the conflicting results in terms of whether being GSTM1 +ve or -ve provides 
greater protection against PCa from GLS may be due to other polymorphisms present in the 
populations studied.  
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1.4.1 Modes of Action 
The means by which SF may confer beneficial effects are well investigated and it has been 
demonstrated that SF has many possible mechanisms of action. The effect of SF on 
carcinogenesis has in particular been intensely studied, the evidence from which suggests SF is 
able to both help prevent initiation [102] and slow progression of the disease. The many 
modes by which SF acts and pathways it alters can often overlap making defining its precise 
role difficult to determine. Here the main mechanisms by which SF can help protect health, 
namely suppression of oxidative stress, regulation of phase I and II enzymes, reduction of 
inflammation, initiation of the heat shock response, inhibition of histone deacetylases, 
suppression of the cell cycle, induction of apoptosis, inhibition of angiogenesis, and reduction 
of migration and metastasis, are discussed (Figure 1.10 and Figure 1 .11).  
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Figure 1.10. Modes of action of sulforaphane (excluding apoptosis).  
Simplified drawing of the direct and indirect cytoprotective mechanisms of SF. Green and red 
lines represent pathways up and down-regulated respectively by SF. The dotted lines indicate 
translocation to the nucleus.  
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1.4.1.1 Oxidative Stress 
Oxidative stress occurs when there is an imbalance between the production and elimination of 
reactive oxygen species (ROS) which can result in cellular damage. Antioxidants that act to 
protect the cell from ROS induced damage can either act as direct antioxidants, scavenging 
ROS directly, or as indirectly by initiating defensive mechanisms.  
 
Sulforaphane acts as an indirect antioxidant regulating cellular defence mechanisms notably 
activating the nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway.  Nrf2 is a transcription 
factor that plays a key role in regulating the enzymes and other molecules that help protect 
the cell from oxidative stress. Under normal circumstances Nrf2 is sequestered in the 
cytoplasm by kelch-like ECH-associated protein 1 (Keap1) which targets it for degradation.  
 
During oxidative stress Keap1 is modified causing a conformational change that leads to the 
release and activation of Nrf2. Nrf2 translocates to the nucleus where it binds to promoters 
containing the antioxidant response element (ARE) upregulating the transcription of 
cytoprotective enzymes. SF is able to activate this pathway by activating Nrf2 leading to an 
increase in downstream markers such as heme oxygenase-1 (HO-1) and NAD(P)H: quinine 
oxidoreductase 1 (Nqo1) protecting against oxidative damage [103-104].  
 
 
1.4.1.2 Phase 1 and 2 Enzymes 
Along with ROS, other molecules, including foreign chemicals from the environment and food, 
are capable of causing cellular damage. Foreign chemicals are metabolised by phase I 
cytochrome P450 (CYP450) enzymes that catalyze their conversion to a more hydrophilic form, 
allowing their conjugation to endogenous ligands, a process catalyzed by phase II 
detoxification enzymes, in order for them to be excreted from the body. In metabolising these 
foreign chemicals phase I enzymes convert pre-cursors of chemical carcinogens to their active 
state. Without sufficient phase II enzyme activity to clear them from the body cellular damage 
will occur which can ultimately lead to disease.  
 
Sulforaphane inhibits the activity of phase I enzymes [105] including CYP2E1, a phase I iso-
enzyme which is expressed in the liver where it metabolically activates a number of 
carcinogens including N-nitrosodimethylamine (NDMA), a carcinogen found in tobacco smoke, 
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cured meats and fish. Sulforaphane thereby reduces NDMA mutagenicity and unscheduled 
DNA synthesis protecting against malignancy [106].  
 
In conjunction with this, SF stimulates transcription of phase II enzymes which help protect 
against carcinogenic intermediates including HO-1, NQO1, superoxide dismutase (SOD) and 
thioredoxin reductase (TR) [107-108]. As mentioned above, SF activates the Nrf2 pathway 
whose targets include a number of phase II enzymes [108-109]. In addition to this SF 
stimulates mitogen-activated protein kinase (MAPK) which in turn activates extracellular 
signal-regulated protein kinase 2 (ERK2) thereby inducing the activation of AREs promoting the 
expression of quinone reductase, a phase II detoxifying enzyme and ARE-linked reporter gene 
[110]. SF also increases the expression of the phase II enzymes GSTM1 and NQO1 [111]. By 
both inhibiting phase I enzymes and activating phase II enzymes SF is able to improve cellular 
defence against carcinogens and help prevent potential mutagenic events.  
 
 
1.4.1.3 Inflammation 
More recently SF has been implicated in protection against inflammation.  It has been shown 
that in rat microglia cells SF significantly reduces lipopolysaccharide (LPS)-induced expression 
of proinflammatory cytokines IL-1B, IL-6 and TNFα, inhibits nitric oxide production, reduces 
phosphorylation of ERK1/2 and JNK, and attenuates NFκB p65 translocation to the nucleus. 
Additionally in the murine microglia cell line, BV2, SF inhibits LPS-induced activator protein 1 
(AP1) and NFκB mediated reporter activity [103].  
 
Also involved in inflammation are TLRs which recognise microorganisms and non-microbial 
endogenous molecules initiating an inflammatory response. SF is able to inhibit 
oligomerization of TLR4 thereby reducing interleukin-receptor associated kinase-1 (IRAK-1) 
degradation, an early marker of TLR4 activation, in turn suppressing the activation of 
downstream transcription factors NFκB and IRF3, and reducing LPS-induced proinflammatory 
cytokine expression [112]. In endothelial cells, the activation of the Nrf2 pathway by SF, as 
mentioned previously, is able to reduce inflammation by inhibiting p38-VCAM-1 signalling 
[113]. SF can also inhibit LPS-induced expression of TNF-α, IL-1β, COX-2 and iNOS via the Nrf-2 
pathway [114].  
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Further evidence of pro-inflammatory cytokine inhibition by SF includes reduction of IL-8, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-1β in airway epithelial cells 
[111]. Overall all these factors combine to demonstrate how SF is capable of suppressing 
inflammation. 
 
 
1.4.1.4 Heat Shock Response 
One of the most recent hypotheses regarding cytoprotection by SF is the suggestion that SF is 
capable of initiating a heat shock response. The heat shock response is the induction of the 
expression of heat shock proteins in response to misfolded proteins which occurs as a result of 
stressed conditions. Of prime importance in this response is the proteasome which acts to 
control the normal turnover of proteins and also to remove abnormal proteins. 
 
Sulforaphane increases proteasome activity by causing the dissociation of heat shock 
transcription factor 1 (HSF-1) from heat shock protein (HSP) 90 and 70, which sequester it in 
the cytoplasm. This results in the translocation of HSF-1 to the nucleus and subsequent 
hyperphosphorylation, both markers of HSF-1 activation, leading to a HSF-1-dependent 
increase in HSP27, a known regulator of proteasome activity [115].  
 
Hu and colleagues also suggested a role for SF in proteasome activity as they observed that SF 
altered the expression of Nrf2-dependent proteasome subunit genes. In their study they 
further noted the Nrf2-dependent increase of a number of heat shock proteins in response to 
SF treatment including glucose regulated protein (GRP) 78 and HSP-1, -8 and -105  [116].  
 
Sulforaphane indirectly alters the activation state of HSP90, a molecular chaperone whose 
clients include many involved in apoptosis, suggesting another method by which SF may help 
induce apoptosis and therefore help protect the cell [117]. 
 
 
1.4.1.5 Histone Deacteylases 
Histone deacetylases (HDACs) are proteins that can remove acetyl groups from other proteins 
controlling gene expression and protein function. HDACs are often up-regulated in cancer and 
other diseases. It has been reported that SF can inhibit their activity thereby preventing any 
HDAC-induced changes [118]. Sulforaphane can inhibit HDAC activity increasing histone 
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acetylation leading to an increase in p21
 
and Bax expression which can alter cell cycle 
progression, induce caspase-dependent apoptosis [119] and can suppress tumour 
development [120]. 
 
 
1.4.1.6 Cell Cycle 
The cell cycle is the process by which the cell proliferates and this process is divided into five 
phases: quiescence/senescence (G0); gap phase where the cell increases in size (G1); S phase 
when DNA replication occurs (S); gap 2 during which the cell prepares to divide (G2); and 
mitosis when the cell divides (M). There are three major checkpoints that control progression 
to the next phase: G1/S, G2/M and metaphase. The progression of the cell cycle is controlled by 
the expression of cyclins, cyclin-dependent kinase (CDK) inhibitors and other proteins.  
 
Sulforaphane has been shown to inhibit cell cycle progression by modulating a number of 
these proteins increasing the expression of cyclin A and B1, cell cycle inhibitors p21
 
and p27
KIP1
, 
causing retinoblastoma (Rb) hyperphosphorylation and inhibiting cyclin d1 [89, 121-124]. A 
single study by Hu and colleagues suggested that SF increased cell cycle proteins by a Nrf-2 
dependent manner including CDK4, CDK7, CDK9, CDKI1A, cyclin D1, cyclin E2, and cyclin T2 
[116]. 
 
 
1.4.1.7 Apoptosis 
A major well-researched activity of sulforaphane is the induction of apoptosis, which has been 
recorded in a number of different cell lines. In HT29 human colon carcinoma cells, SF-induced 
condensation of nuclear chromatin and cell surface expression of the phospholipid 
phosphatidylserine, both hallmarks of apoptosis [122]. Whilst in pancreatic cancer cells, SF was 
observed to induce apoptosis by increasing caspase-3 activation. Furthermore, SF also reduced 
the phosphorylation of AKT and ERK inhibiting the PI3K/AKT and MEK/ERK pathways 
respectively, activating forkhead members of the class O (FOXO) transcription factors which 
control apoptosis [123].  
 
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a 
number of cancer cells but not in normal cells by binding to death receptors (DR)-4 and -5. 
Some cells are TRAIL-resistance but can be sensitised by inhibiting AKT and NF-κB, both 
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pathways that SF can inhibit. Sulforaphane increased TRAIL-induced apoptosis in PC3 prostate 
cancer cells and sensitised TRAIL-resistant LNCaP prostate cancer cells. Sulforaphane-induced 
apoptosis correlated with increased ROS production, collapse of mitochondrial membrane 
potential, activation of caspase-3 and -9, and increase in DR4 and DR5. Further to this, SF 
induced the expression of pro-apoptotic proteins Bax, Bak, Bim and Noxa, and inhibited the 
expression of anti-apoptotic proteins Bcl-2, Bcl-XL and Mcl-1 [125]. SF also increased 
phosphorylation of JNK1/2, Elk-1 and c-Jun inducing AP-1 leading to an increase in apoptosis 
via decreased Bcl-2 [126]. Furthermore, SF increased intracellular free Ca2+, upregulating 
calpain, activating caspase-12 and subsequently caspase-9. Sulforaphane also induced Bax, and 
inhibited Bcl-2, triggering the release of cytochrome c from the mitochondria leading to the 
activation of caspase-9 and then caspase-3. There was also a decrease in NFκB and increase in 
NFκBα all of which combine to induce apoptosis in glioblastoma cells [127] (Figure 1.11).  
 
 
1.4.1.8 Angiogenesis 
Angiogenesis is essential to cancer progression as without the formation of new blood vessels 
tumour growth is limited as all cells must be within 200µm of blood vessels, the diffusion limit 
of oxygen [26].   
 
Using human umbilical vein endothelial cells (HUVECs), a model of angiogenesis, SF was shown 
to reduce proliferation by increasing apoptosis and thereby inhibiting angiogenesis [128]. 
Sulforaphane also inhibits the expression of vascular endothelial growth factor (VEGF) and its 
receptor, and the angiogenesis-associated transcription factors hypoxia-inducible factor-1a 
and c-Myc as well as MMP-2, reducing cell migration thereby preventing angiogenesis [129].  
 
 
1.4.1.9 Migration and Metastasis 
Metastasis is an important step in the carcinogenic process as once the cancer cells travel 
away from the site of origin, establishing new tumours, it becomes much more difficult to 
treat. Inhibiting this process would keep the tumour contained making treatment easier and 
improving the prognosis of a large number of patients. Sulforaphane has been shown to 
increase the lifespan of animals with metastatic tumours by inhibiting migration and 
metastasis via reducing the secretion of matrix metalloproteinases (MMPs) [89, 130-131].  
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Figure 1.11. Activation of apoptosis by SF.  
Simplified drawing showing the major pathways SF alters to induce apoptosis. Green and red 
lines represent pathways and processes promoted and inhibited respectively by SF, the blue 
line represents the normal mode of action of pathways shown. The dotted lines indicate 
translocation.  
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1.4.1.10 Sulforaphane in the Prostate 
From the evidence above it is clear that SF is able to act via a number of mechanisms to 
beneficially alter cellular processes in a wide range of tissues. Due to the natural variations in 
tissue and cell types in the body it may be that some of the mechanisms by which SF can act 
and subsequent effects may be tissue or cell type specific. The effect of SF on the prostate in 
particular has been much researched and has suggested some prostate specific effects.  
 
Global analysis of the effects of SF on gene expression in LNCaP prostate cancer cells revealed 
25µM SF altered 2579 transcripts, 10µM SF altered 3601 transcripts and broccoli sprouts 
(lyophilised and reconstituted to 10µM SF) altered 1496 transcript compared to untreated 
cells. The 10µM SF and broccoli sprout results had the highest degree of overlap which is not 
surprising considering the broccoli sprouts were reconstituted to a concentration of 10µM SF.  
The expression patterns of 575 transcripts were found to be highly similar between the three 
treated datasets and of these genes the greatest association was seen with cell cycle 
regulation. Of the transcripts observed to be altered, the greatest increase was in genes 
associated with phase 2 enzymes, including NQO1 and GSTM1. Other functions identified as 
important included cellular assembly and organization, and cancer associated pathways. 
Analysis of cell cycle phase showed that SF increased the expression of many transcripts 
associated with G2/M suggesting that SF may act at this point of the cell cycle to induce 
growth arrest [132].  
 
Androgens and the androgen receptor (AR) have been implicated as essential to prostate 
health and inhibition of this pathway is of interest in both prevention and treatment of 
disease.  Evidence is accumulating to suggest that SF can inhibit AR indicating a novel method 
by which SF can be of particular benefit to prostate health. The AR is a known client of HSP90, 
itself a target of HDAC6. Histone deacetylase 6 is known to deacetylate and activate HSP90, 
leading to enhanced binding to client proteins inhibiting degradation of these proteins.  It has 
been shown that in LNCaP PCa cells, SF inhibits HDAC6 enzymatic function increasing HSP90 
acetylation leading to dissociation from AR and degradation of AR by the proteasome.  As a 
result of this there is less AR bound to androgen response elements (AREs) and subsequently a 
reduction in AR target gene expression such as PSA [117].  
 
A further study confirmed that SF treatment decreases AR levels and thereby reduced AR 
nuclear translocation but suggest that this is due to suppressed AR transcription as opposed to 
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increased AR degradation. In addition, they further went on to demonstrate that SF inhibited 
androgen-induced LNCaP cell growth suggesting that SF may be able to inhibit tumour cell 
growth in vivo [133].  
 
Myzak and colleagues have also demonstrated the ability of SF to inhibit HDAC activity in 
prostate cells including BPH-1, LNCaP and PC3 cells resulting in increased histone acetylation 
levels. This resulted in increased p21 expression and altered expression of pro- and anti- 
apoptotic proteins including decreasing Bcl-2 and increasing Bax. They also demonstrated 
increased caspase activity and showed that SF caused cell cycle arrest at G2/M phase leading 
to an increase in apoptosis [119]. They then went on to show that SF specifically inhibited the 
growth of PC3 xenografts in mice and in these tumours observed reduced HDAC activity. The 
same effect was seen in mouse prostates as well as mouse monoclonal blood cells and human 
peripheral blood mononuclear cells [134]. 
 
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that is over-expressed in many 
cancers including PCa. Hypoxia-inducible factor-1 expression can be induced by hypoxia, 
growth factors and oncogenes and its activity is associated with tumorigenicity, angiogenesis 
and metastasis. Under normoxia, HIF-1 is constitutively expressed but rapidly degraded by the 
proteasome, however under hypoxia HIF-1 accumulates. Hypoxia-inducible factor-1 controls 
the transcription of VEGF, a key player in tumour angiogenesis, growth and metastasis, so it is 
clear to see how increased HIF-1 can positively influence tumour progression. In DU145 PCa 
cells, SF is able to inhibit HIF-1 expression by activating the ERK and JNK signalling pathways, 
which are known to regulate HIF-1, thereby reducing its synthesis. The observed reduction in 
HIF-1 also correlated with reduced VEGF demonstrating another mechanism by which SF can 
act [135].  
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1.5 Models to Explore Diet Interactions 
In order to test hypotheses and investigate the relationships between what we consume and 
the effect on our bodies researchers need models in which to explore these interactions. There 
are three main methods available; in vitro models such as cell culture, the simplest model that 
allows the investigation of interactions with a single cell type; ex vivo models, for example 
tissue culture, which allows the exploration of relationships between different types of cells 
within a single tissue type; and in vivo models of whole organisms (human and animal studies), 
where the complex interactions that occur within our bodies come into play. All three systems 
have a role to play in understanding how our bodies work hopefully ultimately allowing us to 
develop new treatments and prevent diseases from occurring.  
 
 
1.5.1 In Vitro 
In vitro cell culture techniques have been in common laboratory use since the mid-20
th
 century 
to directly investigate how cells behave. There are two main types of cell culture: primary, cells 
that are cultured directly from a subject and typically have a limited lifespan; and established 
cell lines, immortalized cells which can proliferate indefinitely due to either random mutations 
or deliberate modification. With particular reference to cell lines these are often cells which 
are representative of a cell type and are well characterised allowing researchers to use the cell 
type most relevant to their investigations. Working with cell lines allows experiments to be 
repeated many times confirming the reproducibility of results.  
 
In comparison to other methods cell culture is by far the cheapest and the simplicity of this 
system makes it easier to elucidate how compounds act and cells respond. Cell culture 
experiments have most value in allowing researchers to investigate the exact relationship 
between molecules, without the confounding effects caused by natural variation, if the 
experiments were to be performed in a more complex subject.  
 
Established cell lines have long been derived from prostate tissue at various stages of 
dysregulation, from healthy through to BPH and onto highly metastatic PCa. These cell lines 
can be highly useful in initially establishing and studying the effect of certain conditions but 
their relevance is limited as other factors such as the stroma play an important role in the 
function of the prostate, something cell culture models do not replicate. Established human 
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prostate cell lines include PNT1a, a normal epithelial prostatic cell line, and DU145, a 
tumorigenic cell line.  
 
The use of cell lines has greatly improved our understanding of signalling pathways in the 
prostate including the discovery that SF can cause transcriptional repression of the androgen 
receptor and prevent it’s translocation to the nucleus in PCa cell lines, an important piece of 
information considering the crucial role AR plays in prostate development and disease [133]. 
 
 
1.5.2 Ex Vivo 
Compared to cell culture, ex vivo tissue culture is less routinely performed. This may be due to 
the availability of tissue as there are stringent rules regarding the use of human samples and 
strict ethical procedures must be adhered to before commencing any work. Sourcing suitable 
tissue can be difficult depending on the exact nature of the experiment, and reproducibility of 
results is impossible as each sample is unique.  
 
Understanding results can also be much more complex as natural variation within humans, and 
therefore human samples, will ultimately lead to greater variation in results. However, despite 
these issues, tissue culture has great experimental value providing a much more complex and 
more relevant experimental model than cell culture alone is able to offer. A number of 
previous studies have been undertaken to develop and characterise models for human 
prostate organ culture, in order to study the effects of various conditions and treatments on 
the tissue.  
 
By establishing a method for the viable culture of prostate tissue it will allow studies to be 
conducted that will more precisely replicate the in vivo condition although there will still be 
limitations on the value of results obtained. Larger sample numbers will help reduce the effect 
of human variation and make it easier to identify patterns within results.  
 
The relevance of this technique was demonstrated by Bronte and colleagues who, using 
prostate samples in culture, showed that the tumour microenvironment is immunosuppressive 
for TC cells and were able to inhibit this suppression, which coupled with immunotherapy may 
provide a novel therapy for patients with metastatic hormone-refractory PCa [136]. 
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1.5.3 In Vivo 
A further step up from both laboratory culture methods is the use of whole organisms in either 
in vivo animal or human studies. There are of course a number of issues that need to be dealt 
with including the many rules and regulations, expense, recruitment of volunteers, or selection 
of the most appropriate animal model.  Researchers must also contend with the variation in 
results that comes with using such a complex system, but these studies allow researchers to 
test hypotheses developed in less complex systems in a whole organism.  
 
Among the most commonly used animal models are rats and mice due to practical aspects in 
ease of their care, their rapid maturation and quick breeding turnaround. Many strains have 
been developed to provide suitable systems to test hypothesis, including those with mutations 
leading to spontaneous tumour development. With specific regards to PCa, murine models 
include transgenic adenocarcinoma of the mouse prostate (TRAMP) and PTENL/L;PB-Cre4 
mice.  
 
Using the TRAMP murine model Singh and colleagues observed that SF was able to inhibit 
prostate carcinogenesis and reduce metastasis providing further evidence for the anti-
carcinogenic properties of SF [137].  
 
Although the use of animal model can add to our understanding, the ideal model for 
examining the effect of dietary agents on health is human studies. Such studies allow 
researchers to gather data on the effect of diet on the body but due to the complexity of our 
bodies and the vast natural variation that exists between individuals large sample numbers are 
often required in order to obtain statistically significant data. Smaller targeted studies can be 
just as useful, as demonstrated by Traka and colleagues. Using a sample number of 21 men 
with high-grade PIN, they showed that broccoli consumption altered gene expression in the 
prostate dependent on GSTM1 genotype, resulting in changes to signalling pathways involved 
in inflammation and carcinogenesis [95].  
 
In conclusion, the use of in vitro, ex vivo, and in vivo models, both separately or in combination 
with each other, is essential to facilitate and enhance our understanding of mechanisms within 
the human body with the long-term aim of helping to prevent and cure disease.  
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1.6 Thesis Aims 
Previously the majority of studies to investigate the effect of SF on prostate health have been 
undertaken using in vitro models. In this study, an ex vivo model of BPH tissue was used to 
more closely replicate in vivo conditions in the prostate.  
 
As inflammation has been proposed to have a crucial role in both BPH and PCa, the BPH tissue 
was initially used as a model of inflammation to test the hypothesis that SF can reduce 
inflammation. Following on from this, the effect of SF on global protein expression in BPH 
tissue was investigated. The four major objectives of my thesis were:  
 
1. Develop a method for the culture of BPH tissue to replicate in vivo conditions using an 
ex vivo model. 
 
2. Establish whether SF is able to modulate inflammation in the ex vivo model as has 
been previously observed in in vitro models. 
 
3. Determine what effect SF has on global protein expression in BPH tissue ex vivo. 
 
4. Confirm the effect of SF on a selected protein, as identified from aim 3, using a greater 
sample number and investigate further to determine whether this effect may have any 
biological significance for prostate health. 
 
  
 
 
 
 
Chapter Two 
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Chapter 2. Tissue Culture Method Development 
2.0.1. Summary 
In this chapter, the development of a method for the culture of benign prostatic tissue (BPH) 
tissue as an ex vivo model which more closely replicates conditions in vivo than in vitro cell 
lines is described. More specifically, the effect of different culture media formulations and the 
addition of dihydrotestosterone (DHT) to the culture medium on the tissue were investigated 
by measuring prostate specific antigen (PSA) and lactate dehydrogenase (LDH) secretion. The 
histology of the tissue was also assessed to determine the effect of culture.  
 
No significant difference was observed between the RPMI and KGM media with regards to PSA 
or LDH secretion. Prostate specific antigen levels were seen to rapidly drop when tissue was 
cultured for longer than 24 hours, correlating with the histological observation that large 
portions of epithelium died within the same time period. Thereby suggesting this method was 
not suitable for culturing tissue for long periods of time. The addition of DHT was not seen to 
have any effect on either PSA or LDH levels.  
 
Histological evaluation showed increased cell death as culture time progressed, although some 
cells persisted. There was also evidence of basal cells differentiating into squamous cells in a 
manner similar to that seen after injury. An edge effect caused by the diathermy was also 
evident.  
 
Evaluation of these results resulted in the decision to culture the tissue in KGM media without 
DHT supplementation for a maximum of 24 hours.  
 
This method is used in the proceeding chapters to investigate the effect of SF on inflammatory 
markers using a targeted method, and global protein expression using an untargeted 
approach. 
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2.1 Introduction 
The establishment of a suitable tissue culture method is essential in order to investigate the 
effect of sulforaphane (SF) on prostate tissue ex vivo, so that the model replicates conditions in 
vivo as closely as possible.  
 
Previous work investigating the effect of SF on the prostate, have primarily used either in vitro 
cell line models, or in vivo models. Using an ex vivo model provides closer replication of in vivo 
conditions than in vitro models, but allows easier manipulation of the system and 
measurement of the response, than in vivo models.  
 
Although studies have reported similar experimental protocols to establish and maintain 
prostate tissue culture, to date a standard method has not been established. In previous 
reports, human prostate tissue has been obtained from patients undergoing radical 
prostatectomy. The tissue is then examined to determine its health status, or to perform 
histological and pathological evaluation (BPH, PIN and PCa detection). Tissue was transported 
to the laboratory as soon as possible after surgery in either ice cold medium 199, 
supplemented with antibiotics and glutamine [138], or DMEM, with the addition of antibiotics 
[139]. The samples were then processed within 2-4 hours [138-139]. Sections were routinely 
taken for histological analysis, and the remaining tissue prepared for culture by the removal of 
necrotic tissue.  
 
The most commonly used preparation method of prostate tissue is cutting it into 1-3mm
3
 
pieces [136, 140]. More recently, a method using precision cut slices has been developed. The 
tissue is then commonly cultured in 6- or 24- well tissue culture plates, with often multiple 
pieces in a single well. In the study performed by Nevalainen and colleagues [138],  samples 
were laid on lens paper on stainless steel grids within Petri dishes, whilst others placed the 
tissue pieces on collagen sponges in 6-well plates [136, 139].  
 
Concerning tissue culture media, different formulations have been evaluated to date. Both 
Varani and colleagues [141], and Parrish and colleagues [142], reported the use of  
Keratinocyte Growth Medium (KGM) supplemented with epidermal growth factor, insulin, 
pituitary extract (PE), hydrocortisone and antibiotics. Further to this, they experimented with 
the addition of dihydrotestosterone (DHT), CaCl2 and phorbol myristate acetate (PMA) [141]. 
Other media have been used, such as RPMI 1640 [136], medium 199 supplemented with 5% 
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fetal calf serum (FCS) [138], and DMEM with 10% fetal calf serum (FBS) and DHT [139]. Media 
were commonly changed every other day, and tissue cultured for around a week, although 
some studies cultured the tissue for longer in order to test the long term viability of their 
system [138, 141].  
 
To measure the viability of the tissue, and to evaluate the culture method used, the majority of 
studies examined the histology of the tissue at various time points during the culture period. 
Further tests performed to determine viability include measuring prostate specific antigen 
(PSA), and lactate dehydrogenase (LDH) activity.  
 
Prostate specific antigen, or kallikrein III, is a serine protease secreted by epithelial cells in the 
prostate, which is widely used as a cancer biomarker. A high level of PSA in the plasma is 
correlated with prostate carcinoma (PCa), and is used as a screening tool [143]. Prostate 
specific antigen secretion naturally increases with age, so the upper limit for the normal range 
is age-adjusted. Although widely used to detect PCa, it is common for hyperplastic conditions 
to be associated with increased PSA, whilst some cases of PCa do not manifest with a higher 
PSA level. As such this has led some to question its validity as a method for the detection of 
prostate disease. Regardless of this issue, secretion of PSA is a function of healthy prostate, so 
it is suitable for use as a method for measuring whether normal prostate homeostasis is 
maintained in culture. An ideal culture method would result in the constant secretion of PSA as 
would occur naturally in the body.  
 
Lactate dehydrogenase (LDH) is a cytoplasmic enzyme found within cells that reduces 
nicotinamide adenine dinucleotide (NAD
+
) to NADH. This reaction can be utilized in the 
conversion of a dye, resulting in a coloured compound that can be measured 
spectrophotometrically. Lactate dehydrogenase is only released from the cell when there is a 
loss of membrane integrity. Measuring LDH in the media of cells or tissue can be used as an 
indicator of cell viability in culture. The viability test is necessary in order to assess the 
effectiveness of the culture method, and for how long it may be appropriate to culture tissue 
for in such conditions [144-145].  
 
The use of the two tests in combination gives a clearer representation of the viability of the 
culture sample as PSA secretion is specific to luminal cells, whilst LDH is released by all cell 
types.  
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2.2 Materials & Methods 
2.2.1 Tissue Collection  
Tissue was obtained from Partners in Cancer Research Human Tissue Bank (Norwich, UK). 
Ethical consent for the project was received from the Essex 2 Research Ethics Committee 
(project reference 09/H0302/75). Tissue was collected by transurethral resection of the 
prostate (TURP) as part of routine clinical treatment for benign prostatic hyperplasia (BPH) at 
the Norwich and Norfolk University Hospital. Informed consent was obtained by standard 
hospital procedures to allow tissue to be used for research. Tissue was transported in saline 
solution and prepared for culture within four hours. 
 
 
2.2.2 Tissue Preparation 
Samples were prepared by removing any tissue that appeared necrotic, or had a visible 
diathermy
1
 effect, using a disposable scalpel. Tissue was cut into ~2mm
3
 pieces and six pieces 
placed in each well (Figure 2.1) with each well acting as a biological replicate. Where specified 
technical replicates are where multiple measurements are made from a single biological 
replicate (one well). 
 
 
2.2.3 Tissue Culture 
Tissue was cultured at 37
o
C in Corning® 24-well plates with 1ml media per well in a humidified 
atmosphere with 5% CO2. Culture media used were either RPMI 1640 supplemented with 50 
mg/ml penicillin/streptomycin antibiotics (Invitrogen) and 10% (v/v) fetal calf serum (FCS), or 
KGM (Lonza, Switzerland) media supplemented with the KGM BulletKit containing bovine 
pituitary extract, human epidermal growth factor, insulin, hydrocortisone and GA-1000 
(Gentamicin, Amphotericin). When required, DHT (5α-Androstan-17β-ol-3-one; Sigma-Aldrich) 
was dissolved in water and added to media at a final concentration of 0.8µg/ml.  
 
                                                          
1
 Surgical technique where electrically induced heat is used to cut tissue or seal blood vessels 
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Figure 2.1. Tissue sample preparation.  
(a) Tissue in saline solution as obtained from the tissue bank, (b) An unprocessed TURP chip, 
(c) With necrotic tissue removed, (d) ~2mm
3
 piece of tissue prepared for culture. 
 
 
2.2.4 Sample collection and storage 
Media were collected in aliquots, immediately frozen in dry ice and stored at -80
o
C prior to 
analysis. Tissue for histological evaluation was placed in Accustain® Formalin Solution 10% 
Neutral Buffered (Sigma-Aldrich) for 24 hours and then transferred to 70% ethanol, both at 
4
o
C. Samples were then transferred to the Cotman Centre (Norfolk & Norwich University 
Hospital, UK) for paraffin wax-embedding and sectioning using standard methods. Sections 
from each block were stained with haematoxylin and eosin (H&E).  
 
 
2.2.5 LDH Assay 
The LDH concentration of the tissue culture media was quantified using the In Vitro Toxicology 
Assay Kit Lactate Dehydrogenase Based (Sigma-Aldrich). The method was adapted from the 
provided protocol to ensure its suitability for tissue culture. Briefly, a 100µl sample of the 
media was incubated with 200µl LDH Assay Mixture in a 96-well plate for 30 minutes at room 
temperature in the dark. The reaction was terminated by adding 30µl HCl 1N to each well. 
Absorbance was measured at 490nm, and background absorbance measured at 690nm, using 
a b 
c d 
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the Benchmark Plus Microplate Spectrophotometer (Bio-Rad). Duplicate readings were 
performed for each sample. 
 
 
2.2.6 PSA Assay 
PSA concentration was measured using an enzyme-linked immunosorbent assay (ELISA) (R&D 
Systems). ELISA was performed as per protocol (see Figure 2.2), duplicate wells performed for 
all standards and samples. Antibodies (Ab) provided in kit: capture Ab, mouse anti-human PSA; 
detection Ab, biotinylated goat anti-human PSA. Absorbance at 450nm with wavelength 
correction set at 540nm was measured using the Benchmark Plus Microplate 
Spectrophotometer (Bio-Rad). Microplate Manager 5.2.1. (Bio-Rad) was used to reduce the 
data from the standards to generate a four parameter logistic (4-PL) graph, and sample 
concentrations calculated from the curve. 
 
 
2.2.7 Histological evaluation 
Histological evaluation of tissue sections with H&E staining was performed under the guidance 
of Professor Richard Ball, Consultant Histopathologist at the Cotman Centre (Norfolk and 
Norwich University Hospital, UK). Slides were assessed for any changes in architecture, 
cytological characteristics and viability over the time period studied. Slides were viewed using 
an Olympus BX60 microscope with Brightfield illumination, and representative images were 
taken using the attached Olympus U-TV1X camera controlled by ProgRes Capture 2.1.0. 
software (JENOPTIK Laser, Optik, Systeme GmbH, Germany). 
 
 
2.2.8 Statistics 
Statistical analysis performed in Minitab 15 (LEAD Technologies, Ltd). Student’s paired t-test 
performed to compare treatments at each time point (see Figures 2.3 and 2.4). 
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Figure 2.2. PSA Assay Protocol.  
Diagram to show the ELISA method for detection of PSA in media using the Human Kallikrein 
3/PSA DuoSet (R&D Systems). Adapted from the provided datasheet. 
Coat a 96-well plate overnight with capture antibody.
Aspirate and wash four times.
Block with reagent diluent for 1 hour.
Aspirate and wash four times.
Prepare all reagents and standards as directed.
Add 100µl sample media or standard per well. 
Cover and incubate for 1 hour.
Aspirate and wash four times.
Add 100µl detection antibody.
Cover and incubate for 2 hours.
Aspirate and wash four times.
Add 100µl Streptavidin-HRP.
Cover and incubate for 20 minutes out of direct light.
Aspirate and wash four times.
Add 100µl Substrate Solution
Add 50µl stop solution.
Read at 450nm within 30 minutes. λ correction 540nm.
Plate 
Preparation 
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2.3 Results  
2.3.1 Comparison of the effect of culture media on BPH tissue viability 
Initially, a suitable culture medium to develop a method for the BPH tissue culture was 
evaluated. Previous studies have used a range of media [136, 138-139, 141-142] and two of 
the most commonly used were selected, RPMI and KGM. To determine the effect of both 
media on the tissue, two markers were measured: LDH, which is secreted from cells when a 
loss of membrane integrity occurs and represents a measure of cell viability, and PSA, which is 
specifically secreted by normal epithelial cells and can therefore be used to determine their 
health.  
 
In both culture media, LDH secretion was at its highest on day one, with both peaking at an 
absorbance of 3.75, after which it started to decline. LDH secretion in the KGM media 
decreased steadily, until on day five the secretion was 25% of the starting value. LDH secretion 
in RPMI media also reduced by 75% over the five day period, but initially declined dramatically 
reaching this level by day three, at which point it reached a plateau. Statistical analysis showed 
there to be no significant difference between the LDH levels in the two media for all days, 
except day three (p-value = 0.024). On this day, the level of LDH in the RPMI was lower than 
that in KGM (Figure 2.3a).  
 
At day one, PSA was present in both media, but rapidly reduced until on day four and five 
there was no detectable PSA. PSA secretion in KGM reduced at a marginally lower rate than in 
RPMI, and at day three was still measurable, whilst the PSA concentration in RPMI was, in all 
but one replicate, undetectable. The only significant difference between the two media was on 
day three when PSA secretion in KGM media was on average 10.8ng/ml compared to 1.7ng/ml 
in RPMI (p-value = 0.009) (Figure 2.3b). 
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Figure 2.3. Comparison of the effect of media on BPH tissue ex vivo. 
BPH tissue from a single patient was cultured in either KGM or RPMI media for five days at 
37
o
C with four biological replicates of each condition. Media were collected and replaced daily. 
(a) LDH and (b) PSA secretion were measured. Means ± standard deviation are plotted. There 
was no significant difference (p-values >0.05) between either LDH or PSA secretion in the two 
media except at day three (*p-values ≤0.03, Student’s paired t-test). 
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2.3.2 Determining the effect of DHT on BPH tissue viability 
In previous studies, addition of DHT to the culture medium had a positive effect on BPH tissue 
in culture [139, 141]. In this study, the effect of DHT on tissue viability was also determined.  
 
On day one, LDH secretion both with and without DHT supplementation was at similar levels. 
Over the five days, both treatments were associated with a reduction in LDH secretion. 
However, during this time the LDH levels stayed higher only in the tissue samples cultured with 
DHT supplementation, although not reaching statistical significance. In the samples with no 
DHT supplementation, LDH secretion reduced by 70% from day one to day two, and then 
another 26% from day two to day five. LDH secretion in the samples with DHT 
supplementation reduced at a steadier rate, with daily reductions of 35, 21, 24 and 8% over 
the five days (Figure 2.4a). 
 
The concentrations of PSA both with and without DHT supplementation were at comparable 
levels, although the DHT supplemented samples had a higher starting concentration, but not 
significantly so. The DHT supplemented samples had almost undetectable levels of PSA by day 
five, but those without DHT still secreted an average of 20ng/ml on day five (Figure 2.4b). 
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Figure 2.4. Determining the effect of DHT on BPH tissue ex vivo. 
BPH tissue from three patients with three biological replicates for each condition was cultured 
with or without DHT for five days at 37
o
C. Media were collected and replaced daily. (a) LDH 
and (b) PSA secretion were measured. Means ± standard deviation are plotted. The only 
significant difference (*p-value ≤0.05) was seen on day one when PSA secretion was 
significantly higher in the presence of DHT. 
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2.3.3 Histological structure of BPH tissue  
To further study the effect of culture on the BPH tissue, pieces were fixed, wax-embedded, 
sectioned, and stained with H&E for histological assessment. The normal structure of prostate 
tissue is made up of fibro-muscular stroma punctuated with glands and ducts. The glandular 
epithelium consists of a base layer of basal cells upon which sit luminal (or epithelial) secretory 
cells (Figure 2.5). 
 
 
 
 
 
Figure 2.5. Normal prostate structure.  
Images from H&E stained prostate tissue showing the normal structure of the prostate. (a) The 
normal structure of glands and stroma (x10 magnification), (b) the structure of the glandular 
epithelium (x40 magnification). 
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2.3.3.1 Histological assessment of tissue in culture for up to five days 
BPH tissue samples cultured for up to five days were fixed and wax-embedded prior to H&E 
staining for histological evaluation. Unprocessed tissue was examined and good gland 
architecture was observed (Figure 2.6). However, the effect of diathermy due to cauterisation 
during the TURP procedure was clearly noted (Figure 2.6). The diathermy edge effect resulted 
in a band of either dead and/or distorted cells resulting in a smudgy nuclear appearance at the 
periphery of the section (Figure 2.6a + c).  
 
Tissue that had been prepared for culture was fixed at time zero to act as a control for the 
effect of culture. Examination of this tissue showed that removal of visibly necrotic or 
cauterised tissue had removed tissue affected by diathermy (Figure 2.7). At time zero, the 
tissue looked viable.  
 
On day one, reduced staining of nuclei was seen, indicating reduced cell number, thereby 
suggesting extensive cell death, although some epithelial cells were surviving.  
 
On day two, there was further cell death, but some surviving areas with enlarged nuclei, 
suggesting proliferation (Figure 2.8a). Also observed, was the presence of dead cells (pink 
cytoplasm with very dark condensed nuclei) in the middle of a gland similar to that observed in 
comedocarcinoma
2
 (Figure 2.8a), so this observation may be inherent to the tissue sample as 
opposed to an effect of culture.  
 
Further cell death with some surviving areas and enlarged nuclei, as seen on day two, were 
also observed on day three.  
 
On day four, in some sections of surviving epithelium, the basal cells had elongated with 
enlarged nuclei, suggesting they had started to differentiate into squamous cells, a process 
known as squamous metaplasia, with visible intercellular bridges (Figure 2.8b), making them 
more resilient. When cells become squamous, they form tight junctions, and upon fixing, the 
cells shrink, causing the appearance of ‘hairs’, or intercellular bridges, between the cells where 
the membranes are being pulled.  
 
                                                          
2
 A malignant intraductal neoplasm of the breast in which the central cells degenerate 
Tissue Culture Method Development 
 
54 
 
By day five, squamous differentiation was more apparent, but viability had further decreased. 
Examination of the tissue showed random sample piece specific death, with some sections 
surviving better than others. It was also clear that as time progressed, tissue viability 
decreased, although a small percentage of cells persisted, and started to adapt to the culture 
conditions. There was also evidence of the presence of inflammatory cells in the stroma 
(Figure 2.8c).  
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Figure 2.6. Diathermy edge effect.  
BPH tissue removed by TURP is performed using cauterisation which causes a diathermy edge 
effect. Abnormal features were identified and examples shown here. (a) On the right side of 
the tissue the cauterised edge is visible, and the band of cells close to this edge are dead or 
dying, whilst those cells further away from the edge display normal morphology (dotted line 
indicates the approximate boundary of the diathermy edge effect), (b) the diathermy edge 
effect with loss of normal glandular epithelium (indicated by arrow; magnified section of image 
(a) lower right edge), (c) smudgy nuclei (examples indicated by arrows) as a result of 
diathermy, (d) further away from the cauterised edge normal tissue morphology is maintained 
(magnified centre section of image (a)). Magnification: (a) x4, (b) x10, (c) and (d) x20. 
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Figure 2.7. BPH tissue in culture for 5 days.  
BPH tissue was cultured for up to 5 days, samples fixed and wax-embedded, sectioned, and 
stained with H&E. Samples assessed for histological changes. Experiment was performed with 
tissue from two samples and representative images from one sample shown here. x10/20 
magnification as specified.  
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Figure 2.8. Abnormal histological features in prostate tissue.  
(a) Cells with enlarged nuclei and central dead cells reminiscent of comedocarcinoma, (b) an 
intercellular bridge between cells in an area of squamous metaplasia (inset: close-up of the 
intercellular bridge), (c) lymphocytes infiltrating the stroma, (d) enlarged gland exhibiting cystic 
atrophy of luminal cells. All images x40 magnification.  
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2.3.3.2 24 Hours 
Fixed and embedded tissue cultured for various times up to 24 hours was stained with H&E 
(Figure 2.9). Tissue at time zero was fixed to act as a control for the effect of culture.  
 
The experiment was performed with two individual tissue samples, but upon histological 
examination one was diagnosed as high-grade cancer (image not shown) so the effect of 
culture was assessed using a single BPH sample.  
 
At time 0, prior to culture, it was clear to see enlarged glands, a hallmark of BPH, exhibiting 
cystic atrophy, where the luminal cells had increased in number but decreased in size (Figure 
2.8d). At 2 and 6 hours, good preservation was seen but at 9 hours the tissue was looking less 
viable, with the viability decreasing further at 18 hours. By 24 hours, although some sections 
remained viable, there was a great loss in viability.  
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Figure 2.9. BPH tissue in culture for 24 hours.  
BPH tissue was cultured for up to 24 hours, samples fixed and wax-embedded, sectioned, and 
stained with H&E. Samples were then assessed for histological changes. Experiment was 
performed with tissue from two samples and example images from one sample are shown as 
the other was identified as high-grade cancer upon histological examination. Images shown of 
x10/20 magnification. 
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2.4 Discussion 
To investigate the effect of SF on BPH tissue, an ex vivo method of tissue culture has been 
optimised to replicate conditions in vivo.  A review of previous methods used resulted in the 
decision to test two different media, and to assess the effect of DHT supplementation. To 
investigate the effects of the different culture conditions, both tissue viability and functionality 
were measured by LDH and PSA secretion, respectively. Additionally, data obtained have been 
confirmed by histological evaluation.   
 
 
2.4.1 Tissue Viability 
To determine the effect of different culture conditions on the tissue, the accumulation of LDH 
in the media was measured (Figure 2.3a). LDH is released from cells only when there is a loss 
of membrane integrity, or the cell membrane is in some way injured allowing its release. As 
such, LDH levels in the media can be used as a measure of cell viability.  
 
In all samples tested, LDH secretion was highest within the first 24 hours. During this period, 
the high release of LDH may largely be attributed to the collection and the processing of the 
tissue. Removal of the tissue from the body, cauterisation of the sample and storage in saline 
solution, can all induce stress in the tissue triggering cell death. Furthermore, during 
preparation of the tissue, cutting the sample with a scalpel may physically break open a 
number of cells allowing the release of LDH. As a result, when the tissue is first placed in the 
culture dish, due to these external factors, a high number of cells may release LDH into the 
media immediately, leading to the high reading on day one. Another contributing factor to the 
high LDH concentration on day one may be cell death due to the culture process itself, as cells 
need time to adjust to the new environment.  
 
During the rest of the culture period, LDH secretion steadily declined (media was collected and 
replenished daily so there is no cumulative effect), suggesting three possible explanations: 1) 
cells are adjusting to the culture medium and therefore fewer are dying; 2) cells surviving after 
the first day are less sensitive to the ex vivo conditions; and 3) previous cell death reduces the 
number of cells in culture, and low LDH secretion is not related to better growth conditions 
preventing cell death, but to the decreasing number of cells (eg. if 10% of all the cells die each 
day the actual number of cells within that 10% would get smaller: Day 1: 10% of 1000 = 100 die 
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so 900 left, Day 2: 10% of 900 = 90 die etc resulting in the appearance that 10% less cells died 
on day two than day one, so a reduction in LDH secretion is seen).  
 
From histological evaluation of the tissue (Figure 2.7) it was apparent to see that there was a 
significant loss of viability within the first 24 hours. Over the remaining culture period, further 
cell death was apparent but the differences in viability between the time points reduced, 
correlating with LDH secretion which was detected at all time points, but at reducing 
concentrations as time progressed.  
 
From examination of the tissue, it appears there are three zones or sets of cells: those that 
died due to diathermy (Figure 2.6), those that died within the first 24 hours, and those that are 
still persisting and surviving. Due to the first massive loss as a result of diathermy, it is essential 
to ensure all affected tissue is removed prior to culture.  
 
In the tissue there was also evidence of karyolysis
3
, evidenced by nuclei fading away, which 
occurs mainly as a result of necrosis, not apoptosis. However, in some areas there was 
evidence of apoptosis, suggesting that some cells were able to carry on normal cellular 
processes during culture.  
 
It must also be taken into account that there is variability within tissue samples obtained from 
a single patient. For example, within a single TURP sample there is both glandular and 
muscular stromal tissue. Although the assignment of tissue pieces to each culture well is as 
random as possible, it may be that the different wells have different proportions of tissue type, 
making it difficult to compare fairly between all days.  
 
With regards to the effect of diathermy, this is an effect of the TURP collection procedure, and 
does not occur as a result of radical prostatectomy, so using tissue collected using an 
alternative method may eliminate this issue. However, collection of prostate tissue by radical 
prostatectomy is a longer procedure compared to TURP, which is very rapid. This may result in 
alternative issues, such as reduced viability, which may arise as a result of the different 
collection procedure, as each collection procedure may have its own unique inherent 
associated issues. Furthermore, radical prostatectomy is often carried out as treatment for 
                                                          
3
 Complete dissolution of the chromatin matter of a dying cell 
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PCa, so by its very nature the tissue will behave differently due to its disease state, and 
therefore could not be used to answer questions regarding BPH.  
 
 
2.4.2 Tissue Function 
PSA is secreted from luminal cells in the prostatic epithelium, and in previous research these 
cells have been observed to be lost during tissue culture [138-139, 141].Therefore, PSA was 
measured to assess the presence of these cells in the culture and the maintenance of normal 
prostate architecture.  
 
At day one, PSA is present in all samples but then rapidly reduces to negligible levels (Figure 
2.3b). The loss of PSA secretion suggests that these cells have either been lost or have stopped 
producing PSA. Histological evaluation showed luminal cell death, suggesting that the 
reduction in PSA was due to loss of these cells, and not to their compromised functional 
activity (Figure 2.7).  
 
The initial death of the luminal cells correlates with observations of other studies [138-139, 
141], including Nevalainen and colleagues, who also observed a considerable loss of secretory 
epithelium during the first few days, followed by adjustment to the culture conditions. In their 
study, Nevalainen and colleagues maintained the tissue culture for up to fourteen days, 
although seven days culture was sufficient for their experimental protocol [138]. However, in 
the study performed here, the tissue was cultured for a short period and significant tissue 
adaptation was not observed during this time.  Results obtained suggest that this experimental 
protocol may not be suitable for use as a long-term ex vivo model of prostate tissue as a major 
cell type was rapidly lost during the culture period.  
 
At the same time as the death of luminal cells was witnessed, there were still small sections of 
tissue surviving, primarily composed of basal cells [141], that had started to adapt to the 
environment and undergo squamous metaplasia (Figure 2.9b), also observed by others [138-
139]. Squamous metaplasia refers to reversible benign changes to epithelium in which cells 
start to take on a more squamous appearance becoming larger and flatter. It often occurs as a 
result of stress to the tissue such as that cause of injury or infection [146] ,so it may be that 
this metaplasia was triggered either by injury during TURP or as a result of stress during 
culture. In this tissue, the luminal cells die, but there is a selective advantage for the underlying 
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basal cells which are tougher, and adapt to the environment by undergoing squamous 
metaplasia.  
 
It has long been thought that the PCa originates from the luminal cells in the prostatic 
epithelium, as the disease is characterised by luminal cell expansion and loss of basal cells 
[147].  More recently, research has reported that different factors may be involved in this 
process. It has been shown that over expression of Akt and ets related gene (ERG), two 
oncogenes commonly upregulated in PCa, in basal and luminal cells results in the development 
of abnormal structures resembling PIN in the basal cells only. Furthermore, additional 
overexpression of AR resulted in progression to cancer [148]. It is therefore interesting that the 
cells from which PCa can arise, are the ones that can adapt to the culture conditions. However, 
it must be noted that evidence contrarily suggests PCa can arise from other cell types.  
 
Although the role of luminal cells in the prostate is clear, producing and secreting growth 
factors and enzymes, the function of basal cells is less well understood. However, it has been 
suggested that they are essential for maintaining ductal integrity and ensuring correct 
differentiation of luminal cells [149]. Research has also shown that the majority of proliferation 
that occurs in the normal adult prostate is in the basal layer, which may contribute to these 
cells surviving longer than luminal cells [150-151].  This may suggest that basal cells are more 
tolerant and more responsive to change than any other cell type in the prostatic epithelium, 
explaining the reason for their ability to survive and adapt in response to the new conditions in 
ex vivo models. 
 
 
2.4.3 DHT Supplementation 
Dihydrotestosterone (DHT) is the more potent form of testosterone, and is essential in normal 
function of the prostate. Previous studies suggested it was necessary in culture to maintain 
normal tissue function and architecture. Following results obtained in previous studies [139, 
141], the effect of the addition of DHT to the culture medium was investigated. In this study, 
DHT supplementation was seen to have no significant effect on either tissue viability or PSA 
secretion, suggesting that in the culture method used it was not able to influence the 
behaviour of the tissue (Figure 2.4).  
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Nevalainen and colleagues reported that DHT prevented metaplastic changes, such as 
squamous metaplasia, and maintained the luminal cells [138].  Our results suggest that DHT 
did not have a positive effect on the luminal cells viability or function, or viability of the tissue 
in general, as both PSA and LDH secretion were not significantly altered by DHT 
supplementation (Figure 2.4). It must be noted though, that Nevalainen and colleagues were 
using tissue collected by radical prostatectomy, which may behave differently in culture.  
 
Nevalainen and colleagues also noted an increase in immunohistochemical staining for PSA in 
the tissue cultured with DHT, but we found no difference in PSA secretion between tissue 
cultured with or without DHT. Varani and colleagues suggested that without the addition of 
DHT squamous differentiation was more apparent [141], and in another study DHT was found 
to maintain the luminal cell layer [139].  
 
Histological examination of DHT treated tissue was not performed in our study, but from our 
data it is clear that the DHT supplementation had no effect on PSA or LDH secretion in the 
culture media. Histological examination of these samples may have been beneficial, as it would 
allow us to confirm whether DHT offered any protective effect on the architecture of the 
tissue. However, the significant reduction of PSA over time observed in the samples 
supplemented with DHT, was in line with that observed in tissue minus DHT. Thus suggesting 
that in this study DHT had no protective effect on luminal cell functionality as has been 
reported by others [138-140]. Furthermore, as no effect was seen on LDH concentration with 
DHT, this suggests that, in this study, DHT did not have a positive effect on the viability of the 
tissue in culture. 
 
 
2.4.4 Conclusions 
Considering data obtained from culturing the prostate tissue with either KGM or RPMI 
medium, supplemented or not with DHT, it was decided to use KGM medium. KGM medium 
was selected as our method presented some similarities with the study carried out by Varani 
and colleagues in which they successfully cultured tissue in this medium [140]. As DHT 
supplementation showed no significant effect it appears unnecessary to include it, and all 
further experiments were performed without DHT. Furthermore, it is obvious that the tissue 
rapidly loses viability, and the majority of epithelial cells are lost after 24 hours. For this 
Tissue Culture Method Development 
 
65 
 
reason, any results obtained after 24 hours culture will not be considered to be a realistic 
comparison for the behaviour of BPH in vivo.  
 
The method developed here will be implemented in the next two chapters to investigate the 
effect of SF on protein expression. Two approaches will be used: a targeted method to 
measure inflammatory cytokines, and a non-targeted approach to assess global protein 
expression. 
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Chapter 3. Benign Prostatic Hyperplasia & Inflammation 
3.0.1 Summary 
Following successful determination of ex vivo culture conditions for prostate tissue, the effect 
of SF on inflammatory markers was investigated. The majority of benign prostatic hyperplasia 
(BPH) specimens contain inflammatory infiltrates, and the levels of a number of pro- and anti-
inflammatory cytokines have been noted as altered in BPH compared to normal prostate 
tissue. Previous work has suggested a protective role for sulforaphane (SF) in the prostate, 
whilst recent evidence has suggested that SF can reduce inflammation. The use of the ex vivo 
model will replicate more closely the in vivo environment than the use of a cell line, but still 
allows targeted treatment with SF, and direct measurement of the response.  
 
This chapter reports the concentration of selected inflammatory cytokines secreted from BPH 
tissue ex vivo, and the effect of SF on these levels. Cytokines IL-4, IL-6, IL-8, IL-17, IFN-y and 
FGF-2 were all measured by ELISA, but IL-4, IL-17 and IFN-y were not detected. IL-6 and IL-8 
were shown to be secreted at similar levels, but FGF-2 was four-fold lower. 25µM SF 
significantly reduced both basal levels of IL-6 and IL-8 secretion, but had no effect on FGF-2. A 
dose-dependent effect of SF on IL-6 secretion was observed, with a concentration as low as 
10µM having a significant effect.  
 
These results support the hypothesis that SF has anti-inflammatory properties, and suggest 
that SF may be beneficial to those suffering from BPH by reducing inflammation in the 
prostate.  
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3.1 Introduction 
The majority of BPH specimens contain inflammatory infiltrates and display altered expression 
of a wide range of cytokines [18, 20-22]. Cytokines are a large group of signalling molecules 
that are involved in cell communication, and are often modulated during inflammation [152]. 
They can be categorised as either pro- or anti-inflammatory, but due to their pleiotropic 
nature, many can function as both, depending on circumstance, making classification difficult. 
Included amongst the cytokines that have been observed to be altered in BPH are interleukins 
(IL) -4, -6, -8, & -17, as well as interferon-γ  (IFN-γ), and fibroblast growth factor 2 (FGF-2) [10]. 
In particular IL-6 has been demonstrated to be important in prostate pathogenesis, and has 
been implicated in PCa progression through activation of androgen receptor (AR) [153-156]. 
More recently, it has been shown that in benign prostate epithelial cells, IL-6 can induce 
tumorigenic conversion and further progression to an invasive phenotype [157].  
 
Previously, consumption of broccoli was reported to reduce symptoms associated with BPH 
and alter inflammatory pathways within the prostate [95]. This may be due to sulforaphane 
(SF), the main bioactive compound derived from broccoli. Sulforaphane is suggested to have 
anti-inflammatory activity, and research has shown that SF can reduce the levels of pro-
inflammatory cytokines, including IL-6 [103, 158-159] and IL-8 [111].  
 
To investigate the effect of SF in an ex vivo model, SF is added to the culture media, and 
therefore is directly applied to the tissue. However, in vivo the route for SF to the prostate is  
much more indirect, as broccoli has to first be consumed, glucoraphanin converted to SF, SF 
absorbed and conjugated with glutathione, before circulation in the plasma. Therefore, 
consumption of broccoli does not necessarily guarantee that SF will reach the prostate in vivo, 
whilst ex vivo and in vitro experiments directly add a known concentration of SF.  
 
Biological relevance is of huge importance when investigating the role of dietary agents in 
human health. To know whether the concentrations of SF being used are of any relevance, it is 
crucial to know whether, and at what concentration, SF reaches the prostate after broccoli 
consumption. Indirect evidence that SF reaches the prostate after broccoli consumption is 
provided in a human study by Traka and colleagues [95]. They reported that consumption of 
broccoli altered signalling pathways in the prostate, indicating that SF did reach the prostate, 
eliciting an effect. Evidence that the alteration in signalling arises from SF is provided by a 
further study by Traka and colleagues [160]. In this study, mice were fed a diet supplemented 
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with SF, which resulted in changes in prostate gene expression similar to that seen in humans 
on a broccoli-rich diet. This suggests that the consumption of broccoli can alter gene 
expression in the prostate due to its SF content.  
 
Analysis of plasma SF levels after consumption of high-glucosinolate broccoli has shown SF in 
the circulation at concentrations of up to 7.4µM ± 3.08 at 2 hours after consumption. After 
this, the level of SF rapidly drops and only trace concentrations are detectable at 24 hours 
[100], providing direct evidence that broccoli consumption results in an increase in SF in the 
circulation. A pilot study with eight participants reported the presence of SF metabolites in 
breast tissue 50 minutes after consumption of a single dose of broccoli sprouts, with a 
maximum concentration of 2 pmol/mg tissue ± 1.95 [161]. This observation indicates that SF 
reaches tissue rapidly after consumption, leading to the hypothesis that if it is detectable in 
breast tissue it is likely to be detectable in other tissues, including the prostate.  
 
All this data combined provides evidence that the consumption of broccoli results in an 
increase in circulating SF, and that it is likely to reach the prostate at a concentration at which 
it can modulate gene expression influencing prostate health.  
 
Taking into consideration the prevalence of inflammatory cytokines in BPH tissue, the 
proposed role for inflammation in prostate pathogenesis, and the evidence suggesting a 
protective role for sulforaphane in prostate health, the hypothesis that SF can reduce the 
secretion of inflammatory cytokines from BPH tissue in culture is tested. 
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3.2 Methods 
3.2.1 Tissue Collection and Preparation 
Tissue was collected and prepared for culture as described in Chapter 2.1.1-2. 
 
 
3.2.2 Tissue Culture  
Tissue was cultured in KGM media as previously described in Chapter 2.2.3. Sulforaphane (SF; 
LKT Laboratories) diluted in dimethyl sulfoxide (DMSO; Sigma) to 100mM and subsequently 
diluted to 1mM in 10% PBS (Invitrogen). Sulforaphane added to media at final concentration of 
2, 5, 10 or 25µM. Final DMSO concentration <0.025%, final PBS concentration <0.25%. Control 
samples supplemented with DMSO and PBS to a final concentration of 0.025 and 0.25% 
respectively. 
 
 
3.2.3 Sample collection and storage 
Media were collected in aliquots, and tissue collected in pairs and washed in 10% PBS, 
immediately frozen in dry ice and stored at -80
o
C prior to analysis.  
 
 
3.2.4 ELISA 
Media collected from tissue culture were analysed for inflammatory markers using 
commercially available Quantikine ELISA (R&D Systems) for IL-4, IL-6, IL-8, IL-17, FGF-2, and 
IFN-γ. Limit of detection was 10, 0.70, 1.5-7.5 (mean 3.5), 15, 3 and 8 pg/ml respectively.  ELISA 
performed according to kit instructions (see Figure 3.1). Media was diluted 1:100 prior to 
measuring IL-6. Absorbance was measured at 450nm with wavelength correction set at 540nm 
using the Benchmark Plus Microplate Spectrophotometer (Bio-Rad). Microplate Manager 
5.2.1. (Biorad) was used to reduce the data from the standards to generate a four parameter 
logistic (4-PL) graph and sample concentrations calculated from the curve. 
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Figure 3.1. Quantikine ELISA Protocol.  
Taken from kit protocol provided by R&D Systems, same protocol used for all ELISAs but with 
the following changes: *50µl for IL-4 and IL-8 ELISA, **100µl for the IL-8 ELISA. 
Prepare all reagents, standards and samples as directed.
Add 100µl Assay Diluent to each well. 
Add 100µl* standard, control, or sample to each well. 
Cover and incubate for 2 hours.
Aspirate and wash four times.
Add 200µl** Conjugate to each well.
Cover and incubate for 2 hours.
Aspirate and wash four times.
Add 200µl Substrate Solution to each well.
Cover and incubate for 30 minutes out of direct light.
Add 50µl stop solution.
Read at 450nm within 30 minutes. λ correction 540nm.
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3.2.5 Statistics 
Statistical analysis performed in Minitab 15 (LEAD Technologies, Ltd) and R as necessary. 
Analysis in R was performed by Dr Jack Dainty. Minitab was used to perform Student’s paired 
t-tests to compare treatment at each time point (see Figure 3.3). Data for the dose-dependent 
effect of SF on IL-6 (Figure 3.4) was normalised to minimise between patient variation, and 
then transformed to ensure normal distribution of residuals. Data was analysed in R using 
repeated measures ANOVA, with subsequent Dunnett’s post hoc tests for pair-wise 
comparison. 
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3.3 Results 
3.3.1 Inflammatory cytokines in BPH tissue  
The majority of BPH specimens contain inflammatory infiltrates, suggesting that inflammation 
plays a key role in the aetiology of the disease. A number of inflammatory cytokines have been 
observed as elevated in BPH tissue, so selected cytokines were analysed as a measure of 
inflammation in the tissue. The cytokines measured were IL-4, IL-6, IL-8, IL-17, FGF-2 and IFN-γ. 
Media from tissue samples incubated for 24 hours were analysed by ELISA to detect cytokine 
level. IL-4, IL-17 and IFN-γ were not detectable in the sample media, so if they were present in 
the media it was at levels below the detection limit of the ELISA. Both IL-6 and IL-8 were found 
to have an average concentration of 4ng/ml, which was approximately four times higher than 
FGF-2, which had an average concentration of 1ng/ml (Figure 3.2).   
 
 
 
 
Figure 3.2. Basal Levels of Inflammatory cytokines in BPH tissue. 
BPH tissue samples from three patients with three biological replicates were cultured for 24 
hours at 37
o
C. Media was collected and inflammatory marker levels measured by ELISA. Means 
plotted ± standard deviation. IL-4, IL-17 and IFN-γ were all assayed but not detected in any 
samples (data not shown). IL-6 and IL-8 levels were highly similar, but FGF-2 levels were 4-fold 
lower. 
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3.3.2 Modulation of inflammatory cytokines by sulforaphane 
Sulforaphane has been demonstrated to have anti-inflammatory properties, so whether SF 
could reduce the secretion of inflammatory markers from BPH tissue ex vivo was investigated. 
Tissue was cultured with 25µM SF for three days, with media collected and replenished daily. 
Media samples from each day were analysed by ELISA. An initial concentration of 25µM SF was 
investigated as this corresponds to concentrations often used in the literature [117, 132-133, 
135, 162], and this high concentration of SF would most likely make any effect more visible as 
this ex vivo model is more complex than the in vitro models most commonly used.  
 
Over the three day period IL-6 secretion declined, starting at 4.03ng/ml, reducing by 32% in 
the next 24 hours to 2.76ng/ml, and by day three had reduced to 0.82ng/ml, a reduction of 
80% compared to day one. In a similar pattern to the control samples, IL-6 secretion in the 
treated samples also declined over the three days, reducing 89% from day one to day two, and 
by day three secretion had decreased 98% compared to day one. On day one, IL-6 in the 
samples treated with 25µM SF was 40% lower than the control (p-value = 0.089). However by 
day two, SF had almost abolished IL-6 secretion from BPH tissue, and compared to the control 
samples, IL-6 secretion was significantly reduced on both day two and three (p-values ≤0.001) 
(Figure 3.3a). 
 
In contrast, IL-8 secretion remained fairly stable throughout the three day culture period in 
both the control and treated samples. In the control samples, IL-8 secretion was measured at 
4.07ng/ml on day one, increasing slightly on day two to 4.35ng/ml, and ending on 4.10ng/ml 
on day three. In the samples cultured with 25µM SF, IL-8 secretion was significantly reduced 
on all three days, with levels decreased by 75, 90 and 85% on days one, two and three 
respectively (p-values ≤0.001) (Figure 3.3b). 
 
In a similar pattern to IL-6, FGF-2 secretion reduced over the time period measured. In contrast 
to both IL-6 and IL-8, the initial concentration of FGF-2 was four times lower at 1.03ng/ml in 
the control samples. This reduced by 48% to 0.50ng/ml on day two, dropping to 0.23ng/ml on 
day three, a total reduction of 78% compared to day one. Sulforaphane reduced FGF-2 
secretion by 20, 55 and 43% on the three days respectively compared to the levels in the 
control samples, but this was not statistically significant (Figure 3.3c). 
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Figure 3.3. The effect of 25µM SF on inflammatory cytokines in BPH tissue. 
BPH tissue samples from three patients were cultured for three days with three biological 
replicates with or without 25µM SF. Media was removed and replenished daily. Media samples 
from each day were assayed using ELISA for (a) IL-6, (b) IL-8 and (c) FGF-2. Means ± standard 
deviation are plotted. IL-6 was significantly reduced by 25µM SF on days two and three, IL-8 
was significantly reduced on all three days (**p-values ≤0.001) but FGF-2 was not significantly 
altered at any point.  
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3.3.3 Dose-dependent effect of SF on IL-6 secretion  
As it was seen that 25µM SF was able to reduce the secretion of inflammatory cytokines, the 
dose-dependent effect of SF on IL-6 secretion was investigated.  
 
Notably, the average IL-6 secretion concentration without SF varied from sample to sample, 
with a range of values from 5907pg/ml to 45776pg/ml. Therefore, data were normalised to 
0µM SF for each sample to allow clearer comparison between all patients with regard to 
reduction for each treatment. Data was then transformed to ensure normal distribution of the 
residuals. Repeated measures ANOVA revealed treatment to be highly significant (p-value 
<0.001). Post hoc Dunnett’s tests showed that both the 10µM (p-value = 0.0086) and the 25µM 
(p-value <0.001) treatments had a significant effect on the level of IL-6 secreted compared to 
the control tissue. 10 and 25µM SF reduced the levels of IL-6 by 40% and 75% respectively. The 
2µM and the 5µM treatments resulted in non-significant p-values of 0.366 and 0.756, with 
reductions of 25 and 13% respectively (Figure 3.4).  
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Figure 3.4. Dose-dependent effect of SF on IL-6 secretion from BPH tissue.  
BPH tissue samples from five patients with biological triplicates each were cultured with 0, 2, 
5, 10 or 25µM SF for 24 hours. Media was collected and assayed for IL-6 using ELISA. Results 
normalised to 0µM SF for each sample to allow for variations in baseline IL-6 secretion. 
Medians (line in box) plotted along with 25
th
 and 75
th
 percentiles (box), 10
th
 and 90
th
 
percentiles (whiskers), and outliers (black circles). Compared to control, no significant effect 
was observed in the 2 or 5µM SF treatments but 10 and 25µM both significantly reduced IL-6 
secretion. N.S. = non-significant.  
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3.4 Discussion 
3.4.1 Inflammatory markers in BPH tissue 
As it has previously been shown that BPH samples express altered levels of cytokines, a range 
of cytokines that had previously been reported to be expressed and altered in BPH were 
selected for analysis (Figure 3.2) [163-165]. Of the six cytokines selected and assayed in the 
media, three could not be measured: IL-4, IL-17 and IFN-γ, despite being previously measured 
in BPH. This may either be because they were not present in the media sample, or they were 
below the limit of detection of the ELISA.  
 
It is interesting to note that the limit of detection of the ELISAs for these three cytokines were 
higher than those for the cytokines that were successfully measured. The lower limit of 
detection for the IL-4, IL-17 and IFN-γ ELISAs were 10, 15 and 8 pg/ml respectively, compared 
to 0.7, 3.5 and 3pg/ml for IL-6, IL-8 and FGF-2. However, if these cytokines were not 
measurable as they were below the limit of detection of the ELISA, then their levels would still 
be far smaller than those detected for IL-6, IL-8 and FGF-2, which were recorded as 4000 pg/ml 
for both IL-6 and IL-8, and 1000 pg/ml for FGF-2, suggesting that if they were secreted, then 
they were at negligible concentrations.   
 
It is interesting that these cytokines were not detected in these samples as their expression in 
BPH has previously been recorded. It was expected that IL-4 would be detected as previous 
work has shown de novo IL-4 mRNA expression in BPH tissue compared to healthy prostates 
[20]. That IL-4 has been shown to be expressed in BPH tissue, but not healthy prostates, is 
interesting, as it has been shown to inhibit the proliferation of normal prostate-derived 
stromal cells (SCs), but this control is lost in BPH-derived SCs. IL-4 has been shown to activate 
androgen receptor (AR) and can promote the growth of androgen-responsive cancer cells. 
Thus suggesting that the de novo IL-4 expression observed in BPH may work through the AR to 
contribute to the progression of BPH, and possibly further disease development [166].The fact 
that IL-4 was not detected here may be because de novo expression had not occurred, it had 
degraded in the media, or it may not have been secreted from the cells.  
 
Also assayed, but not detected, was IFN-y, which stimulates BPH-derived, but not normal 
prostate-derived, SC proliferation [20]. Whether IFN-y expression is increased or decreased in 
BPH is unclear, as levels in seminal plasma have been reported to decrease from 25pg/ml in 
healthy tissue to 15pg/ml in BPH tissue [167], whilst another study found that IFN-γ mRNA 
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increased in BPH compared to healthy prostate tissue [20]. The study in which IFN-y was 
measured in the seminal plasma also measured IL-6 and IL-8 concentration, and reported both 
of these to be much higher than the levels of IFN-y [167]. If IFN-γ was secreted by the tissue in 
the present culture experiments at a similar ratio to IL-6 and IL-8 as seen in that study, it would 
have been below the detection limit of the ELISA, suggesting a possible explanation as to why 
it was not detected here. 
 
Finally, it is surprising that IL-17 is not detected as it has been reported as over-expressed in 
79% of BPH tissue samples, although further investigation suggests it is only released by 
activated T cells [22]. It is possible that the samples cultured here were in the 21% of BPH 
samples that were reported to not over-express IL-17, or that there were either no T cells, or 
the T cells that were present were not activated, leading to lack of IL-17 secretion. 
Lymphocytes were observed in the tissue (Figure 2.8c) during histological examination, 
although whether these were T cells is unknown. However, the use of specific stains such as 
CD45, selective for T cells, would allow us to confirm their identity.  
 
Leading on from the detectable absence of IL-17, it is interesting that both IL-6 and IL-8 were 
easily detectable, when it has been shown that IL-17 stimulates their production [22]. It could 
be that the levels of IL-6 and IL-8 measured would be comparable to levels detected in healthy 
tissue treated in the same way, or that their secretion was stimulated by an alternative 
pathway. Furthermore, IL-17 may have been present in the tissue but not detectable in the 
media, as it may not have been secreted or may have been degraded.  
 
Of the cytokines that were successfully measured, it is interesting that the two with the 
greatest concentration were IL-6 and IL-8, the favoured executors of stromal growth in BPH 
[165, 168]. IL-6 is an autocrine growth factor [168] whilst IL-8 is a paracrine inducer of FGF-2 
[169], the third cytokine that was detected in the media. The results of the ELISAs revealed 
that secretion of IL-6 and IL-8 was highly comparable, at ~4000pg/ml, but were 4-fold higher 
than the concentration of FGF-2, which was ~1000pg/ml. There are no previous data 
concerning secretion concentrations of these cytokines in BPH tissue in culture with which to 
directly compare these results, but their relative levels, and effect on prostate health have 
been reported.  
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IL-6 has been reported to be increased 3-fold in expressed prostatic secretions of large 
prostates (>60g) compared to small prostates (<40g), suggesting it is involved in prostate 
enlargement [170]. Similarly IL-6 protein expression in prostate tissue has been observed to 
increase in BPH and PCa compared to normal prostates [163]. Drachenburg and colleagues 
further investigated the correlation between circulating IL-6 levels in serum, and prostatic 
disease. Their results revealed a mean concentration of 0.7pg/ml in healthy patients compared 
to 1.9pg/ml in BPH patients, 1.1pg/ml in PIN and 1.7pg/ml in those with localized PCa. IL-6 
levels further increased to 3.9pg/ml  1.6 in advance hormone-dependent disease, and 
5.7pg/ml ± 1.9 in advanced hormone-refractory disease [171]. Thereby suggesting that IL-6 is 
positively correlated with prostate dysregulation. It is interesting to note that IL-6 was 
recorded as higher in BPH patients compared to those with PIN and localized PCa, although 
this may be because inflammation plays a greater role in BPH than PCa. All of these results 
confirm that IL-6 is positively correlated with BPH, suggesting a role for IL-6 in either BPH 
initiation or progression.  
 
The correlation of IL-8 with prostate health has also previously been investigated.  Hochreiter 
and colleagues reported no difference in the IL-8 concentration of expressed prostatic 
secretions from control and BPH samples (approx. 3000pg/ml) [164]. Measurement of IL-8 in 
serum also showed no significant difference between healthy and BPH patients, with 
concentrations of 6.8pg/ml and 6.5pg/ml respectively. However, IL-8 was seen to be elevated 
in PCa, increasing to a mean of 15.6pg/ml in localized disease, and 27.8pg/ml in metastatic 
disease [172]. Levels of IL-8 were found to be positively correlated with prostate size and 
cellular senescence, and IL-8 found to promote proliferation of both primary and immortalized 
prostatic epithelial cells in culture [165]. Such data suggests that there is little relation 
between IL-8 and BPH, but that it is correlated with PCa, indicating it can play a role in prostate 
pathogenesis, but that it may not be of direct importance in the study of BPH tissue.  
 
Basal levels of IL-6 and IL-8 secretion have been measured from PCa cell lines in culture, with 
IL-6 secreted at 8.5pg/ml and 155pg/ml in LNCaP and PC3 cell lines respectively, whilst IL-8 
was measured at 442pg/ml and 378pg/ml [42]. These results once again demonstrate that IL-6 
increases when PCa progresses to a hormone refractory state [171]. In contrast, these results 
suggest that IL-8 decreases, although it is not known whether this reduction is significant as 
statistical comparison was not performed.  
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In a study by Penna and colleagues of cytokines in seminal plasma from healthy and BPH 
prostates, the median IL-6 concentration was seen to increase from 16pg/ml to 74pg/ml in 
healthy and BPH samples respectively. Likewise, IL-8 increased from 1984pg/ml to 5044pg/ml 
[167]. Compared to the results I obtained, it is interesting to see that IL-8 in seminal plasma 
from BPH tissue was so much higher than IL-6, when I found them to be at highly similar 
concentrations. In terms of comparison to my results, this is probably the closest comparison, 
as both measured the secreted concentration as opposed to mRNA expression or tissue 
protein levels.  
 
However, in my experimental setup the tissue was cultured prior to cytokine measurement. 
Therefore, the culture environment may have had an effect on cytokine secretion either 
stimulating IL-6 or inhibiting IL-8 secretion, so that the levels secreted were highly similar. 
Unfortunately, due to the nature of the method used in this study, it is not possible to obtain a 
time zero secretion value, so the question remains whether this result is representative of the 
tissue sample, or caused by culture.  
 
A further explanation for the discrepancy between the two results, may be due to the sample 
being assayed, as they were measuring levels in seminal plasma, whilst I was measuring culture 
media, so their constituents may naturally differ. It is interesting that in the study by Penna 
and colleagues, they found IL-8 increased in BPH. This does not correspond with other data 
discussed above [164, 172], where no correlation was reported, suggesting the possibility that 
there may be some relationship between IL-8 and BPH, although the role is not clear. 
 
The expression of FGF-2 has previously been observed to be unchanged in BPH samples 
compared to normal tissue [20]. This was corroborated in a further study that reported FGF2 
mRNA remained stable in 54% of BPH samples analysed, whilst it was overexpressed in 44% of 
PCa samples. However, statistical analysis indicated a similar expression pattern in both BPH 
and PCa, suggesting a common role for FGF-2 in both disease states [173]. Others have 
observed an increase in FGF-2 in BPH, and reported a role in stromal proliferation [169, 174-
175]. These data indicate that FGF-2 may be involved in BPH and PCa, although less data exists 
concerning the relationship between FGF-2 and prostate dysregulation, making it difficult to 
draw firm conclusions. 
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Overall the above data confirms the importance of cytokines in BPH highlighting the 
inflammatory nature of the disease.  
 
 
3.4.2 Reduction of inflammatory markers by SF 
Previously, SF has been shown to reduce the levels of some cytokines. This led to the 
hypothesis that SF would reduce the secretion of pro-inflammatory cytokines from the BPH 
tissue ex vivo. The results of my experiment suggest this hypothesis to be true, as 25µM SF was 
seen to reduce both IL-6 and IL-8 secretion (Figure 3.3). This correlates with results in the 
literature, including reports that SF inhibits diesel extract-induced IL-8 production in airway 
epithelial cells [111]. Although some cytokines assayed were undetected in this study, SF has 
also been shown to inhibit IL-17 production by rheumatoid T cells [176], and reduce expression 
of IL-4, IL-6 and IFN-y in aggressive breast carcinoma cells [158]. 
 
Initially, the effect of SF on cytokine secretion was measured using 25µM SF, as this 
corresponds to concentrations often used in the literature [117, 132-133, 135, 162]. It was 
hoped this high concentration of SF would make any effect more apparent, as due to the 
complexity of the tissue model compared to cell models most commonly used, it was thought 
a higher dose may be needed to elicit an effect.  
 
Using concentrations of biological relevance is of great importance when investigating dietary 
components. Levels of SF recorded in plasma after broccoli consumption, have been recorded 
at a maximum of 7.4µM ± 3.08 [100], much lower than the 25µM SF used here. However, 
25µM SF could be achieved by supplementation, meaning it is not outside the bounds of 
human relevance. In this study, 25µM SF was shown to have a more significant effect on IL-8 
secretion than IL-6. Despite this, due to evidence suggesting an important role for IL-6 in 
prostate inflammation and pathogenesis in general, and a clearer correlation between IL-6 
levels and BPH than IL-8, it was decided to further investigate the dose-dependent effect of SF 
on IL-6, not IL-8.  
 
Results from the dose-dependent experiment showed that the lowest concentration at which 
significance was achieved, was 10µM SF and that 2 and 5µM had no significant effect (Figure 
3.4). 10µM SF was therefore chosen as the concentration for all subsequent experiments, as 
not only were the results statistically significant, but it is a more biologically relevant 
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concentration than 25µM SF. As mentioned above, SF levels in plasma after consumption of 
high-glucosinolate broccoli have been recorded at 7.4µM ± 3.08 (n = 7), suggesting that 10µM 
SF is at the upper limit of levels achievable in plasma through diet [100].  
 
Reduction of IL-6 by SF corresponds with the literature, although this effect has not previously 
been shown in prostatic tissue. Previously, it has been shown that 1µM SF can significantly 
reduce LPS-induced IL-6 expression in rat microglia [103], and that 2.5 and 5µM SF reduced the 
secretion of IL-6 20% and 35% respectively in aggressive breast carcinoma cells after 48 hours 
[158]. 10 and 20µM SF were also shown to reduce norepinephrine-induced IL-6 secretion by 
pancreatic duct epithelial cells by 50 and 80% respectively [159]. Compared to the first two of 
these studies, the concentration of SF needed to see a significant effect here was much 
greater. This may be due to the more complex model being investigated, as previous reports 
were using in vitro cell models which are much simpler systems. 
 
Sulforaphane has also been shown to inhibit IL-6-induced activation of signal transducer and 
activator of transcription 3 (STAT3), which has anti-apoptotic and proliferative effects, 
contributing to the induction of apoptosis by SF. This suggests a mechanism by which the 
reduction of IL-6 by SF may contribute to the pro-apoptotic protective effects of SF [177]. 
However, the mechanism by which SF is reducing cytokine secretion in the tissue model is 
unknown. 
 
In the tissue SF may modulate cytokine secretion by two difference mechanisms. Firstly, SF 
may reduce the expression or secretion of the cytokines, subsequently decreasing the 
concentrations in the media. Secondly, it may be inducing cell death, thereby reducing the 
number of cells secreting cytokines into the media.  
 
Previous work has shown that SF can modulate pathways controlling cytokine expression and 
secretion whilst not altering cell death [111], suggesting that this may be a possible 
explanation for the reduction seen here. However, as SF is known to have pro-apoptotic 
properties, it can not be ruled out that SF may be inducing cell death in this model. Further 
evidence for this possibility is provided in Chapter 5, where SF is reported to alter the 
expression of a number of proteins involved in the apoptotic process, suggesting SF can 
promote apoptosis in this model.  
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As neither hypothesis can be proven or discredited, it must also be considered that the 
reduction observed here could be due to a combination of the two, with SF both increasing cell 
death, but also reducing the expression and secretion of cytokines from the surviving cells.  
 
 
3.4.3 Conclusions 
It is apparent from the experiments performed that BPH tissue ex vivo secretes a range of 
cytokines, supporting the idea that inflammation is a key component of BPH. It has also been 
shown that SF can reduce pro-inflammatory cytokines in a dose-dependent manner, thereby 
demonstrating a possible method by which SF can have a beneficial effect on prostate health. 
As such this may help to explain why the consumption of broccoli is associated with improved 
prostate health, and correlates with the observation that broccoli can reduce BPH-related 
symptoms and alter inflammatory pathways in the prostate [95]. To further investigate the 
activity of SF in the ex vivo model, the next chapter will employ an untargeted method which 
will hopefully allow for the discovery of novel targets of SF activity in the prostate. 
  
 
 
 
 
Chapter Four 
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Chapter 4. Proteomics & Protein Identification 
4.0.1 Summary 
Chapter 3 described the effect of sulforaphane (SF) on inflammatory cytokines in benign 
prostatic hyperplasia (BPH) tissue ex vivo using a targeted approach. The next two chapters will 
describe the effect of SF in the ex vivo model using an untargeted approach to assess changes 
in global protein expression, with the aim of identifying novel targets of SF activity. This 
chapter focuses on the technical aspects of proteomics, whilst discussion of the proteins 
identified will be undertaken in the following chapter.  
 
Protein extracted from BPH tissue from three patients cultured with or without 10µM SF in 
triplicate, was separated by 2D gel electrophoresis, and the resulting gels compared. Analysis 
of the gels identified four sources of variation: replicate, patient, treatment and technical. 
Assessment of baseline global protein expression showed a significant difference between 
patients 13 and 14, and patient 16. In each patient, a number of individual spots were found to 
be altered due to SF treatment, but total global protein expression was only significantly 
altered in patients 13 and 14. Comparison of the spots altered by SF in each patient revealed 
there was very little overlap, indicating that the samples from the individual patients 
responded in unique and varying ways. Protein spots that were altered due to patient or 
treatment variation were selected, corrected for technical variation, and identified by mass 
spectrometry.  
 
These results show that SF can alter proteins within BPH tissue, but that there is a high degree 
of human variation evident.  
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4.1 Introduction 
In the previous chapter, the hypothesis that SF could reduce the secretion of pro-inflammatory 
cytokines from BPH tissue in culture was tested using a targeted method to measure the effect 
of SF on specific selected cytokines. In this chapter, this work is expanded with the use of a 
non-targeted approach to investigate the effect of SF on global protein expression in BPH 
tissue ex vivo (Figure 4.1).  
 
Compared to a targeted approach, a non-targeted approach will remove any bias in the 
selection of proteins measured, and will hopefully allow for the identification of novel targets 
of modulation by SF. Furthermore, the use of the two techniques will hopefully mitigate any 
limitations intrinsic to each. For example, 2D gel electrophoresis is often not sensitive enough 
to detect inflammatory cytokines, so the use of the targeted ELISA, which has higher 
sensitivity, will facilitate the detection and measurement of these markers. However, 2D gel 
electrophoresis has advantages over ELISA due to its untargeted nature. One such advantage, 
is that it allows the identification of different protein isoforms or modifications, which may, 
due to the specificity of the antibodies used in ELISA, lead to a false negative [178]. 
 
The aim of this work is to investigate the effect of SF on global protein expression, and to 
identify the proteins altered, providing a greater understanding of the mechanisms by which 
SF can have a beneficial effect on the prostate. In addition, it is also hoped that a novel target 
of SF activity may be indentified for further investigation. 2D gels have previously been used to 
identify targets of SF activity, including: down-regulation of serotonin receptors in a colorectal 
cancer cell line [179]; induction of apoptosis by down regulation of phosphoglucomutase 3 in a 
prostate cancer cell line [180]; and inhibition of cell growth and induction of apoptosis by 
binding to tubulin and inhibiting its polymerization in a lung cancer cell line [181]. The use of 
this technique in the analysis of BPH tissue cultured ex vivo, which is novel in itself, is hoped to 
elicit a novel target for SF activity, as has been achieved in studies using established cell lines. 
  
In this chapter, I will use 2D gel electrophoresis to separate proteins extracted from BPH tissue 
cultured with or without 10µM SF, the lowest concentration at which SF significantly reduced 
IL-6 secretion (see Chapter 3). I will analyse the overall effect on global protein expression, and 
then select specific spots for identification. The aim of this work is to provide a greater 
understanding of which proteins SF is capable of modulating, and to try and understand how 
SF may have a beneficial effect on prostate health. 
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Figure 4.1. Proteomic analysis overview.  
Simplified process diagram showing the major steps in sample collection, preparation and 
proteomic analysis using 2D gel electrophoresis. 
 
  
Collect BPH tissue samples and prepare for culture.
Culture tissue in triplicates +/- 10µM SF. 
Collect tissue, wash in PBS and freeze on dry ice.
Extract protein from the tissue and quantify.
Prepare 100µg protein per sample for 2D gel electrophoresis.
Transfer the sample to an IPG Strip and run the 1st Dimension to 
seperate the proteins by isoelectric focussing point.
Condition the IPG Strip and run the 2nd Dimension on a 
acrylamide gel to separate the proteins by mass.
Stain the gel with SYPRO Ruby Protein Gel Stain.
Image the gels.
Overlay and align gel images using SameSpots software.
Find and pick spots that have been significantly altered between 
gels.
In-gel Trypsin digest the spots, and analyse by mass 
spectrometry.
Identify the proteins from the peptide mass peak list using 
Mascot.
Proteomics & Protein Identification 
 
 
88 
 
4.2 Methods 
4.2.1 Tissue collection 
BPH prostate tissue collected in Chapter 3 was used in this chapter. Previously, media samples 
from tissue culture were assessed for the dose-dependent effect of SF on IL-6 secretion (see 
Chapter 3.3.3). The lowest concentration of SF at which an effect was seen was 10µM. Tissue 
samples from five patients were cultured for 24 hours and media samples assayed. The three 
tissue samples which showed the greatest response to 10µM SF were selected for the 2D gel 
electrophoresis work. The samples were washed in warm PBS, collected in pairs, immediately 
frozen in dry ice, and stored at -80
o
C for later analysis.  
 
 
4.2.2 Protein extraction 
Two pieces of snap-frozen tissue were transferred into a grind tube (Sample Grinding Kit, GE 
Healthcare) with 100µl Reagent 1 (40mM Tris-BASE (5ml), supplemented with 15µl 1M MgCl2, 
12.5µl Protease Inhibitor Cocktail (Sigma P-8340), 25µl DNase (I unit/µl Promega M6101) and 
2.5µl RNAse A (10mg/ml Sigma R6513)), and ground using a pestle until homogenized. The 
sample was centrifuged at 10,000rpm and 4
o
C for 1 minute and the supernatant collected. A 
further 100µl Reagent 1 was added, and the sample ground and centrifuged again as before, 
and the supernatant collected. 100µl of ReadyPrep Sequential Extraction Kit Reagent 3 
supplemented 1:100 with Tributylphosphine (TBP) Reducing Reagent (both BioRad) was added 
to the sample, ground and centrifuged (at 15
o
C) as before; and the supernatant collected in a 
new tube, this step was then repeated. Both supernatants were spun for 5 mins at 15,000 rpm 
and 5
o
C or 15
o
C for Reagent 1 and 3 supernatants respectively. Supernatants were removed 
and labelled ‘Supernatant 1’ (Reagent 1) and ‘Supernatant 2’ (Reagent 3) and stored at -80
o
C. 
Supernatant 2 (Reagent 3) was used for all protein analysis. 
 
 
4.2.3 Protein quantification 
Protein extracted from tissue was quantified using the 2D Quant Kit (GE Healthcare) as per 
instructions. Briefly: a standard curve was prepared using the BSA standard provided, samples 
were prepared using 15µl supernatant 2, 500µl precipitant was added to all standards and 
samples prior to  a brief vortex, and incubated for 2-3 minutes. 500µl co-precipitant was added 
and mixed by inversion, samples centrifuged at 10,000 x g for 5 minutes, supernatants 
immediately decanted, tubes briefly re-centrifuged, and all remaining supernatant carefully 
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removed using a pipette. 100µl copper solution and 400µl distilled water was added to each 
tube and vortexed. 1ml working colour reagent added, mixed by inversion, and incubated for 
15-20 minutes. Samples were transferred to cuvettes (Sarstedt), and the absorbance read at 
480nm, with water as a blank, in a spectrophotometer (DU 640 Spectrophotometer 
(Beckman)). Standards were plotted to produce a curve, which was then used to calculate 
sample concentrations. 
 
 
4.2.4 2D gels 
Protein was run on 2D gels to separate the proteins by both mass and isoelectric focussing 
point. For each patient three biological triplicates with or without 10µM SF were run. 
 
 
4.2.4.1 Sample Preparation 
A sample volume equivalent to 100µg protein was added to a Biomax 5K NMWL Membrane 
Ultrafree 0.5ml centrifugal filter (Millipore) along with 400µl non-bromophenol blue 
rehydration buffer (7M Urea, 2M Thiourea and 2% CHAPS) and concentrated to  approximately 
50µl at 12,000g and 20
o
C. The concentrate was mixed with an IPG Strip Rehydration Buffer, 
containing 7M Urea, 2M Thiourea, 2% CHAPS, bromophenol blue, 0.018M DTT and 0.5% pH 3-
11NL IPG Buffer (GE Healthcare), to a final volume of 450µl. 
 
 
4.2.4.2 1
st
 Dimension 
The whole volume was transferred into one well of the Immobiline Dry Strip re-swelling tray, 
and IPG strips (24cm, pH 3-11; GE Healthcare) were rehydrated overnight at 20
o
C. Each strip 
was then transferred to a ceramic strip-holder, and the iso-electric focusing run with a ‘step-n-
hold’ at 500 V for 1 hour, a gradient step up to 1000V over 1 hour, a gradient step up to 8,000V 
over 3 hours and a ‘step-n-hold’ at 8000 V for 3.75 hours (Ettan IPGphor  Manifold IEF System, 
GE Heathcare). After completion strips were stored at -80
o
C.  
 
 
4.2.4.3 2
nd
 Dimension 
The second-dimension was carried out on 1mm thick 10% polyacrylamide (Duracryl) gels 
prepared in 28 x 23cm gel-plate cassettes. Focused IPG strips were rinsed free of excess 
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mineral oil and conditioned in filtered (0.45µm) equilibration buffer (Tris Acetate Equilibration 
Buffer (5% SDS, 0.01% bromophenol blue, 0.122M Tris/Acetate,), supplement with a further 
5mg/ml final volume SDS, 360mg/ml final volume urea and 30% final volume glycerol). To re-
enforce disulphide bond separation and prevent proteins from re-folding, strips were first 
treated with 8mg/ml DTT in the equilibration buffer (9ml for 30 minutes with gentle shaking) 
and then transferred into 25mg/ml iodoacetamide in equilibration buffer (9ml for 30 minutes 
with gentle shaking). Acrylamide gels (28 x 23cm, 1mm thick) were prepared for use in the 2
nd
 
Dimension Running System (Millipore), and IPG strips placed in the well of the gel cassette 
ensuring good contact with the gel. The top reservoir contained the cathode buffer (14mM 
SDS, 200mM Tris Base, 200mM Tricine), and the bottom reservoir contained the anode buffer 
(26mM Tris Base, 0.08% Acetic Acid). Electrophoresis conditions were set to give a maximum 
voltage of 500 V, power of 20,000mW/gel and a total run time ~4 hours.     
 
 
4.2.4.4 Sypro Ruby Staining 
After electrophoresis, the gels were fixed overnight in 400ml Fixing Solution (40% methanol, 
10% acetic acid), and then stained overnight using 330ml SYPRO Ruby Protein Gel Stain 
(Invitrogen) in the dark. They were then destained for 4 hours in a 400ml 10% methanol, 6% 
acetic acid solution in the dark.  
 
 
4.2.4.5 Imaging 
Gels were imaged at 100µm resolution using the Pharos FX Plus Molecular Imager with the 
GS800 Calibration Densitometer and Quantity One imaging software (all Bio-Rad) employing 
the Excitation 532nm laser and 605nm BP Emission filter. The photo multiplier tube (PMT) 
laser strength was determined empirically for each gel, the range used was 48-60%, using the 
strongest spot on each gel to achieve the maximum signal (65,500) without causing bleaching 
or peak slicing. 
 
 
4.2.4.6 SameSpots Software 
Images were analysed using Progenesis SameSpots software (Nonlinear Dynamics). Each gel 
was aligned to a reference gel prior to automatic spot detection. Each gel then had the same 
spot shown on that position on the image.  Spurious spots were filtered out and the gels were 
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then grouped into their experimental conditions.  Finally, manual editing was performed to 
ensure spots were correctly defined.  Comparisons of spots on gels were made between 
multiple groups to look at the inter-individual variation, intra-individual variation and the 
effect of treatment on the group as a whole. 
 
 
4.2.4.7 Spot picking 
Selected spots were excised from a gel using the ProPick excision robot (Genomic Solutions). 
Gel plugs underwent manual in-gel Trypsin digestion. Gel plugs were first conditioned with two 
20 minute incubations in 200mmol/L ammonium bicarbonate (ABC) in 50% acetonitrile, 
followed by washing, and a 10 minute incubation with acetonitrile, before air-drying for 10 
minutes. 50ng Trypsin Gold (Promega) dissolved in 10mM ABC was added to each gel plug (5µl 
per well) and incubated at 37
o
C for 3 hours. Digestion was stopped and peptides extracted 
using 5µl 5% formic acid incubated for 10 minutes. Samples were flash frozen in liquid nitrogen 
and stored at -70
o
C. 
 
 
4.2.5 Mass spectrometry 
Samples were analysed by mass spectrometry by Dr Fran Mulholland as a service as part of the 
IFR Proteomics Partnership using the following procedure. 
 
 
4.2.5.1 Sample preparation 
The supernatant from the in-gel digest was recovered from digest reaction tube and put into a 
1.5ml Eppendorf tube. To extract further peptides 20µl 50% Acetonitrile was added to the gel 
piece and left at room temperature for 3-5mins before the liquid removed and added to the 
Eppendorf tube.  The sample was then dried down at the Low Drying setting (no heat) on a 
Speed Vac SC110 (Savant) fitted with a Refrigerated Condensation Trap and a Vac V-500 
(Buchi).  The sample was frozen at -70°C or immediately reconstituted for LC-MS/MS analysis.  
 
To prepare the sample for the LC-MS/MS analysis, the sample was redissolved in 30-100µl 
0.5% formic acid and vortexed for 20 seconds before sitting in a sonicating water bath (Kerry) 
for 5 minutes at room temperature to facilitate dissolution.  The sample was then briefly pulse 
centrifuged before the appropriate volume (25-50µl) was dispensed into a 0.2ml skirted  96-
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well PCR plate (ThermoAB-800). Once all samples were added to the plate it was sealed with 
an adhesive PCR foil seal. 
 
 
4.2.5.2 LC-MS/MS analysis  
LC-MS/MS analysis was performed using a LTQ-Orbitrap mass spectrometer (Thermo Electron) 
and a nanoflow-HPLC system (nanoACQUITY; Waters, US).  Peptides were trapped on line to a 
Symmetry C18 Trap (5 µm, 180 µm x 20 mm) which was then switched in-line to a UPLC BEH 
C18 Column, (1.7 µm, 75 µm x 250 mm) held at 45°C.  Peptides were eluted by a gradient of 0–
80% acetonitrile in 0.1% formic acid over 50 min at a flow rate of 250 nL min−1. The mass 
spectrometer was operated in positive ion mode with a nano-spray source at a capillary 
temperature of 200°C.  
 
The Orbitrap was run with a resolution of 60,000 over the mass range m/z 300–2000 and an 
MS target of 10
6
 and 1 s maximum scan time. The MS/MS was triggered by a minimal signal of 
2000 with an Automatic Gain Control target of 30000 ions and maximum scan time of 150 ms.  
For MS/MS events selection of 2+and 3+charge states selection were used. Dynamic  exclusion 
was set to 1 count and 30 s exclusion time with an exclusion mass window of ±20 ppm.  
 
 
4.2.6 Identification of proteins using Mascot  
Proteins were identified from the mfg file (prepared from the Orbitrap-derived RAW data file 
using DTAsupercharger) using an in–house version of the Mascot LC-MS-MS search tool from 
Matrix Science. The search parameters were as follows: the taxonomy group searched was 
Homo sapiens of the SPtrEMBL database, tryptic digest was assumed to have a maximum of up 
to two missed cleavages, the carbamidomethylation of cysteine residues was a fixed 
modification, and oxidation of methionine residues was a variable modification, peptide 
masses were monoisotopic and either 2+ or 3+ charged, and the peptide and fragment mass 
tolerances were set at 5ppm and 0.5Da respectively. Individual ions scores >23 indicated 
identity or extensive homology (p-value <0.05).  From the resulting analysis identified proteins 
with overall scores >100 were investigated further. The predicted pI and mass were noted for 
all hits with an overall protein score >100, and compared to the position of the spot on the gel. 
The peptide coverage pattern of the sequence was examined to determine whether the 
protein may have fragmented, in which case the predicted pI and molecular weight of the 
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fragment were calculated using the ExPASY Proteomics Server Compute pI/Mw tool 
(http://www.expasy.ch/tools/pi_tool.h tml). Proteins with a mass or pI which did not 
correspond with the position of the spot on the gel were eliminated. The process used to 
identify proteins using the Mascot results is described in greater detail below using spot 397 as 
an example. 
 
Spot number 397 returned 22 protein hits with 11 of these scoring >100. One of these hits was 
a control and the other possible identifications included endoplasmin, desmin, collagen-α 1 
(IV) and several keratins (Table 4.1).  
 
 
Table 4.1. Possible identifications for spot 397.  
 
ID No. Accession Name Score Mass pI 
1 P14625 Endoplasmin 2212 92696  4.76 
2 P04264 Keratin, type II cytoskeletal 1 990 66170 8.15 
3 P35527 Keratin, type I cytoskeletal 9 531 62255 5.14 
4 P13645 Keratin, type I cytoskeletal 10 327 59020  5.13 
5 P35908 Keratin, type II cytoskeletal 2 
epidermal 
292 65678 8.07 
  - Fragment  33628 5.04 
6 P02533 Keratin, type I cytoskeletal 14 277 51872 5.09 
7 P12109 Collagen alpha-1(VI) chain 213 109602 5.26 
8 P13647 Keratin, type II cytoskeletal 5 168 62568 7.59 
9 P17661 Desmin 116 53560 5.21 
10 P04259 Keratin, type II cytoskeletal 6B 108 60315 8.09 
 
Possible protein identifications for spot 397 as elicited from searching Orbitrap data using 
Mascot. 22 possible matches were found but all IDs with a score <100 were eliminated (data 
not shown) as these were below the arbitrary threshold.  
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From noting down the mass and pI of each possible ID (Figure 4.2), and comparing to the 
position of the spot on the gel (Figure 4.3), IDs 2, 5 (un-fragmented), 8 & 10 can be eliminated 
as their pIs are too high. It is unlikely to be IDs 3, 4, 5 (fragment), 6 & 9 as their mass would 
indicate they would have run further down the gel.  Keratins are also recognised contaminants 
of this type of experimental data and can usually be ignored.  This leaves only two possible IDs; 
(1) endoplasmin or (7) collagen alpha-1(VI) chain.  
 
 
Figure 4.2. Mascot search result.  
Information shown includes accession number, score, name, mass and pI of a possible ID for 
spot 397. This information is generated for each possible ID. 
 
 
 
 
 
Figure 4.3. Position of spot 397 on a 2D gel.  
An example image of a 2D gel showing the position of spot 397. The spot is positioned towards 
the top left of the gel indicating that it has a low pI and the mass is relatively large.  
pH 
3 11 
Mass 
(kDa) 
Large 
>100kDa 
Small 
<10kDa 
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Assessment of the sequence coverage reveals 38% coverage for endoplasmin (Figure 4.4), and 
5% coverage for collagen alpha-1(VI) chain (Figure 4.5), suggesting the most likely ID for spot 
397 is (1) endoplasmin. Previous papers have also been published that had identified 
endoplasmin (also known as gp96, GRP94 and HSP901) in the same position on the gel 
further validating the identification [182-183]. 
 
 
 
Figure 4.4. Peptide Sequence of endoplasmin (P14625).  
Matched peptides shown in bold red with 38% sequence coverage. 
 
 
 
 
Figure 4.5. Peptide Sequence of collagen alpha-1(VI) chain (P12109).  
Matched peptides shown in bold red with 5% sequence coverage. 
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In some cases, if there was good coverage in a specific section of the sequence but no matches 
throughout the rest of the sequence, fragmentation of the protein was considered and the 
mass and pI of the proposed fragment calculated using the online Protein Mass Calculator 
(Bioinformatics at the Cancer Research UK Clinical Centre, University of Leeds, 
http://www.proteomics.leeds.ac.uk/cgi-bin/masscalc) and Compute pI/Mw tool (ExPASY 
Proteomics Server, Swiss Institute of Bioinformatics, http://www.expasy.ch/tools/pi_tool.html) 
respectively. The calculated mass and pI were compared to the position of the spot on the gel 
to decide whether this proposed fragment could be a possible ID for the spot of interest. 
 
 
4.2.7 Statistics 
Data was statistically analysed to identify sources of variation using ANOVA, repeated 
measures and 1-way, and subsequent Tukey HSD post hoc tests as appropriate (Table 4.2). 
Individual protein spots were analysed by 1-way ANOVA (Table 4.3). Analysis was performed in 
R by Dr Jack Dainty. Results were not corrected for multiple testing, as this was deemed to 
stringent for this type of data, due to the natural variation present within human samples. 
Production of a Venn diagram, showing the overlap between protein spots altered by 10µM 
SF, and selected for identification in the three patients, was performed in R under the 
guidance of Dr Maria Traka (Figure 4.6). 
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4.3 Results 
4.3.1 Analysis of sources of variation within 2D gels 
To investigate the effect of SF on global protein expression in BPH tissue in culture, tissue 
stored from a previous experiment (Chapter 3.3.3), where samples were cultured with or 
without 10µM SF for 24 hours in triplicate, was used. Protein was extracted from the tissue, 
and then run by 2D gel electrophoresis to separate the proteins, firstly by isoelectric point, and 
secondly by mass. Gels were stained with SYPRO Ruby, a fluorescent stain which binds to 
proteins, with a lower detection limit of 1-10ng, to visualise the spots. Images of each gel were 
taken, and analysed using SameSpots software (Figure 4.6). Initial analysis was performed to 
identify any sources of variation between the gels.  Three sources of variation were examined: 
replicate, patient and treatment. 
 
 
4.3.1.1 Replicate 
Analysis for replicate effect throughout the gels using repeated measures ANOVA indicated 
there was significant difference between the replicates (p-value <0.001) (Table 4.2). 1-way 
ANOVA of the control and 10µM treatment groups showed that the difference was arising 
from the control group (p-value = 0.068 compared to 0.672 for the 10µM SF group). Further 1-
way ANOVA of the control group revealed that the variation resulted from patient 16 (p-value 
= 0.0072) and not patients 13 or 14 (p-value = 0.649 and 0.614 respectively). Tukey HSD post 
hoc tests indicated that replicate 2 was significantly different to replicates 1 and 3 (p-values for 
replicate 1 vs. 3 = 0.734, 2 vs. 3 = 0.0073, and 2 vs. 1 = 0.061). Removal of the second replicate 
from all groups reduced the overall significance of replicate effect greatly (from p-value <0.001 
to 0.0462), although the p-value remained just within the values for significance, which is likely 
due to the decreased sample size from which the calculation was made.  
 
This data demonstrated that overall there was little replicate variation, suggesting that the 
replicate variation observed from replicate 2 of patient 16 control group was an anomaly. This 
may have been caused by either technical issues that occurred during running and staining, or 
inherent biological variability in the sample, such as the presence of different cell types. All 
further analysis using data from patient 16 control group was performed with replicate 2 
removed from all groups involved to ensure balanced statistical analysis. 
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4.3.1.2 Patient  
Comparison of tissue from the three patients without treatment using 1-way ANOVA revealed 
significant difference between the patients (p-value = 0.001) (Table 4.2). Further analysis using 
Tukey HSD post hoc tests, for pair-wise comparison with in-built multiple test correction, 
showed that patients 13 and 14 were statistically similar (p-value = 0.3429), but that patient 16 
was significantly different to both patients 13 and 14 (p-value = 0.037 and <0.001 respectively). 
This highlights that the global protein expression in BPH tissue naturally varies from patient to 
patient.  
 
 
4.3.1.3 Treatment 
Lastly, the effect of treatment was examined to determine whether 10µM SF had altered the 
global protein expression of the tissue compared to the control group, also referred to as the 
baseline. Repeated measures ANOVA showed there was a statistically significant effect of 
treatment (p value <0.001) (Table 4.2). Further 1-way ANOVA showed that the greatest effect 
of treatment occurred in patient 14 (p-value <0.001), and that patient 13 was also significantly 
effected by the SF (p-value = 0.0037). No significant effect of treatment was observed on 
patient 16 (p-value = 0.9265).  
 
It is interesting that it was patient 16 which showed the least response to treatment. Patient 
16 showed the greatest variance to the other patients without treatment, and displayed an 
effect of replicate in the control group.  
 
These results suggest that 10µM SF is capable of altering global protein expression in BPH after 
24 hours of culture, but that different patients respond in diverse ways, once again 
highlighting the natural variation between individuals.  
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Patient Control 10µM SF 
13 
  
14 
  
16 
  
   
Figure 4.6. 2D Gels of protein extracted from BPH tissue cultured with or without 10µM SF.  
 BPH tissue from three patients was cultured with or without 10µM SF for 24 hours with 3 
biological replicates. Protein was extracted and 100µg run using 2D gel electrophoresis. A 
representative 2D gel for each patient with or without 10µM SF is shown here.  
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Table 4.2. Statistical analysis of the sources of variation within the 2D gels.  
 
Variable Patient Replicate  p-value 
Replicate All  All   <0.001 
 All Replicate 2 removed  0.0462* 
 All control  All   0.068 
 13 control All  0.649 
 14 control All  0.614 
 16 control All  0.0072 
  1 vs 3  0.734 
  2 vs 3  0.0073 
  1 vs 2  0.061 
 All 10µM SF All  0.672 
 13 10µM SF All  0.645 
 14 10µM SF All  0.812 
 16 10µM SF All  0.503 
Patient All control Replicate 2 removed  0.001* 
 13 vs 14 control All  0.343 
 13 vs 16 control Replicate 2 removed  0.037* 
 14 vs 16 control Replicate 2 removed  <0.001* 
Treatment (10µM SF) All Replicate 2 removed  <0.001* 
 13 All  0.0037 
 14 All  <0.001 
 16 Replicate 2 removed  0.9265* 
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF for 24 
hours with three biological replicates. Protein was separated by 2D gel electrophoresis and the resulting 
gels compared using SameSpots software. Statistical analysis was performed to determine the sources 
of variation within the experiment: patient, replicate and treatment. ANOVA (1-way and repeated 
measures), and Tukey HSD tests were used to calculate significance as appropriate. The data shows 
replication error from replicate 2 of the patient 16 control group. Patient 16 was significantly different 
to patients 13 & 14 at baseline whereas patient 13 & 14 were not significantly different. Patients 13 & 
14 were significantly affected by treatment whereas patient 16 was not. *Replicate 2 of patient 16 
control was found to be statistically significantly different to other replicates, so replicate 2 of all 
patients, with or without 10µM SF, are excluded from analysis when the analysis includes patient 16 
control group. 
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4.3.2 Selection of protein spots for identification 
After analysis of the sources of variation within the 2D gels, individual spots were then 
analysed to identify individual spots that were significantly altered either due to natural 
variation between the patients at baseline (patient variation), or due to the effect of the 10µM 
SF, either on all the patients as a population, or on each patient individually (treatment 
variation).  
 
All protein spots were assigned an ID by the SameSpots software, and a value calculated from 
the spot volume and intensity. These values were then compared between gels using 1-way 
ANOVA for each spot ID to identify any changes (Table 4.3). Results were not corrected for 
multiple testing. Instead all spots that were reported to be significantly changed were 
manually visually assessed to verify the statistical result. Any ‘false positives’ obtained due to 
artefacts, such as excess SYPRO staining, were eliminated resulting in a list of spots to be 
picked for identification (Table 4.3). Spots chosen for identification are shown in Figure 4.7 
which demonstrates the position of the spots on the gel for each variable in which the spots 
selected were altered.  
 
Ten spots were identified as significantly variable between patients without SF treatment 
(Figure 4.7a), and 4 spots were significantly altered in all 3 patients after SF treatment (Figure 
4.7b). For patients 13, 14 and 16, 20, 38 and 5 spots, respectively, were identified as altered by 
SF (Figure 4.7a, b, c). From the spots identified as significantly altered, it is clear to see that the 
greatest number of changes was observed in patient 14, and that patient 13 had almost half 
that number. In comparison, very few changes were observed in patient 16 as a result of SF 
treatment. These results correlate with the statistical analysis (Table 4.2), which showed that a 
greater statistical variation was observed in patient 14 (p-value <0.001) as a result of SF 
treatment compared to patient 13 and 16 (p-values = 0.0037 and 0.9265 respectively).  
 
Comparison of the spots chosen for identification from the three patients (Figure 4.8) shows 
there is little overlap between the spots altered and the patients, in fact there is only one spot 
overlap between patients 13 and 14, another between patient 13 and 16 but none between 
patient 14 and 16, and none that overlap between all three.  
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This once again highlights how different patients respond in very different manners to SF 
treatment.  The spread of the spots on the gels also demonstrates that there is no correlation 
between mass or pI, and the proteins that SF modulated (Figure 4.7).  
 
 
Table 4.3. Number of spots found to be statistically significantly altered (p-value <0.05) and 
chosen for identification.  
 
Variable Statistically 
Significantly 
Altered Spots  
Spots Picked 
For 
Identification 
Patient  188 10 
Treatment  All patients  59 4 
Patient  13  78 20 
Patient 14 199 38 
Patient 16 65 5 
TOTAL*  482 70 
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF 
for 24 hours in triplicate. Protein was run on by 2D gel electrophoresis and the resulting gels 
compared using SameSpots software. The spots found to be statistically significantly altered 
were identified by statistical analysis of the data generated by the SameSpots software. Each 
spot was then manually assessed and any ‘false positives’ obtained due to artefacts were 
eliminated resulting in the spots picked for identification. The effect of patient was measured 
in the control group. Statistics were not adjusted for multiple testing. *Due to overlap 
between spot IDs in the different variable groups the totals are less than the sum of spots in 
each column.  
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Figure 4.7. Spots picked for identification.  
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF for 24 hours in triplicate. Protein was run by 2D gel 
electrophoresis and the resulting gels compared using SameSpots software. Spots found to be significantly altered and chosen for identification due to 
different sources of variation are shown on example gels: (a) patient variation, and treatment effect on (b) all patients, (c) patient 13, (d) patient 14 and (e) 
patient 16. 
a b 
c d e 
Patient Treatment- All Patients 
Treatment- Patient 13 Treatment- Patient 14 Treatment- Patient 16 
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Figure 4.8. Overlap between spots picked for identification due to the effect of SF on each 
patient. 
This Venn diagram shows the overlap between the spot IDs identified as altered due to the 
effect of 10µM SF on BPH tissue in culture, and selected for protein identification in the tissue 
samples from the three patients. Red = patient 13, green = patient 14, blue = patient 16. 
0
1 0
1
18 37
4
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4.3.3 Identification of proteins 
Spots chosen for identification were picked and underwent in-gel Trypsin digestion. The 
resulting peptides were analysed on an LTQ-Orbitrap Mass Spectrometer and the proteins 
identified by Mascot. From the 70 spots analysed (Table 4.3), 55 positive identifications were 
made, the remaining 15 were not identified, either as protein levels were below the detectable 
limit, or the score returned in Mascot did not reach the arbitrary threshold of significance. The 
positions of the spots that were successfully identified are shown in Figure 4.9, and their 
corresponding protein identifications listed in Table 4.4.  
 
Proteins were identified from Mascot results using the method described in Chapter 4.2.8. In 
most case where proteins were identified, several were found in each spot. To reduce the 
complexity, those identifications that returned a score of <100 were immediately eliminated as 
these were assumed to be minor components within the spot. The mass and pI of the 
remaining IDs were compared to the position of the spot on the gel, and any that did not 
correspond were also discounted.  
 
Finally, sequence coverage was assessed to determine the likelihood of a true identification. In 
some cases, if there was good coverage in a specific section of the sequence, fragmentation of 
the protein was considered, and the mass and pI of the proposed fragment calculated. The 
calculated mass and pI was compared to the position of the spot on the gel to decide whether 
this was a possible ID.  
 
Of the 55 spots that were positively identified, 12 were identified as possible fragments. The pI 
and mass for both the whole protein, and the possible fragment, is listed in Table 4.4.  
 
For some spots more than one possible identification was made as, using the above steps, a 
single identification could not be arrived at, so both possible IDs have been listed. From the 55 
spots that returned a positive ID, 11 of these have more than one possible protein ID. 
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Figure 4.9. Spots identified from 2D Gels.  
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF 
for 24 hours in triplicate. Protein was run by 2D gel electrophoresis, the resulting gels 
compared using SameSpots software and spots selected for identification. Protein spots of 
interest were excised from the gel using the ProPick (Genomic  Solutions), and in-gel Trypsin 
digested. The resulting peptides were analysed on an LTQ-Orbitrap Mass Spectrometer 
(Thermo), and the proteins identified by Mascot (Matrix Sciences). An example gel is shown, 
with spots labelled corresponding to Spot ID in table 4.4, spots that were picked but had no 
positive ID returned by mass spectrometry are not shown.  
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Table 4.4. Identification of protein spots by mass spectrometry. 
  
Spot ID Protein Score Coverage 
(%) 
Accession 
No. 
Mass 
(kDa) 
pI 
352 Myosin-11 5523 18 Q3MIV8 225(86) 5.44(5.17) 
397 Endoplasmin 2212 38 P14625 92696 4.76 
497 Fibulin-1 1698 22 P23142 81 5.07 
504 Fibulin-1 923 13 P23142 81 5.07 
505 Myosin-11 
Collagen Alpha-3(VI) 
Chain 
2506 
 
409 
20 
 
5 
Q3MIV8 
 
P12111 
224(85) 
 
345(131) 
5.44(5.16) 
 
6.26(5.54) 
557 Myosin-11 
Collagen Alpha-3(VI) 
Chain 
647 
 
266 
8 
 
3 
P35749  
 
P12111 
228(85) 
 
345(145) 
5.42(5.13) 
 
6.26(5.6) 
560 Protein Disulfide-
Isomerase A4 
 
327 
 
10 
 
P13667 
 
73 
 
4.96 
580 Myosin-11 119 3 P35749 228(59) 5.42(5.1) 
587 Myosin-11 3259 19 Q3MIV8 224(106) 5.44(5.22) 
593 Myosin-11 464 6 Q3MIV8 224(79) 5.44(5.15) 
649 Collagen Alpha-3(VI) 
Chain 
Filamin-A 
Alpha-Actinin-1 
 
759 
487 
328 
 
5 
3 
10 
 
P12111 
P21333 
P12814 
 
345(157) 
283(141)
103 
 
6.26(5.48) 
5.7(5.15) 
5.25 
682 
 
 
Myosin-11 
Collagen Alpha-3(VI) 
Chain 
962 
 
732 
11 
 
5 
P35749 
 
P12111 
228 (85) 
 
345(119) 
5.42 (5.13) 
 
6.26 (5.59) 
770 Serotransferrin 864 24 P02787 79 6.81 
778 Serotransferrin 812 23 P02787 79 6.81 
859 Protein Disulfide-
Isomerase A4 
 
366 
 
10 
 
P13667 
 
73 
 
4.96 
881 Lumican 282 15 P51884 38 6.16 
998 Serum Albumin 692 29 P02768 71 5.92 
      [CONTINUED] 
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[TABLE 4.4 CONTINUED]  
1045 Collagen Alpha-3(VI) 
Chain 
Heat Shock 70 kDa 
Protein 1A/1B 
 
338 
 
211 
 
3 
 
17 
 
P12111 
 
P08107 
 
345(116) 
 
70 
 
6.26 (5.53) 
 
5.48 
1095 78 kDa Glucose-
Regulated Protein 
 
1897 
 
37 
 
P11021 
 
72 
 
5.07 
1097 ATP Synthase Subunit 
Alpha, Mitochondrial 
 
1463 
 
34 
 
P25705 
 
59 
 
9.16 
1172 Keratin, Type II 
Cytoskeletal 1 
 
392 
 
8 
 
P04264 
 
66 (31) 
 
8.15 (4.83) 
1342 Protein Disulfide-
Isomerase 
 
334 
 
19 
 
P07237 
 
57 
 
4.76 
1430 Calreticulin 226 15 P27797 48 4.29 
1519 ATP Synthase Subunit 
Alpha, Mitochondrial 
 
1950 
 
42 
 
P25705 
 
59 
 
9.16 
1528 ATP Synthase Subunit 
Alpha, Mitochondrial 
 
1218 
 
36 
 
P25705 
 
59 
 
9.16 
1709 Fibulin-5 424 17 Q9UBX5 52 4.58 
1809 Trifunctional Enzyme 
Subunit Beta, 
Mitochondrial 
Elongation Factor 1-
Alpha  
 
418 
 
250 
 
19 
 
12 
 
P55084 
 
P68104 
 
51 
 
50 
 
9.45 
 
9.10 
2142 Creatine Kinase B-Type 777 27 P12277 42 5.34 
2465 Glyceraldehyde-3-
Phosphate 
Dehydrogenase 
 
 
216 
 
 
44 
 
 
P04406 
 
 
36 
 
 
8.57 
2483 Actin, Cytoplasmic 2 399 16 P63261 42 5.3 
2504 Annexin A2 1148 58 P07355 38 7.57 
2642 Tubulin Beta-2C Chain 
Actin, Alpha Skeletal 
Muscle 
208 
 
204 
14 
 
14 
P68371 
 
P68133 
50 
 
42 
4.79 
 
5.23 
      [CONTINUED] 
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[TABLE 4.4 CONTINUED]  
 
 
 
2703 Actin, Alpha Skeletal 
Muscle Microfibril-
Associated Glycoprotein 
4 
175 
 
150 
12 
 
23 
P68133 
 
P55083 
42 
 
28 
5.23 
 
5.38 
2717 L-Lactate 
Dehydrogenase A Chain 
 
318 
 
17 
 
P00338 
 
36 
 
8.44 
2905 Actin, Gamma-Enteric 
Smooth Muscle 
Keratin, Type 1 
Cytoskeletal 10- 
Fragment 
 
664 
 
 
374 
 
28 
 
 
16 
 
P63267 
 
 
P13645 
 
42 
 
 
34 
 
5.31 
 
 
4.62 
2943 Annexin A5 2239 42 P08758 35 4.94 
3038 Actin, Aortic Smooth 
Muscle 
 
793 
 
44 
 
P62736 
 
42 
 
5.23 
3166 Keratin, Type I 
Cytoskeletal 16- 
Fragment 
 
 
152 
 
 
22 
 
 
P08779 
 
 
51(41) 
 
 
4.99(4.82) 
3176 Keratin, Type II 
Cytoskeletal 1- 
Fragment 
 
710 
 
13 
 
P04264 
 
66 
 
8.15 
3247 14-3-3 Epsilon 2634 55 P62258 29 4.63 
3387 Actin, Cytoplasmic 2 434 18 P63261 42 5.31 
3404 14-3-3 Theta 671 32 P27348 28 4.68 
3496 Triosephosphate 
Isomerase 
 
703 
 
61 
 
P60174 
 
26 
 
6.45 
3531 Actin, Alpha Skeletal 
Muscle 
 
377 
 
20 
 
P68133 
 
42 
 
5.23 
3783 Transgelin 889 47 Q01995 22 8.87 
      [CONTINUED] 
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[TABLE 4.4 CONTINUED]  
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF 
for 24 hours in triplicate. Protein was run on by 2D gel electrophoresis, the resulting gels 
compared using SameSpots software and spots selected for identification. Protein spots of 
interest were excised from the gel using the ProPick (Genomic  Solutions) and in-gel Trypsin 
digested; the resulting peptides were analysed on an LTQ-Orbitrap Mass Spectrometer 
(Thermo) and the proteins identified by Mascot (Matrix Sciences). Masses and pIs given in 
brackets are estimated for a predicted fragment according to the sequence coverage. 
 
3802 Keratin, Type II 
Cytoskeletal 1 
Desmin- Fragment 
 
908 
607 
 
15 
21 
 
P04264 
P17661 
 
66(32) 
53 
 
8.15(4.9) 
5.21 
3862 Desmin 469 14 P17661 53 5.21 
3868 Actin, Aortic Smooth 
Muscle 
 
733 
 
23 
 
P62736 
 
42 
 
5.23 
4576 Heat Shock Protein Beta 
6 
 
426 
 
30 
 
O14558 
 
17 
 
5.95 
4743 Transgelin- Fragment 321 47 Q01995 22 8.87 
4828 Myosin Light Chain 6B 1249 22 P14649 22 5.56 
5602 Keratin, Type II 
Cytoskeletal 1- 
Fragment 
 
636 
 
9 
 
P04264 
 
66 
 
8.15 
5656 Keratin, Type II 
Cytoskeletal 1- 
Fragment 
 
230 
 
6 
 
P04264 
 
66 
 
8.15 
5803 Keratin, Type II 
Cytoskeletal 1- 
Fragment  
Actin, Aortic Smooth 
Muscle- Fragment 
 
197 
 
171 
 
6 
 
7 
 
P04264 
 
P62736 
 
66 
 
42 
 
8.15 
 
5.23 
5810 Keratin, Type I 
Cytoskeletal 10- 
Fragment 
 
 
315 
 
 
9 
 
 
P13645 
 
 
59 
 
 
5.13 
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4.4 Discussion 
4.4.1 Sources of Variation 
Within the experiment there were four main sources of variation: replication, patient, 
treatment and technology. The aim of this experiment was to measure the variation of the SF 
treatment, but to ensure high quality significant results, the effect of replication, patient and 
technical variation first had to be assessed.  
 
 
4.4.1.1 Replication 
Analysis of replication variability revealed little difference between replicates, the only 
variation that was observed was that replicate 2 of patient 16 in the control group was 
significantly different to the other replicates (Table 4.2). As the variability between all other 
replicates was insignificant, it was decided to exclude replicate 2 of all patients and treatments 
when performing analysis that would otherwise include replicate 2 of the patient 16 control 
group.  This decision was made to ensure balanced statistical analysis, although as a result 
some statistical power was lost.  
 
The source of this variation could be either of two things, either this replicate was biologically 
different to the other replicates, or technical error may have occurred resulting in the 
significant variation. Without running this replicate again by 2D gel electrophoresis, to confirm 
or eliminate technical error, it is difficult to identify the cause of the variation. Due to the good 
replication seen in all other samples, treating this replicate as an anomaly, and excluding it 
from analysis, seemed the fairest decision to prevent any skewing of results.  
 
 
4.4.1.2 Patient 
To understand any effect of SF treatment, it was first necessary to look at variability in the 
untreated patient samples, due to the natural variation that is known to exist in humans.  
 
Altered gene expression is commonly used to describe and explain many diseases, including 
cancer, but it is possible that many of these changes may not actually be specific to disease, 
but related to other factors such as polymorphisms among individuals and populations. 
Natural variation within humans arises not only from inherited genes but also from 
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environmental factors such as lifestyle, diet, and aging. Natural variation has been widely 
reported, but little research has investigated how significant this effect can be.  
 
To investigate this precise question, Whitehead and Crawford examined the expression of 192 
metabolic genes in a fish model. They reported that the expression of 48% of the genes altered 
between individuals in the same population, despite being raised in controlled conditions 
[184]. As a result, they suggested the same variation in gene expression would be expected in 
humans, and highlighted the need for biological replicates in order to ascribe differences in 
gene expression to treatment, rather than inter-individual variation.  
 
The variation between individuals found by Whitehead and Crawford [184] was very high 
compared to other studies, in which natural variation of 24 and 25% has been reported in 
yeast and Drosphila respectively. The high variation in the study by Whitehead and Crawford 
may be explained by the targeted measurement of metabolic genes only. A separate study, by 
Oleksiak and colleagues [185], using the same fish model reported 18% of genes varied. 
However, they measured 907 genes, compared to the 192 assayed by Whitehead and 
Crawford. The 18% variation observed by Oleksiak and colleagues more closely matched the 
variation reported in other models.  
 
Variation has also been investigated in human samples, with a study of gene expression 
patterns in human blood reporting variation in 370 genes between samples. These changes 
were attributed to factors such as relative proportions of specific cell subsets, gender, age, and 
time of day that the samples were collected at [186]. Human variation was also considered an 
important factor in a study by Bouwman and colleagues, who noted the importance of 
replicate number as a result of this variation, and also due to the subtlety of the effects that 
are normally induced by dietary agents [178].  
 
In the study performed here, out of the tissue from three patients analysed, it was interesting 
to note that global protein expression at baseline in patients 13 and 14 was similar, but that in 
patient 16 was significantly different (Table 4.2). Out of the 1817 spots assigned an ID, 188 
(10%) were noted as statistically significantly varied between patients at baseline, but after 
manual assessment only 10 were selected for identification (Table 4.3). Whether the natural 
variation observed between patients resulted from the expression of different proteins (eg. 
patient 13 expressed protein A whilst patient 14 expressed protein B), or significant 
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differences in the levels of protein expression (eg. patients 13 and 14 both expressed protein A 
but it is expressed at a significantly higher level in patient 14) is unknown. However, this 
highlights the natural variation which exists between patients, and therefore needs to be 
considered when analysing the effect of SF treatment on the different patients. 
 
 
4.4.1.3 Technical 
A further source of error arose in the automatic selection and value calculation of the spots by 
SameSpots software, leading to the need for the manual assessment of the spots. During the 
initial stages of spot selection and gel alignment, such error occured due to the size or shape of 
the spot, as sometimes the automatic selection would create multiple spots from a spot that, 
upon manual inspection, would be analysed as a whole (Figure 4.10a). Once the gels were 
correctly aligned and the spot selection verified, the gels were analysed, producing a list of 
spot IDs that were statistically significantly altered. All such spots were then manually assessed 
for any artefacts that may affect the analysis and produce false positives. The two main factors 
that were looked for were excess Sypro spots and watermark spots.  
 
Excess Sypro spots occur where the surface of the gel is not perfectly smooth forming small 
pockets where the Sypro stain gets trapped, causing small intense spots. Although these 
pockets are very small and the program does not identify them as spots, if they are within the 
selection boundary of a spot they are included in the calculation of the spot value. As they are 
often intensely stained, their inclusion can skew the spot value, so that upon statistical analysis 
a false positive or negative may be obtained (Figure 4.10b).  
 
Further to this, the SameSpots programme is highly sensitive, and can therefore detect very 
small changes in the gel image. Due to this, it can detect and select altered spots that would be 
missed by the naked eye. However, this sensitivity can lead to the detection of spots that 
appear to be no more than a watermark, so these kinds of spots were eliminated as they may 
not be a true result of the sample. In addition, the level of any protein in such spots is at the 
limit of detection so would result in huge variability in identification (Figure 4.10c).   
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Figure 4.10. Technical Sources of Error in 2D Gel Analysis.  
Example images of sources of error that can affect the analysis of 2D gels. All gels are assessed 
manually to identify and correct these errors. (a) Spot splitting: Automatic spot selection using 
SameSpots can sometimes result in spots being ‘split’ by the software but can be corrected 
manually. The blue selection is the spot selected by SameSpots, the red selection shows the 
approximate area that would be selected as a spot after manual correction. (b) Excess Sypro 
staining: small indents in the gel surface form pockets trapping Sypro stain, and producing 
small intense spots that can interfere with spot value calculation, and therefore analysis. In the 
middle image, within the blue boundary is a Sypro spot, without this spot the staining of the 
selected area is visibly less intense than that in the lower image and at a similar level to that in 
the top image. However, due to the Sypro spot the calculated value of the spot in the middle 
image (15 x 10
4
 units) is closer to that of the lower image (17 x 10
4
 units) than the top image (9 
x 10
4
 units). This would therefore affect any statistical analysis performed, so such spots need 
to be identified manually and this artefact noted, so as not to produce any false results. (c) 
Watermark spot: SameSpots is highly sensitive and can detect changes in the gel image that 
the naked eye would otherwise miss leading to the selection of spots that look like 
watermarks. Such spots are not selected for identification as these spots may not be a true 
result of the sample, and the level of protein in such spots it at the limit of detection so would 
result in huge variability in identification.  
 
 
  
Volume: 9 x 10
4
 
Volume: 15 x 10
4
 
Volume: 17 x 10
4
 
a b c 
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4.4.2 The effect of SF on global protein expression 
Treatment with 10µM SF had a highly significant effect on the global protein expression (p-
value <0.001) in the patients when analysed as a whole population. A total of 59 spots were 
identified as altered, although only 4 were chosen for identification (Table 4.3).  
 
When analysed individually, both patient 13 and 14 responded significantly (p-values = 0.0037 
and <0.001 respectively), patient 14 especially so, but no effect was observed on patient 16 (p-
value = 0.9265) (Table 4.2). These results correspond with the number of spots that were 
found to be statistically significantly altered; 78 in patient 13, 199 in patient 14, and 65 in 
patient 16. However, only 20, 38 and 5 spots were selected for identification respectively 
(Table 4.3). Interestingly, there was very little overlap between the proteins altered in the 
three patients (Figure 4.8).  
 
These results show that in a population you would expect sulforaphane, or the consumption of 
broccoli, to have an effect on protein expression in the prostate. This corresponds with 
previous research that has shown the consumption of cruciferous vegetables can modify 
disease risk [52, 70, 72-75]. However, the individual nature of the response of each patient 
highlights the natural variation present in human tissue. This demonstrates the different ways 
by which tissue can respond to the same treatment, and therefore the necessity for larger 
patient numbers when dealing with human samples in order to obtain data of wider 
significance.   
 
 
4.4.3 Spots chosen for identification 
Out of all the spots chosen for identification it is interesting to note that the positions of the 
spots are widely spread over the gel, indicating that none of the sources of variation affect 
proteins with a particular mass or pI (Figures 4.7). There are some areas of the gel that 
comparatively have a higher percentage of the gel IDs within them, but these correspond to 
areas that have a greater protein density, in particular towards the lower end of the pH scale 
and in the top half of the mass scale. Some of these spots appear to be in ‘sets’ or run 
together, so it may be these proteins are highly homologous, or belong to the same family of 
proteins. Therefore, they may have similar properties, so in samples where one member of a 
family has greater expression, another member of the same family may be reduced, the 
expression pattern of which may then be reversed in a different sample. 
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4.4.4 Identification of proteins 
Out of the 70 proteins that were picked for identification, only 55 returned a positive ID (Table 
4.4). This may be because the amount of protein in the spot was too low, and therefore below 
the detection limit of the mass spectrometry. In other cases protein was detected, but the 
score returned was <100, which was set as an arbitrary threshold of significance. Scores below 
this were rejected and therefore no positive ID made.  
 
It is difficult to assess the success of the identification rate, here it was 71%, as papers do not 
generally state whether the number of spots identified was the same as the number picked. 
However, from the data that is available I would suggest that the identification rate compares 
favourably. Polley and colleagues [187] did not specify how many spots were picked for 
identification but they identified 26 spots out of a possible 291 as they stated that the others 
were too weakly expressed to be identified. Lee and colleagues [180] successfully identified all 
spots selected, but as they only selected the 9 spots from a possible 300 which were noted as 
altered, they increased their chances of success by only selecting spots with high expression. In 
comparison, in the study performed here, all spots identified as altered were selected. As a 
result, it is not surprising that not all spots picked were identified in this study as they were not 
selected based on expression strength, so it is in line with previous data that weaker spots 
were not identified. 
 
After Trypsin-digestion, the resulting peptides were analysed by mass spectrometry in batches 
on a number of different runs. On the first run, an error occurred with the machine and only 
partial identifications obtained. These spots were re-picked and identified. For the majority of 
the samples that had returned a result on the original run, the new run produced the same 
outcome further verifying these identifications. As the same results could be obtained from 
the same spot from different gels, this indicates good reproducibility of results, and therefore 
greater confidence that the results obtained are correct. It is good practice to replicate analysis 
of proteins by mass spectrometry to demonstrate reproducibility of results but this is often not 
done due to cost limitations. 
 
Some of the spots identified had more than one possible protein ID returned that could not be 
eliminated, and as a result, all probable IDs for that spot are listed (Table 4.4). For example, 
spot 649 returned three possible IDs, two of which may be fragments, whilst spot 2642 could 
be one of two proteins, or a combination of both. Such results suggest sequence homology 
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between proteins, or may be due to more than one protein being present in the spot, so the 
multiple identifications may actually be representative of the spot picked. In the majority of 
cases, a single identification could be reached by comparison of mass, pI and sequence 
coverage, but in some cases all values were highly comparable and therefore no single ID could 
be arrived at. 
 
 
4.4.5 Conclusions 
2D gel electrophoresis produced good replication, and was a reliable method for the unbiased 
detection of protein changes, although there were limits, such as the identification of low 
volume spots. The results demonstrate that global protein expression naturally varies in BPH 
samples between individuals.  
 
It is also clear to see that biologically relevant levels of SF can significantly alter global protein 
expression in BPH tissue after 24 hours of culture, but that individual patients respond in 
varying manners. These results demonstrated that natural variation was highly apparent in the 
patients, both at baseline and in their response to SF. This highlights the need to use large 
sample numbers to obtain results that can be considered representative of the general 
population. The biological role of the proteins identified and any previously reported 
relationships with SF are discussed in the next chapter. 
 
  
 
 
 
 
Chapter Five 
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Chapter 5. Analysis of proteins altered in BPH tissue 
5.0.1 Summary 
In the previous chapter, protein extracted from BPH tissue from three patients, cultured with 
or without 10µM SF in triplicate, was separated by 2D gel electrophoresis. The resulting 
protein spots that were altered, either between patients at baseline, or as a result of SF 
treatment, were identified by mass spectrometry. Of the 70 spots chosen for identification, 55 
returned a positive ID, of which there were only 37 unique proteins. The proteins identified are 
discussed in this chapter. 
 
Analysis of the proteins using the Gene Ontology website, indicated five main biological 
processes that the proteins were involved in, and the majority of the proteins could be sorted 
into three molecular function groups. The greatest overlap between the two sets of groups 
was between the molecular chaperone functional group, and the apoptosis biological process 
group. Apoptosis is a critical biological process, so the proteins that overlapped between the 
groups were chosen for further analysis. These proteins were HSP90β1, calreticulin, 14-3-3ε, 
GRP78 and HSP70. 
 
These results demonstrate that SF is capable of altering proteins involved in biological 
processes critical to normal cell function. Dysregulation of molecular chaperones has been 
implicated in disease, including cancer, so it is interesting that SF can alter these proteins. Little 
research has been done with regard to the effect of SF on molecular chaperones, so this may 
be a promising area of research. 
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5.1 Introduction 
Previously, protein extracted from BPH tissue, cultured with and without 10µM SF for 24 
hours, was analysed using 2D gel electrophoresis. From this untargeted approach, a number of 
spots that altered either between patients due to natural variation, or as a result of SF, either 
in one patient, or in the patients as a whole population, were selected. Using mass 
spectrometry, the protein identity of these spots was discovered. In this chapter, the proteins 
identified as altered are discussed, and any patterns in the molecular functions and biological 
processes these proteins are involved in are analysed. This analysis was performed to identify 
a possible novel target of SF activity for further investigation.  
 
The proteins are classified using the Gene Ontology (GO) website [188]. The GO website is a 
database designed to provide consistent descriptions of gene products in terms of their 
associated biological processes, molecular functions, and cellular components. In this chapter, 
the biological processes and molecular functions are discussed. According to the GO website a 
biological process is defined as being a ‘collection of molecular events with a defined beginning 
and end’, whilst molecular function refers to the job or abilities of a particular protein [189]. 
Therefore, a molecular function can describe the job that a protein does within a biological 
process. Depending on the particular abilities of a protein, a single protein can be capable of 
performing multiple molecular functions in multiple biological processes. Use of the GO 
classifications will allow the proteins identified to be grouped and compared more easily in 
order to identify any patterns in the functions and processes altered.  
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5.2 Methods 
5.2.1 Classification of proteins by molecular function and biological process 
The 55 spots (Table 4.4) successfully identified in the Chapter 4  were searched on the GO 
website (www.geneontology.org) [188], and grouped according to molecular functions and 
biological processes. Many proteins were involved in multiple molecular functions and 
biological processes, therefore, proteins were classified so as to minimise the number of 
groups in order to discover the most common biological processes and molecular functions the 
proteins were involved in.  
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5.3 Results 
5.3.1 Analysis of proteins significantly altered between 2D gels 
Spots that were found to be significantly altered were identified by mass spectrometry (see 
Chapter 4), and separated into groups depending on the variable, baseline variation or effect 
of SF, due to which they altered.  
 
In total, fifty five spots were positively identified (Figure 5.1). Seven varied between the 
patients at baseline (Table 5.1), three were altered as a result of 10µM SF in the patients 
analysed as a population (Table 5.2), and fifty were altered in the individual patients treated 
with SF: fourteen altered in patient 13 (Table 5.3), thirty two in patient 14 (Table 5.4) and four 
in patient 16 (Table 5.5). There was a total overlap of five spots between all the groups 
(baseline and SF treated).  
 
Two of the spots which naturally varied between the patients at baseline were also found to 
be altered by 10µM SF, one in patient 13 (spot 5656) and the other in patient 16 (spot 5602). 
Of the three spots identified as altered by SF in the patients analysed as a population one of 
these was also altered in patient 14 (spot 4828) when analysed individually. Of the spots found 
to be altered in the individual patients in response to SF, one spot was found to be altered in 
patient 13 and 14 (spot 3038), and another was altered in patients 13 and 16 (spot 352), but 
there was no overlap between patients 14 and 16.  
 
 
Figure 5.1. Spots significantly altered between BPH samples ran by 2D gel electrophoresis. 
Diagram showing the grouping of the spots identified from the 2D gels as they were found to 
be altered due to either baseline variation or in response to 10µM SF. Overlap between groups 
also displayed. 
55 Spots Identified
Baseline SF
All 13 14 16
7 3 14 32 4
TREATMENT
PATIENT
SPOTS PER GROUP
OVERLAP
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Of the seven spots that were altered between the patients without SF treatment, three were 
found to have multiple possible IDs, whilst the other four all had a single ID, three of which 
were keratins (Table 5.1).  
 
Table 5.1. Fold-change of proteins identified as statistically significantly (p ≤0.05) different 
between individuals at baseline.  
 
Spot ID Protein Fold-Change 
13vs14 13vs16 14vs16 
1809 Trifunctional Enzyme Subunit Beta, Mitochondrial 
Elongation Factor 1-Alpha 1 
0.87 0.43 0.49 
2504 Annexin A2 0.84 0.54 0.65 
2642 Tubulin Beta-2C Chain 
Actin, Alpha Skeletal Muscle 
1.50 0.49 0.32 
2703 Actin, Alpha Skeletal Muscle  
Microfibril-Associated Glycoprotein 4 
1.74 0.49 0.28 
5602 Keratin, Type II Cytoskeletal 1- Fragment 1.48 0.69 0.47 
5656 Keratin, Type II Cytoskeletal 1- Fragment 0.44 0.22 0.50 
5810 Keratin, Type I Cytoskeletal 10- Fragment 1.22 2.63 2.16 
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured for 24 hours in triplicate. 
Protein was run by 2D gel electrophoresis, the resulting gels compared using SameSpots 
software, and spots selected for identification. 
 
 
  
Analysis of proteins altered in BPH tissue 
 
 
123 
 
In the patients analysed as a population, three spots were altered, all of which were identified 
as single and differing IDs (Table 5.2).  
 
Table 5.2. Fold-change of proteins identified as statistically significantly (p >0.05) altered in 
the population as a whole as a result of sulforaphane treatment.  
 
Spot ID Protein Fold-Change 
881 Lumican 1.21 
1095 78 kDa Glucose-Regulated Protein 0.62 
4828 Myosin Light Chain 6B 0.76 
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF 
for 24 hours in triplicate. Protein was run by 2D gel electrophoresis, the resulting gels 
compared using SameSpots software, and spots selected for identification. 
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Of the fourteen spots altered by SF in patient 13, four spots returned multiple possible IDs, but 
three of these spots were identified as myosin-11 (MYH11) and collagen alpha-3 (VI) chain 
(COL6A3). The remaining ten spots each had single IDs, four of which were identified as 
MYH11, three as actins, and the remaining three all had different IDs (Table 5.3).  
 
Table 5.3. Fold-change of proteins identified as statistically significantly (p  ≤0.05) altered in 
patient 13 as a result of 10µM SF treatment. 
 
Spot ID Protein Fold-Change 
352 Myosin-11 1.29 
505 Myosin-11 
Collagen Alpha-3(VI) Chain 
1.21 
557 Myosin-11 
Collagen Alpha-3(VI) Chain 
0.42 
560 Protein Disulfide-Isomerase A4 0.59 
580 Myosin-11 1.45 
587 Myosin-11 2.01 
593 Myosin-11 1.83 
682 Myosin-11 
Collagen Alpha-3(VI) Chain 
0.26 
3038 Actin, Aortic Smooth Muscle 1.71 
3387 Actin, Cytoplasmic 2 1.44 
3868 Actin, Aortic Smooth Muscle 2.03 
4567 Heat Shock Protein Beta-6 1.78 
5656 Keratin, Type II Cytoskeletal 1- Fragment 0.48 
5803 Keratin, Type II Cytoskeletal 1- Fragment  
Actin, Aortic Smooth Muscle- Fragment 
1.25 
 
BPH tissue from patient 13 was cultured with or without 10µM SF for 24 hours in triplicate. 
Protein was run by 2D gel electrophoresis, the resulting gels compared using SameSpots 
software, and spots selected for identification. 
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Thirty two spots were found to be altered by SF in patient 14, with only three having multiple 
possible IDs. Of the spots with single IDs, only three spots were found to be increased by SF, 
two of which were both identified as serotransferrin (TF). The other twenty six spots were all 
reduced by SF, and included three spots each identified as fibulin (FBLN), ATP synthase subunit 
alpha (ATP5A1), and actin. Whilst protein disulfide isomerase, keratin, transgelin (TAGLN), and 
14-3-3 proteins, were found in two spots each. The remaining nine spots all had different IDs 
(Table 5.4).  
 
Table 5.4. Fold-change of proteins identified as statistically significantly (p  ≤0.05) altered in 
patient 14 as a result of 10µM SF treatment. 
 
Spot ID Protein Fold-Change 
397 Endoplasmin 0.41 
497 Fibulin-1 0.50 
504 Fibulin-1 0.51 
649 Collagen Alpha-3(VI) Chain 
Filamin-A 
Alpha-Actinin-1 
0.75 
770 Serotransferrin 2.19 
778 Serotransferrin 2.93 
859 Protein Disulfide-Isomerase A4 0.25 
1097 ATP Synthase Subunit Alpha, Mitochondrial 0.40 
1172 Keratin, Type II Cytoskeletal 1 2.32 
1342 Protein Disulfide-Isomerase 0.31 
1430 Calreticulin 0.15 
1519 ATP Synthase Subunit Alpha, Mitochondrial 0.25 
1528 ATP Synthase Subunit Alpha, Mitochondrial 0.42 
1709 Fibulin-5 0.35 
2142 Creatine Kinase B-Type 0.52 
2465 Glyceraldehyde-3-Phosphate Dehydrogenase 0.43 
2483 Actin, Cytoplasmic 2 0.51 
2717 L-Lactate Dehydrogenase A Chain 0.33 
  [CONTINUED] 
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[TABLE 5.4 CONTINUED] 
2905 Actin, Gamma-Enteric Smooth Muscle 
Keratin, Type 1 Cytoskeletal 10- Fragment 
0.59 
2943 Annexin A5 0.46 
3038 Actin, Aortic Smooth Muscle 0.54 
3166 Keratin, Type I Cytoskeletal 16- Fragment 0.32 
3176 Keratin, Type II Cytoskeletal 1- Fragment 0.53 
3247 14-3-3 Epsilon 0.26 
3404 14-3-3 Theta 0.37 
3496 Triosephosphate Isomerase 0.46 
3531 Actin, Alpha Skeletal Muscle 0.57 
3783 Transgelin 0.34 
3802 Keratin, Type II Cytoskeletal 1 
Desmin- Fragment 
0.42 
3862 Desmin 0.41 
4743 Transgelin- Fragment 0.53 
4828 Myosin Light Chain 6B 0.43 
 
 
BPH tissue from patient 14 was cultured with or without 10µM SF for 24 hours with in 
triplicate. Protein was run by 2D gel electrophoresis, the resulting gels compared using 
SameSpots software, and spots selected for identification. 
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In patient 16, four spots were identified as altered, one of which returned multiple IDs. The 
other three spots had single IDs (Table 5.5).  
 
Table 5.5. Fold-change of proteins identified as statistically significantly (p  ≤0.05) altered in 
patient 16 as a result of 10µM SF treatment. 
 
Spot ID Protein Fold-Change 
352 Myosin-11 0.82 
998 Serum Albumin 2.05 
1045 Collagen Alpha-3(VI) Chain 
Heat Shock 70 kDa Protein 1A/1B 
1.91 
5602 Keratin, Type II Cytoskeletal 1- Fragment 1.29 
 
BPH tissue from patient 16 was cultured with or without 10µM SF for 24 hours in triplicate. 
Protein was run by 2D gel electrophoresis, the resulting gels compared using SameSpots 
software, and spots selected for identification. 
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5.3.2 Biological process and molecular function analysis 
A number of the spots analysed were identified as being the same protein, so the list of 
proteins from the forty eight spots altered by sulforaphane resulted in thirty three different 
protein IDs. Using the Gene Ontology website, these proteins were then classified into the 
smallest number of biological process and molecular functional groups possible, to identify if 
there were any patterns or similarities in the proteins altered in the tissue.  
 
To try and understand the biological relevance of the proteins altered by SF (Table 5.2 – 5.5), 
they were grouped according to the biological processes in which they were involved. The 
proteins were classified into five biological process groups, although four additional proteins 
were unable to be grouped with any others, and were therefore listed in a sixth group called 
‘Other’. The biological processes identified were (in order of descending number of proteins in 
the group): apoptosis; metabolism; muscle development and contraction; cell proliferation, 
adhesion and angiogenesis; cytoskeleton organization; and other (Table 5.6). 
 
According to molecular function the proteins could be sorted in three broad groups, plus a 
final ‘Other’ group for those that did not correspond with any other protein molecular 
functions. The most common molecular function was structure and adhesion, followed by 
molecular chaperones, and then enzymatic activity (Table 5.7). 
 
Comparison of the Molecular Function and Biological Process groups revealed the greatest 
overlap between the Enzymatic Activity molecular function group and the Metabolism 
biological process group with all seven proteins found in both groups. Five proteins overlapped 
between the Molecular Chaperone molecular functional group and the Apoptosis biological 
process group. All the members of the Cell Proliferation, Adhesion and Angiogenesis biological 
process group and all but one of the seven members, HSPB6, of the Muscle Development and 
Contraction biological process group, were in the Structure and Adhesion molecular function 
group.   
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Table 5.6. Proteins identified from 2D gels classified by biological process.  
 
 Apoptosis 
14-3-3 Epsilon 
Alpha-Actinin-1 
Annexin A5 
Calreticulin 
78 kDa Glucose-Regulated Protein 
Endoplasmin 
Heat Shock 70 kDa Protein 1A/1B 
Serum Albumin 
 
Cell Proliferation, Adhesion and 
Angiogenesis 
Collagen alpha-3(VI) chain 
Fibulin-1 
Fibulin-5 
Keratin, Type I Cytoskeletal 16 
Keratin, Type II Cytoskeletal 1 
Lumican 
 
Cytoskeletal Organization 
Actin, cytoplasmic 2 
Filamin-A 
 
 
 
 
Metabolism 
ATP synthase subunit alpha, mitochondrial 
Glyceraldehyde-3-phosphate 
dehydrogenase 
L-lactate dehydrogenase A chain 
Creatine kinase B-type 
Protein Disulfide-Isomerase 
Protein disulfide-isomerase A4 
Triosephosphate Isomerase 
 
Muscle Development and Contraction 
Actin, alpha skeletal muscle 
Actin, gamma-enteric smooth muscle 
Desmin 
Heat shock protein beta-6 
Myosin-11 
Myosin light-chain 6B 
Transgelin 
 
Other 
Keratin, Type I Cytoskeletal 10 
14-3-3 Theta 
Serotransferrin 
Three BPH tissue samples (patients 13, 14 and 16) were cultured with or without SF for 24 
hours in triplicate. Protein was run by 2D gel electrophoresis, the resulting gels compared 
using SameSpots software, and spots selected for identification. Identified proteins grouped 
into smallest number of biological processes possible as classified by www.geneontology.org 
as the majority of proteins are involved in multiple GO biological processes. 
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Table 5.7. Proteins identified from 2D gels organised into molecular functional groups.  
 
Enzymatic Activity 
L-Lactate Dehydrogenase A Chain 
Glyceraldehyde-3-Phosphate 
Dehydrogenase 
Protein Disulfide-Isomerase 
Protein Disulfide-Isomerase A4 
Creatine Kinase B-Type 
ATP Synthase Subunit Alpha, Mitochondrial 
Triosephosphate Isomerase 
 
 
Others 
Serum Albumin 
Serotransferrin 
Annexin A5 
Heat Shock Protein Beta 6 
 
 
 
Structure and Adhesion (ECM, 
Cytoskeleton, and Muscle) 
Actin, Cytoplasmic 2 
Actin, Gamma-Enteric Smooth Muscle 
Actin, Alpha Skeletal Muscle 
Alpha-Actinin-1 
Desmin 
Filamin-A 
Keratin, Type II Cytoskeletal 1 
Keratin, Type I Cytoskeletal 10 
Keratin, Type I Cytoskeletal 16 
Transgelin 
Collagen Alpha-3(VI) Chain 
Lumican 
Fibulin-1 
Myosin Light-Chain 6B 
Myosin-11 
Fibulin-5 
 
 
 
 
 
 
 
BPH tissue from three patients (patients 13, 14 and 16) was cultured with or without 10µM SF 
for 24 hours in triplicate. Protein was run by 2D gel electrophoresis, the resulting gels 
compared using SameSpots software, and spots selected for identification. Identified proteins 
grouped into smallest number of molecular functions possible as classified by 
www.geneontology.org as the majority of proteins have multiple GO Molecular functions. 
Molecular Chaperones 
14-3-3 Epsilon 
14-3-3 Theta 
Calreticulin 
Endoplasmin 
78 kDa Glucose-Regulated Protein 
Heat Shock 70 kDa Protein 1A/1B 
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5.3.3 The link between protein binding proteins and apoptosis 
Comparison of the most common molecular functions and biological processes the proteins 
altered by 10µM SF were found to be involved in, revealed overlap between proteins that 
acted as molecular chaperones  and were involved in the apoptotic biological process. These 
proteins were then selected as possible novel targets for SF activity as, although the effect of 
SF on apoptosis has been investigated, little research has been conducted regarding SF and 
molecular chaperones, and their role in the biological process. The five proteins are 
endoplasmin (HSP90β1), calreticulin (CALR), 14-3-3ε, 78 kDa glucose-regulated protein 
(GRP78) and heat shock 70 kDa protein 1A/1B (HSP70). 
 
As discussed in the previous chapter, variation was observed in replicate two of patient 16 in 
the control group, so this data was excluded from any analysis performed. Therefore, the data 
shown below for the altered spots, includes replicate two in the analysis of patients 13 and 14, 
but replicate two of patient 16 with and without SF is excluded. When analysed as a 
population, replicate two of all patients and conditions is excluded, as this corresponds with 
handling of data in Chapter 4 to ensure balanced statistical analysis.  
 
SF was seen to significantly reduce HSP90β1 (Figure 5.2) in patient 14 by 60% (p-value = 0.023), 
but had very little effect on its expression in the other patients, although a slight increase was 
observed in patient 16 (p-value = 0.098). Overall, the reduction of HSP90β1 in the patients 
analysed as a whole was not significant (p-value = 0.327).  
 
Calrecticulin (Figure 5.3) was also seen to be significantly reduced (p-value = 0.018) by SF in 
patient 14, although it appeared to be non-significantly increased in patients 13 and 16 (p-
values = 0.307 and 0.374 respectively). Overall, in the population, SF did not have a significant 
effect on calreticulin (p-value = 0.389).  
 
A similar pattern was seen for the effect of SF on 14-3-3ε (Figure 5.4), with its expression being 
reduced in patient 14 (p-value = 0.02), whilst no significant effect was observed on the other 
patients (p-values = 0.406 and 0.938 respectively).  When analysed as a population no effect 
was seen (p-value = 0.244).  
 
GRP78 (Figure 5.5) was observed to be significantly decreased in both patients 14 and 16 (p-
values = 0.015 and 0.013 respectively), but no effect seen on patient 13 (p-value = 0.645). Due 
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to the significant effect seen on two patients, the reduction of GRP78 in the group was highly 
significant (p-value <0.001).  
 
The effect of SF on HSP70 (Figure 5.6) was more complex, with patient 13 showing no effect 
(p-value = 0.839), patient 14 was observed to be slightly decreased (p-value = 0.057), whilst in 
patient 16 it was increased (p-value = 0.041). However, overall no effect was noted (p-value = 
0.649).  
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Figure 5.2. The effect of SF on HSP90β1.  
BPH tissue from three patients (patients 13, 14 and 16) was treated with or without 10µM SF 
for 24 hours in triplicate. Protein was extracted, run on 2D gels, and analysed using SameSpots 
software to identify altered spots which were then identified using mass spectrometry. (a) 
Images of spot 397, identified as HSP90β1, taken from the 2D gels for each patient with or 
without 10µM SF in triplicate are shown, and (b) quantified to statistically determine the effect 
of 10µM SF (Means ± standard deviation are plotted; p-values = 0.735, 0.023, 0.098 
respectively). Replicate 2 of patient 16 was excluded from the analysis due to previously noted 
replication variation (outlined in red in (a)). (c) The effect of SF on the patients as a whole 
population with replicate 2 removed from all patients (p-value = 0.327). * p-value <0.05. 
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Figure 5.3. The effect of SF on calreticulin.  
BPH tissue from three patients (patients 13, 14 and 16) was treated with or without 10µM SF 
for 24 hours in triplicate. Protein was extracted, run on 2D gels, and analysed using SameSpots 
software to identify altered spots which were then identified using mass spectrometry. (a) 
Images of spot 1430, identified as Calreticulin taken, from the 2D gels for each patient with or 
without 10µM SF in triplicate are shown, and (b) quantified to statistically determine the effect 
of 10µM SF (Means ± standard deviation are plotted; p values: 0.307, 0.018, 0.374 
respectively). Replicate 2 of patient 16 was excluded from the analysis due to previously noted 
replication variation (outlined in red in (a)). (c) The effect of SF on the patients as a whole 
population with replicate 2 removed from all patients (p-value = 0.389). * p-value <0.05. 
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Figure 5.4. The effect of SF on 14-3-3ε.  
BPH tissue from three patients (patients 13, 14 and 16) was treated with or without 10µM SF 
for 24 hours in triplicate. Protein was extracted, run on 2D gels, and analysed using SameSpots 
software to identify altered spots which were then identified using mass spectrometry.  (a) 
Images of spot 3247, identified as 14-3-3e, taken from the 2D gels for each patient with or 
without 10µM SF in triplicate are shown, and (b) quantified to statistically determine the effect 
of 10µM SF (Means ± standard deviation are plotted; p values: 0.406, 0.02, 0.938 respectively). 
Replicate 2 of patient 16 was excluded from the analysis due to previously noted replication 
variation (outlined in red in (a)).  (c) The effect of SF on the patients as a whole population with 
replicate 2 removed from all patients (p-value = 0.244). * p-value <0.05. 
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Figure 5.5. The effect of SF on GRP78.  
BPH tissue from three patients (patients 13, 14 and 16) was treated with or without 10µM SF 
for 24 hours in triplicate. Protein was extracted, run on 2D gels, and analysed using SameSpots 
software to identify altered spots which were then identified using mass spectrometry. (a) 
Images of spot 1095, identified as GRP78, taken from the 2D gels for each patient with or 
without 10µM SF in triplicate are shown, and (b) quantified to statistically determine the effect 
of 10µM SF (Means ± standard deviation are plotted; p values: 0.645, 0.015, 0.013 
respectively). Replicate 2 of patient 16 was excluded from the analysis due to previously noted 
replication variation (outlined in red in (a)).  (c) The effect of SF on the patients as a whole 
population with replicate 2 removed from all patients (p-value <0.001). * p-value <0.05., ** p-
value <0.005. 
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Figure 5.6. The effect of SF on HSP70.  
BPH tissue from three patients (patients 13, 14 and 16) was treated with or without 10µM SF 
for 24 hours in triplicate. Protein was extracted, run on 2D gels, and analysed using SameSpots 
software to identify altered spots which were then identified using mass spectrometry.  (a) 
Images of spot 1045, identified as HSP70, taken from the 2D gels for each patient with or 
without 10µM SF in triplicate are shown , and (b) quantified to statistically determine the 
effect of 10µM SF (Means ± standard deviation are plotted; p values: 0.839, 0.056, 0.041 
respectively). Replicate 2 of patient 16 was excluded from the analysis due to previously noted 
replication variation (outlined in red in (a)).  (c) The effect of SF on the patients as a whole 
population with replicate 2 removed from all patients (p-value = 0.649). * p-value <0.05. 
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5.4 Discussion 
In the previous chapter, protein extracted from BPH tissue from three patients cultured with 
or without 10µM SF in triplicate for 24 hours, was separated by 2D gel electrophoresis, and the 
resulting images compared. Protein spots were selected that were altered due to either 
natural variation between patients, or due to SF treatment, and then identified using mass 
spectrometry.  
 
Little data has previously been collected regarding the expression of the proteins identified in 
BPH. However, from the known function of these proteins, and the data that is available 
regarding their expression in the prostate, suggestions as to why they may vary, and what 
effect this variation may have in the tissue, are discussed.  
 
 
5.4.1 Natural variation of protein expression in BPH tissue 
From the 2D gels seven spots were identified that naturally varied between the patients 
without treatment (Table 5.1). Of the seven, two spots were found to have multiple IDs, and 
the final list of proteins identified from the seven spots was: keratins (KRT1 and 10); tubulin 
beta-2C chain (TUBB2C); actin (ACTA1); microfibril-associated glycoprotein 4 (MFAP4); 
elongation factor 1-alpha 1 (EEF1A1); annexin A2 (ANXA2); and trimolecular functional enzyme 
subunit beta (TFP-β).  
 
 
5.4.1.1 Keratin 
Multiple spots were identified as keratin, although often sequence coverage was low, 
suggesting fragmentation of the protein. It is well known that keratin is a common 
contaminant of human samples, meaning the keratin identified in these spots may have come 
from a source other than the BPH tissue, so may not reflect a true variation in protein 
expression between the patients. Keratin is present in all human tissues, so it is easy to 
contaminate samples with keratin from hair or skin during handling. However, the presence of 
keratins in BPH has previously been investigated, so it may be that the results observed here is 
not a consequence of contamination.  
 
Hudson and colleagues [190] suggested that the keratin expression pattern in cells of the BPH 
epithelium alters as they differentiate. They reported that basal stem cells express only 
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keratins 5 and 14, which give rise to a proliferating population, which also express keratins 15, 
17 or 19. These cells then differentiate into luminal cells that express keratins 8, 18 and 19, 
prior to full differentiation, at which point they express only keratins 8 and 18 [190]. However, 
the keratins identified in the present study were KRT1 and 10, which have both previously 
been recorded as expressed in the prostate [191]. Although the exact role of KRT10 and KRT4 
in the prostate is unknown, KRT10 has been associated with differentiation in the epidermis 
[192], so it could play a similar role in the prostate.  
 
In summary, the variation in keratin expression observed here may be due to contamination, 
or it may suggest that the patients had different percentages of differentiated cells, which 
could explain the varied expression (eg. those with higher levels of KRT10 may have a higher 
percentage of differentiated cells). The expression pattern of the keratins within each patient 
could therefore determine the proliferative abilities and differentiation state of the samples, 
which may affect their behaviour ex vivo.  
 
 
5.4.1.2 Tubulin 
Tubulin beta-2C chain (TUBB2C), a cytoskeletal protein, dimerizes with tubulin α, subsequently 
polymerizing to form microtubules, which are structural components within the cell that are 
involved in mitosis and vesicular transport. The formation and disassembly of microtubules is a 
dynamic process, and essential for formation of the spindle during mitosis. Drugs have been 
developed that interfere with this process, preferentially killing dividing cells, and have been 
used to treat some cancers [193].  
 
Tubulin β exists as many isoforms, the expression of which has been examined in BPH and PCa 
samples. Tubulin βIV has the highest expression in both BPH and PCa, but βII expression 
increases greatly in PCa compared to both BPH and normal tissue [194]. The βIII isoform has 
also been correlated with PCa progression and aggressiveness [195]. The isoform of the tubulin 
β identified here is not known, so no comparison to the data above can be drawn, but the 
variation observed may suggest a difference in isoform expression and therefore cell 
proliferation between the samples.  
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5.4.1.3 Actin 
Like TUBB2C, actin is a cytoskeletal protein, but it is also found in thin filaments in muscle. 
Actin can participate in a wide range of processes including muscle contraction, cell division, 
vesicle and organelle movement, cell signalling, and cell junctions [193].  
 
As actin is expressed in muscle, the difference in expression of actin between the patients, 
may be due to the percentage of muscle within each sample. In addition, an increase in α-actin 
expression has been correlated with elevated IL-8 expression, and can its expression can be 
induced by IL-8 [196]. Therefore, it may be that the samples secreted varying concentrations of 
IL-8, resulting in the altered actin expression as observed.  
 
Actin has been reported as decreased in both PCa and BPH compared to normal prostate 
tissue samples, and a change in distribution also observed, suggesting it may be related to 
alterations in adhesion, shape and proliferation [197]. The altered expression of actin may 
therefore be due to differences in the pre-dominant cell type of the sample, such as muscle 
cells, or may reflect a change in expression, which could result in alterations in cell 
interactions, division and signalling.  
 
 
5.4.1.4 Microfibril-associated glycoprotein 4 
Microfibril-associated glycoprotein 4 (MFAP4) is the member of a family of glycoproteins that 
forms microfibrils and covers elastin, forming elastic fibres in the extracellular matrix (ECM) 
[193]. Literature regarding its role and expression in the prostate is sparse, but it has been 
investigated in the context of bladder and ovarian cancer. Microfibril-associated glycoprotein 4  
expression was found to be down-regulated in bladder cancer [198], and has been proposed as 
a biomarker of poor prognosis in ovarian cancer [199]. Therefore, MFAP4 expression may be 
the result of, or may be related to, the viability of the samples.  
 
 
5.4.1.5 Elongation factor 1-alpha 1 
Elongation factor 1-alpha 1 (EEF1A1) is a subunit of the elongation factor-1 complex (EEF1), 
which is responsible for the delivery of amino-acyl tRNAs to the ribosome during protein 
synthesis, and has also been shown to have a role in the nuclear export of proteins [193]. 
Expression of EEF1 has been correlated with androgen-independent proliferation in PCa [200], 
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and suppression of EEF1 in cancer cell lines can inhibit proliferation [201]. The EEF1 expression 
status of the BPH samples may therefore alter its proliferative ability, and it would be 
interesting to investigate whether EEF1 is overexpressed in BPH compared to healthy 
prostates.  
 
 
5.4.1.6 Annexin A2 
Annexin (ANX) A2, a member of the annexin calcium-dependent phospholipid-binding protein 
family, is pleiotropic in nature and can be involved in a wide range of cellular processes. Such 
processes include: epithelial cell motility, cell-ECM interactions, and linkage of membrane-
associated proteins to the actin cytoskeleton.  
 
In BPH, ANXA2 is only expressed in the basal cells, whilst in comparison it also expressed in 
luminal cells in the healthy prostate. The expression pattern observed in BPH was also seen in 
PIN, but ANXA2 expression is further reduced in PCa [202]. However, ANXA2 has been 
observed in some cases of PCa, and has been found to increase IL-6 expression, giving rise to a 
subset of PCa with an aggressive phenotype [203]. Further work has demonstrated that ANXA2 
can regulate adhesion, growth and migration, in PCa [204-205].  
 
The variation in the level detected in the patients in the current study, may therefore be 
explained by the disease state of the tissue, with BPH in the patients with the lower ANXA2 
expression likely to be more advanced. 
 
 
5.4.1.7 Trifunctional enzyme subunit beta 
Trifunctional enzyme subunit beta (TFP-β) is a subunit of the mitochondrial trifunctional 
protein, an enzyme involved in beta oxidation, converting fats into energy. Mutations in either 
subunit can result in deficiency of the enzyme, which can be lethal or result in disease. 
Previously, it has been suggested that beta-oxidation is altered in PCa [206], so it may be the 
case that this also occurs in BPH. Therefore, the altered expression could be in line with this 
suggestion, and reflects variation in beta-oxidation between the samples. 
 
 
 
Analysis of proteins altered in BPH tissue 
 
 
142 
 
5.4.1.8 Summary 
For all the above discussed proteins, it is important to note the small sample number used, and 
the lack of understanding of the relevance of these proteins in BPH. As such, little can be 
drawn from the above discussion, and no conclusions reached, other than to say protein 
expression varies between individuals. Further research needs to be conducted to elucidate 
whether the varied expression observed has any significant relevance. In addition, it would be 
interesting to see whether variation in the expression of these proteins is still observed in a 
larger sample number. 
 
 
5.4.2 The biological processes and molecular functions altered by SF  
Of the spots identified from the 2D gels, the majority were chosen due to the observation that 
they were altered by SF treatment. Of the fifty five spots selected and identified, fifty were 
altered by SF, only three of which were seen to be altered by SF in the population as a whole: 
lumican, GRP78 and myosin-11 (Table 5.2).  
 
As discussed previously, patient 14 exhibited the greatest effect of SF treatment, which was 
reflected in the number of proteins identified, thirty two (Table 5.4), compared to fourteen 
and four for patient 13 and 16 respectively (Table 5.3 and 5.5). Global protein expression in 
patient 16 was not statistically significantly altered as a result of SF treatment (Table 4.2).  
 
Of the fifty proteins altered by SF, fifteen were increased, thirty three were decreased, and 
two were both increased and decreased in different patients, in response to SF.   
 
The proteins were grouped by biological process and molecular function to identify the 
processes and functions most commonly altered by SF in this model. The proteins were 
grouped according to GO classification into the smallest number of groups, as the proteins 
were typically associated with multiple functions and processes (Table 5.6). In order of the 
number of proteins per group, the processes altered were: apoptosis (eight proteins) 
metabolism, muscle contraction and development (both seven proteins), cell proliferation, 
adhesion and angiogenesis (six proteins), and cytoskeletal organization (two proteins). Three 
proteins did not fit into any of these groups. Of the processes of which the proteins altered 
were involved, many have been implicated in dysregulation and disease, in particular 
apoptosis, and cell proliferation, adhesion and angiogenesis.   
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5.4.2.1 Apoptosis 
Apoptosis, also known as programmed cell death, is the process by which cells commit 
‘suicide’. It can be triggered by a number of factors and results in the fragmentation of DNA 
and shrinkage of the cytoplasm, ultimately leading to cell death without lysis or damage to 
surrounding cells. The process of apoptosis is tightly regulated, with a wide number of pro- and 
anti-apoptotic factors controlling the balance between cell survival and death. Dysregulation 
due to mutation or alteration in the expression of proteins involved in the process can result in 
excess or reduced cell death, leading to diseases such as cancer. Correct control of apoptosis is 
therefore vital for maintaining homeostasis [193].  
 
Apoptosis was found to be the biological process in which the greatest number of proteins 
altered by SF, were involved. Previous research has shown that SF has pro-apoptotic 
properties, so it would follow that it may therefore effect the expression of proteins involved 
in this process (Table 5.8).  
 
Annexin A5 is often measured as a marker of apoptosis, including SF-induced apoptosis [207-
208]. It is interesting that here it was observed to be decreased by SF, suggesting a decrease in 
apoptosis in response to SF, which is contradictory to what would be expected.  
 
HSP70, a known anti-apoptotic protein, was, in contrast, the only protein in the apoptosis 
group that was increased by SF. This suggests that SF was exerting an anti-apoptotic, not pro-
apoptotic, effect as would be expected. SF has previously been reported to increase the 
expression of HSP70 and other heat shock proteins by an Nrf2-dependent pathway in the liver 
of mice [116], so the increase in HSP70 observed here is not unprecedented. Confusingly 
though, HSP70 has also been observed to be increased in cells in which SF-induced apoptosis 
has been blocked [209]. Thus suggesting that SF-induced apoptosis would lead to reduced 
levels of HSP70, in contradiction to the reduction we observed. 
 
Serum albumin, here seen to be increased by SF, has previously been shown to form adducts 
with SF in the plasma, with levels of these adducts higher after chronic exposure than a single 
dose [210]. The formation of SF protein adducts in the cell correlates with induction of 
apoptosis, and has been postulated as a critical early event in the induction of apoptosis by SF 
[181]. However, the specific interaction of SF and albumin has not been implicated in 
apoptosis.  
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No relationship or interaction has been reported regarding SF and the remaining proteins in 
the apoptosis group. Instead a brief description of evidence suggesting a correlation for these 
proteins with apoptosis is reported.  
 
14-3-3ε is known to be an anti-apoptotic protein whose increased expression is correlated with 
inhibition of apoptosis [211], whilst disruption of α-actinin-1 (ACTN1) interactions have been 
shown to increase susceptibility of cells to apoptotic stimuli [212]. Furthermore, ACTN1 has 
been found to undergo alternative splicing in cancer [213]. Another protein in this group, 
calreticulin, is a calcium (Ca2
+
)-binding protein that can protect against apoptosis by protecting 
against Ca2+ overload-induced apoptosis, by maintaining calcium homeostasis [214].  
 
As with the majority of glucose-regulated or heat shock proteins (GRP/HSP), GRP78 is believed 
to be anti-apoptotic, and has been shown to protect against drug-induced apoptosis by 
blocking casase-7 activation preventing cytochrome c release. In contrast, other research has 
suggested it may have pro-apoptotic properties, but this activity may be dependent on its 
expression on the cell surface. GRP78 is primarily found in the endoplasmic reticulum, 
however increased cell death due to membrane bound GRP78 has been observed, but only in 
carcinogenic cell lines, not normal cells [215].  
 
Endoplasmin (HSP90β1), another GRP/HSP is also suggested to have anti-apoptotic properties 
which have primarily been attributed to its Ca2
+
 binding properties [216].  
 
Overall, these data suggest that SF altered the expression of a number of apoptotic proteins in 
such a manner that would suggest SF induced apoptosis in the BPH tissue. Although SF 
increased the expression of one anti-apoptotic protein, HSP70, which should  inhibit apoptosis, 
it decreased the expression of multiple anti-apoptotic proteins, suggesting the balance 
between the two opposing actions would most likely result in increased apoptosis. Therefore, 
it is likely that in these samples SF induced apoptosis. Thus indicating a beneficial activity of SF 
in BPH, which is characterized by excess proliferation. 
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Table 5.8. Apoptotic proteins altered by SF: Their role in apoptosis and relationship with SF. 
 
Protein Role in apoptosis and previous evidence of relationship with SF 
Decreased by SF  
Annexin A5 Marker of apoptosis, including SF-induced [207-208] 
Serum Albumin Forms adducts with SF [210] 
Formation of SF protein adducts in the cell correlates with induction of 
apoptosis [181] 
14-3-3ε Increased expression is correlated with inhibition of apoptosis [211] 
α-actinin-1 Disruption of α-actinin-1 interactions sensitize cells to apoptotic stimuli 
[212] 
Calreticulin Protects against Ca2+ overload-induced apoptosis by maintaining calcium 
homeostasis [214] 
GRP78 Protects against drug-induced apoptosis by blocking casase-7 activation 
preventing cytochrome c release [217-218] 
Cell surface expression can induce cell death in carcinogenic cell lines 
[215] 
Endoplasmin Protects against Ca2+ overload-induced apoptosis by maintaining calcium 
homeostasis [216] 
Increased by SF  
HSP70 Increased in cells in which SF-induced apoptosis has been blocked [209] 
Increased by an Nrf2-dependent pathway by SF [116] 
 
Table summarising previous literature discussing the apoptotic properties of the proteins 
identified from the 2D gels as involved in apoptosis, and any previous data suggesting a link 
with SF activity. 
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5.4.2.2 Muscle Development and Contraction 
BPH occurs when the balance between proliferation and apoptosis is lost, and involves over-
proliferation of cells, both in the epithelium and the stroma. Common in the stroma of the 
prostate are smooth muscle cells (SMCs), which along with other cell types over-proliferate in 
BPH.  
 
In response to SF, the majority of the proteins found to be involved in muscle development 
and contraction, were reduced. In combination with the suggestion above, that SF induced 
apoptosis in the BPH samples, it may be that the reduction of the muscle related proteins was 
due to a reduction in muscle cell number as a result of increased apoptosis of SMCs. It is likely 
that the proteins involved in muscle development and contraction are primarily expressed in 
the SMCs in the BPH stroma, so an increase in SMC apoptosis would likely result in a reduction 
in their expression.  
 
Increased expression of gamma-enteric smooth muscle actin (ACTG2) and transgelin (TAGLN), 
has been correlated with transdifferentiation of fibroblasts into myofibroblasts, which exhibit 
increased expression of SMC-associated proteins in response to TGFβ1 treatment [219]. 
Transdifferentiation is a process associated with BPH progression, and SF is known to interact 
with TGFβ1, which is critical in prostate regulation. As such, the reduction of ACTG2 and TAGLN 
observed may have occurred due to SF inhibiting TGFβ1-induced transdifferentiation.  
 
Desmin is often used for the identification of SMCs in prostate stroma [220-221], so as 
proposed above, a reduction in desmin could likely suggest a reduction in the SMC population.  
 
Also reduced by SF, were alpha skeletal muscle actin (ACTA1) and myosin light-chain 6B, 
(MYL6B) although little is know about their specific function in the prostate. Due to the lack of 
information regarding their role in the prostate, all that can be suggested is that they were 
reduced in the samples due to SF-induced apoptosis of SMCs in which they are expressed.  
 
The only protein in this group whose expression was increased by SF was heat shock protein 
beta-6 (HSPB6). Heat shock protein beta-6 is a small heat shock protein involved in contraction 
in smooth muscle. Little is known about its role in BPH, but its function in intimal hyperplasia, 
hyperplastic thickening of the inner layer of a blood vessel, has been investigated. Heat shock 
protein beta-6 has been seen to inhibit intimal hyperplasia, in particular by reducing cell 
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migration, and in some cases proliferation [222]. As BPH is also a hyperplastic condition it may 
be that HSP6B acts in a similar manner and can inhibit migration, and possibly proliferation, in 
BPH. However, HSPB6 was increased by SF in the BPH samples, which suggests a mechanism 
by which SF could promote migration and proliferation in BPH, but without specific 
information regarding HSPB6 expression and function in the prostate, no conclusions can be 
made.  
 
The final protein in the group was myosin-11 (MYH11). From the 2D gels, eight spots that were 
altered by SF were identified as MYH11, although interestingly seven of these spots were 
found in patient 13, whilst the other was found in patient 16, and no spots identified as MYH11 
in patient 14, which was the patient which exhibited the greatest effect. Of the spots identified 
as MYH11, five were increased, and three were decreased by SF. As a result, little can be 
deduced regarding the effect of SF, or how SF may be altering MYH11. A possible explanation 
is that as multiple spots were identified as MYH11, MYH11 may have fragmented or 
undergone post-translational modification. Such events would alter the mass and pI of the 
protein, altering the position at which it ran on the 2D gel, resulting in multiple spots of 
MYH11. This could therefore suggest that SF can alter post-translational modification of 
MYH11, thereby increasing and decreasing the expression of differently modified forms. 
 
 
5.4.2.3 Metabolism 
The expression of all the proteins identified as involved in metabolism were reduced by SF.  
 
Three spots were identified as ATP-synthase subunit alpha (ATP5A1), a subunit of 
mitochondrial ATP-synthase an enzyme involved in ATP synthesis. Increased expression of ATP-
synthase has been reported in a metastatic, highly tumorigenic PCa cells compared to a slow 
growing, poorly tumorigenic PCa cell line [223]. The reduction of ATP5A1 by SF observed here, 
could suggest a decrease in growth in the sample in response to SF treatment, indicating SF 
reduced cell proliferation in the BPH tissue ex vivo.  
 
Three of the proteins, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), L-lactate 
dehydrogenase A chain (LDHA), and triosephosphate isomerise (TPI1), are involved in 
glycolysis, a process often upregulated in cancer. Glyceraldehyde-3-phosphate dehydrogenase 
is routinely used as a housekeeping gene [224-225], so it is interesting to note that here it was 
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altered by SF. However, its expression has previously been reported as increased in PCa 
compared to BPH [226-227], suggesting its expression may relate to prostate dysregulation, 
and thereby the reduction of GAPDH by SF may have a beneficial effect on prostate health.  
 
In both the studies that noted GAPDH expression was increased in PCa, they also reported the 
same observation for lactate dehydrogenase (LDH) expression [226-227]. Lactate 
dehydrogenase has five isoforms which are differentially expressed throughout the body. The 
ratio of two of these isoforms, LDH-1 and -5, was investigated in prostatic secretions, with the 
mean ration of LDH-5/LDH-1 significantly higher in PCa compared to BPH [228]. This suggests 
that LDH isoform expression alters in correlation with prostate disease, but here it was LDH-A, 
a subunit of LDH, which was altered, which is predominantly expressed in muscle cells. It may 
be that SF can alter the isoform expression, but the isoform of the protein identified is not 
known, so this can not be fully discussed. LDH is released from cells when membrane integrity 
is lost, such as in apoptosis. As such, the reduction of LDH protein within the tissue sample as a 
result of SF treatment, may be due to release of LDH into the media in response to SF-induced 
apoptosis, resulting in less LDH in the tissue, thereby suggesting lower expression. Therefore, 
the reduced expression observed may not be a reduction in expression at all, but a loss of LDH 
from the tissue into the media.  
 
The final identified protein involved in glycolysis, triosephosphate isomerase, has been linked 
to PCa [227], with its expression increased compared to BPH [229].  
 
A further protein in the metabolism group, creatine kinase B-type (CKB), is involved in the 
conversion of creatine to phosphocreatine in muscle to create an energy reservoir for muscle 
contraction. Separate studies have reported conflicting results regarding CKB expression in 
prostate disease [230-231], so as with many of these proteins, the reduction of CKB by SF may 
just be a reflection of increased apoptosis.  
 
The final members of the metabolism biological process group were protein disulfide 
isomerase (PDI) and protein disulfide isomerase A4 (PDIA4). Both PDI and PDIA4, the latter is 
also known as ERP70 or ERP72, catalyze the formation and breakage of disulphide bonds 
during protein folding. The expression of PDI has been shown to be increased in PCa compared 
to BPH [232-233], whilst PDIA4 has been correlated with metastatic potential in hepatocellular 
carcinoma [234].  
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5.4.2.4 Cell Proliferation, Adhesion and Angiogenesis 
The six proteins involved in cell proliferation, adhesion, and angiogenesis were collagen alpha-
3(VI) (COL6A3), fibulin-1 and -5 (FBLN1/5), keratin type II cytoskeletal 1 (KRT1), keratin type I 
cytoskeletal 16 (KRT16) and lumican (LUM).  
 
Both COL6A3 and KRT1 were identified in multiple spots which were both up- and down-
regulated, so it is unlikely that SF actually increases or decreases their expression. However, it 
may instead be altering the splice variants expressed, as previously COL6A3 splice variant 
expression has been correlated with cancer, although not specifically in the prostate [213]. 
Previously, SF has been shown to modulate keratin expression, although this was observed in 
skin epithelia [235], so SF may be able to have a similar effect in the prostate.  
 
The other three proteins in this group, FBLN1, FBLN5 and KRT16 were all reduced by SF. 
Fibulins are involved in cell adhesion, and FBLN5 has previously been suggested to have 
anticancerous function. It has been recorded as reduced in PCa [236], so it would appear on 
first glance that downregulation of FBLN5 by SF would most likely enhance BPH progression. 
However, the down-regulation of FBLN5 would most likely reduce cell adhesion which, 
although beneficial for migration and metastasis in PCa, can actually trigger apoptosis in 
healthy cells, so it could be that this down-regulation may contribute to apoptosis of BPH cells.  
 
Keratin type I cytoskeletal 16 is primarily expressed in the epithelium suggesting it would most 
likely effect the proliferation of basal and luminal cells in the prostate. Previously KRT16 
expression has been reported as upregulated in psoriatic lesions which are characterized by 
hyperproliferation [237]. KRT16 may be involved in the hyperplasia seen in BPH, so by reducing 
the expression of KRT16, SF may exert an anti-proliferative on BPH tissue.  
 
Lumican (LUM) is an ECM protein involved in collagen-fibril organization, and can regulate cell 
growth and migration. It has been shown to be upregulated in BPH [238], although it is down-
regulated in PCa [239-240]. That in this study it was increased by SF is interesting considering 
previous data that it is upregulated in BPH compared to normal prostate anyway. However, as 
it is down-regulated in cancer, the increase in LUM by SF may help prevent development of 
PCa. 
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5.4.2.5 Cytoskeletal Organization 
The final defined biological process group was cytoskeletal proteins. These proteins are often 
involved in adhesion, and thereby cell migration, but using the GO classification were not listed 
as involved in these processes, so are grouped separately.  
 
Actin cytoplasmic 2 (ACTG1) is a component of the cytoskeleton expressed in the cytoplasm of 
non-muscle cells. In the 2D gels, two spots were identified as ACTG1 one of which was 
increased by SF, whilst the other was decreased. Transdifferentiation of fibroblasts is a key 
event in BPH pathogenesis and one which is associated with increased ACTG1 expression 
[219], so a reduction of ACTG1 would most likely inhibit the progression of BPH. However, as 
here both a reduction and increase in ACTG1 expression in response to SF was seen, it is 
unlikely that SF has any meaningful effect on this protein and any processes it is involved in in 
BPH.  
 
The other cytoskeletal protein identified was filamin-A (FLNA), which is involved in the 
anchoring of the actin cytoskeleton. Its expression has been reported to be decreased in PCa 
compared to BPH [241], suggesting that its reduction may be involved in prostate 
dysregulation. However, FLNA has been shown to form a complex with AR which leads to cell 
migration [242], so by reducing FLNA SF may inhibit androgen-driven cell migration.   
 
 
5.4.2.6 Other 
The remaining proteins could not be included in any of the other groups discussed above.  
 
Serotransferrin (TF) is an iron-binding protein that controls the level of free iron in the blood 
and tissues. Interestingly, its levels are decreased in inflammation [243], so the increase in TF 
in response to SF may be due to the anti-inflammatory effect of SF.  
 
14-3-3 theta (YWHAQ) is involved in protein targeting and has been implicated as involved in 
Akt-induced cell cycle progression by assisting the cytoplasmic localization of WEE1 [244]. 
Therefore, the reduction of YWHAQ by SF may inhibit cell cycle proliferation.  
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The remaining protein, Keratin type I cytoskeletal 10 (KRT10) was decreased by SF, but was 
also recognised as naturally varying between the patients. The deletion of KRT10 in mice led to 
a reduction in tumour formation in the epidermis due to increased keratinocyte turnover 
[245]. Whilst in the prostate, KRT10 is expressed in the terminally differentiated squamous 
epithelial cells [191]. The reduction of SF observed here may therefore help prevent tumour 
formation in the prostate, or may inhibit the process of squamous metaplasia, which was seen 
in the samples that underwent histological assessment (see Chapter 2).  
 
 
5.4.2.7 Function Comparison 
By classifying the above discussed proteins in terms of molecular function, the proteins altered 
were seen to fall into three main groups; enzymes, molecular chaperones, and structural and 
adhesion proteins, with seven, six and sixteen proteins in each group respectively (Table 5.7). 
Four proteins did not belong in any of these groups.  
 
Comparison of the processes and functions groups revealed that all the proteins involved in 
metabolism, functioned as enzymes, catalyzing reactions. It was of interest to note, that of the 
eight proteins involved in apoptosis, five acted as molecular chaperones. All but one of the 
proteins, HSPB6, involved in cell proliferation, adhesion and angiogenesis, muscle 
development and contraction, and the cytoskeleton, functioned in structure and adhesion in 
some way. 
 
All the proteins found to be altered by SF were all investigated for previous research 
demonstrating a link between their expression and SF activity. However, very few of these 
proteins had previously been reported with regard to SF, but data from those which have is 
included in the discussion above (Chapter 5.4.2.1). 
 
 
5.4.3 Apoptosis and chaperone proteins 
Comparison of the biological processes and molecular functions that the proteins are involved 
in, revealed an overlap between the apoptosis process and molecular chaperone function 
groups. Of these groups, there were five proteins that were in both; HSP90β1, calreticulin, 14-
3-3ε, GRP78 and HSP70. The expression, role and control of these proteins in the prostate has 
previously been investigated, in particular in PCa, but little research has reported a 
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relationship with BPH, or in response to SF. SF has long been linked with increased apoptosis 
but little work has reported, or focussed, on the role of molecular chaperones in SF-induced 
apoptosis.  
 
The control of apoptosis is crucial to maintain homeostasis as its dysregulation is common in 
disease. It is of great importance to understand the apoptotic process in order to be able to 
prevent, treat, and hopefully cure diseases in which apoptosis plays a role. The current 
evidence indicating the function of these proteins in apoptosis, and in particular their 
importance in the prostate, is reviewed below, and the relevance of the effect of SF observed 
discussed (see Table 5.9 for a summary).  
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Table 5.9. The role of molecular chaperones in apoptosis. 
 
Protein Pro-Apoptotic Anti-Apoptotic 
Decreased by SF   
HSP90β1  Down-regulation sensitizes cells to drug-
induced apoptosis [216, 246] 
Protects against apoptosis by maintaining Ca2
+ 
homeostasis [247] 
Androgen-responsive [248-249] 
Correlated with metastatic potential [250] 
GRP78 Expression on the cell 
surface induces cell death 
in carcinogenic cell lines 
[215] 
Induced by (extended exposure to) etoposide 
[246, 250] 
Blocks caspase-7 activation [250] 
Stablizes Raf-2 preventing cytochrome c release 
[217] 
Androgen-responsive [218, 251-252] 
Essential for PTEN-induced PCa development 
[253] 
Calreticulin Down-regulated in PCa, 
over-expression 
associated with inhibition 
of tumour growth and 
metastasis [254] 
Androgen-responsive [255] 
Protects against Ca2
+
-induced apoptosis in 
androgen-sensitive cells [214] 
Over-expressed in metastatic cell lines [182, 
248] 
14-3-3ε Essential role in NADE-
induced apoptosis [256] 
 
Binds phosphorylated Bad, inhibiting apoptosis 
[211] 
Promotes cell cycle progression [257-258] 
Increases TGFβ1 signalling [259] 
Increased by SF   
HSP70  Essential for survival of carcinogenic cells [260] 
Correlated with prostate carcinogenesis and 
protects against apoptosis by stabilizing mutant 
p53 [261-262] 
Interacts with CD10 which is increased in BPH 
but decreased in PCa [262] 
Androgen-responsive [263] 
  
A summary of the evidence for the pro- and anti-apoptotic properties of the molecular 
chaperones involved in apoptosis. The proteins were identified by proteomic analysis of 2D 
gels as altered by SF in BPH tissue.  
  
Analysis of proteins altered in BPH tissue 
 
 
154 
 
5.4.3.1 HSP90β1 
Heat shock protein 90 beta -1 (HSP90β1) is a member of the heat shock family of proteins, and 
is also known as glucose regulated protein 94 (GRP94), gp96, and endoplasmin.  
 
A reduction in HSP90β1 expression is proposed to reduce cell viability, and has been 
demonstrated in human acute T cell leukaemia cells, where a reduction of HSP90β1 sensitised 
the cells to etoposide
4
-induced apoptosis. In the same cell line, it was demonstrated that in 
response to etoposide treatment, HSP90β1 is cleaved by calpain, a cysteine protease, in a 
Ca2
+
-dependent manner, concurrent with the activation of caspase CPP32 and initiation of 
DNA fragmentation [216]. In neuroblastoma cells, suppression of HSP90β1 was once again 
associated with a decrease in cell viability in response to an apoptosis inducer, this time 
A23187, a calcium ionophore. Interestingly treatment with A23187 increased HSP90β1 
expression, but it also activated calpain [246].  
 
HSP90β1 has been suggested to protect against apoptosis by maintaining endoplasmic 
reticulum (ER) calcium (Ca2
+
) homeostasis. Ca2
+
 overload can cause ER stress and trigger 
apoptosis by activating calpain, which in turn triggers the caspase cascade resulting in cell 
death. As a result of etoposide-induced apoptosis in HUVEC cells, HSP90β1 was reduced to 
undetectable levels [247].  
 
With particular reference to its importance in the prostate, HSP90β1 is believed to be 
regulated by N-myc downstream regulated gene 1 (NDRG1) protein, as inhibition of NDRG1 
reduces HSP90β1 expression. NDRG1 plays an important role in androgen-induced cell 
differentiation and inhibition of PCa metastasis, and can itself be induced by androgen, PTEN, 
and p53 [249]. This suggests that HSP90β1 can be indirectly regulated by androgen, which is 
essential in the development of prostate disease, and PTEN, which plays a key role in many 
cases of PCa.  
 
The regulation of HSP90β1 by androgen has been demonstrated in the androgen-responsive 
PCa cell line, LNCaP, which showed an increase in HSP90β1 gene expression in response to 
androgen treatment. Further evidence for androgen regulation was provided by the 
observation that DU145 and PC3 PCa cell lines, which lack a functional androgen receptor, 
express HSP90β1 at significantly lower levels [248]. Comparison of the poorly metastatic 
                                                          
4
 A drug used to as a chemotherapy drug against some cancers including PCa. It causes errors in DNA 
synthesis and promotes apoptosis of the cancer cell. 
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LNCaP, and highly metastatic LNCaP-LN3, PCa cell lines revealed that the expression of 
HSP90β1, GRP78 and calreticulin, were all increased in the metastatic cells [250]. This result 
was corroborated by a separate study who noted HSP90β1 and calreticulin expression was 
higher in the highly metastatic 1E8-H cell line compared to the lowly metastatic 2B4-L cells, 
although these cell lines are androgen-independent [182]. 
 
 
5.4.3.2 GRP78 
Glucose regulated protein, GRP78, is an ER chaperone and member of the HSP70 protein 
family. As with many ER proteins, it participates in Ca2+ homeostasis, influencing apoptosis, as 
well as facilitating protein folding and assembly.  It is essential for embryonic cell survival, and 
its overexpression has been reported in drug-resistant primary lung and ovarian cancer cell 
lines. As with HSP90β1, GRP78 has been suggested to protect against apoptosis by maintaining 
endoplasmic reticulum (ER) calcium (Ca2
+
) homeostasis.  
 
As a result of etoposide-induced apoptosis in HUVEC cells, GRP78 was unexpectedly increased 
2.23-fold [247]. The increase in GRP78 is counter-intuitive and suggests a mechanism by which 
the cell was attempting to prevent apoptosis, although in this case it was not enough. In other 
studies it has been reported that cells that survive long exposure to etoposide treatment over-
express GRP78, so it may be that 24 hours is a long enough period to induce this response 
[217]. It has been suggested that this overexpression of GRP78 can  protect against etoposide-
induced apoptosis by associating with procaspase-7, an activity dependent on its ATP binding 
domain, blocking caspase-7 activation [217]. Furthermore GRP78 can stabilize Raf-1, 
preventing cytochrome c release, and in turn inhibiting ER stress-induced apoptosis [218].  
 
GRP78 has also been associated with AR status and the development of androgen-insensitive 
PCa [251-252]. Androgen treatment resulted in an increase in GRP78 expression at 24 hours 
reducing cell death, but this was only transient with the levels of GRP78 subsequently 
decreasing, coinciding with an increase in cell death [253]. Using a mouse model, Fu and 
colleagues showed that knockout of GRP78 from the prostate epithelium cells suppressed AKT 
activation, and prevented the development of PCa in response to PTEN deletion [260].  
 
However, in contrast, overexpression of GRP78 has also been linked to increased apoptosis in 
carcinogenic prostate cell lines. Burikhanov and colleagues noted that both normal and cancer 
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cells in culture secreted prostate apoptosis response-4 (Par-4), a pro-apoptotic protein. 
Although GRP78 is primarily an ER protein, further investigation revealed that most cancer 
cells, and some normal cells, expressed GRP78 on the cell membrane. Secreted Par-4 was 
shown to bind to GRP78 at the cell surface, triggering ER stress. This resulted in overexpression 
of GRP78, and its translocation to the cell surface, leading to activation of caspases 8 and 3 via 
Fas-Associated protein with Death Domain (FADD), ultimately promoting apoptosis. 
Interestingly though, ER stress and apoptosis in response to extracellular Par-4 was only 
observed in cancer cells, not normal cells [215].  
 
 
5.4.3.3 HSP70 
Of the five proteins selected for investigation HSP70, also known as HSP70-1, was the only one 
increased by SF treatment. It belongs to the same family as GRP78, and much like GRP78, has 
been shown to have anti-apoptotic properties and is correlated with cancer progression. 
 
Deletion of HSP70 results in cell death of tumorigenic cell lines, including PCa cells, but not of 
normal prostate epithelial cells, indicating it is essential for the survival of tumorigenic cells 
[262]. Increased HSP70 expression has been correlated with prostate carcinogenesis, and it has 
been shown to stabilize mutant p53, but not the native protein, protecting the cell from 
apoptosis. The loss of HSP70 has been observed to increase apoptosis and reduce viability in 
PC3 cancer cells [261, 263].  
 
Also of interest, is the finding that HSP70 interacts with CD10. CD10 is a transmembrane 
metallo-endopeptidase which is strongly expressed by normal prostate epithelium. The 
expression of CD10 is increased in BPH tissue, but reduced in PCa. In PCa, its expression is 
observed in only 30% of primary prostate tumours, although conflictingly, CD10 is strongly 
expressed by the majority of lymph node metastases. The exact function of CD10 in PCa is 
unknown, but it has been hypothesised that the loss of CD10 may facilitate androgen 
independent growth of PCa [261]. It has also been shown that HSP70 is under androgen 
regulation, as DHT enhances its expression in androgen-sensitive, but not androgen-insensitive 
PCa cell lines [255].  
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Considering the evidence above it is interesting then that SF increased the expression of 
HSP70, as by doing this it would protect the cell against apoptosis, when previously SF has 
been shown to induce apoptosis.  
 
However, all the data above has been collected from PCa cells, not BPH, and it may be that the 
role of HSP70 depends upon disease state. Little data exists regarding the role and expression 
of HSP70 in BPH, but using 2D gel electrophoresis, Lin and colleagues reported that HSP70 is 
expressed at higher levels in BPH than PCa. However, multiple spots were identified as HSP70 
leading to the suggestion that there were different post-translationally modified isoforms in 
BPH and PCa needle biopsies [241]. 
 
 
5.4.3.4 Calreticulin 
Calreticulin is a Ca2+ binding protein that localizes to the ER and is involved in Ca2+ 
homeostasis, cell adhesion and apoptosis. The expression of calreticulin is induced by 
androgens which are essential in prostate development and disease, suggesting that 
calreticulin may be of importance in prostate dysregulation [254]. Downregulation of 
calreticulin has been observed in PCa, and its overexpression has been associated with 
reduced tumour growth and inhibition of metastasis [264].  
 
In comparison however, two separate studies have noted an increase in calreticulin expression 
in highly metastatic cell lines compared to poorly metastatic cell lines, although one of these 
studies used androgen-independent cell lines [182, 250]. Increased calreticulin has also been 
shown to protect against apoptosis induced by Ca2+ overload, with androgen treatment 
inhibiting Ca2+ overload-induced apoptosis in the androgen-sensitive LNCaP, but not in the 
androgen-insensitive PC3 PCa cell lines [214]. 
 
 
5.4.3.5 14-3-3ε 
14-3-3ε is part of the highly-conserved 14-3-3 family of proteins which are ubiquitously 
expressed in many cell types, and of which approximately 50 genes have been identified in 
plants, animals and yeast. They have been implicated in the regulation of a number of kinases 
involved in signalling pathways, including Rap, Ras, Bcr and protein kinase C, although they can 
perform diverse roles in different systems [265].  
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In neural cells, it has been suggested that 14-3-3ε can modulate apoptosis by binding to 
p75NTR-associated cell death executor (NADE), a protein that interacts with p75 neurotrophin 
receptor (p75NTR), which mediates apoptosis in neural cells. It was seen that a mutant form of 
14-3-3ε inhibited apoptosis, although it still bound to NADE, suggesting 14-3-3ε plays an 
essential role in the p75NTR/NADE apoptotic pathway [256]. 14-3-3ε upregulation has also 
been shown to increase binding to phosphorylated Bad, a pro-apoptotic protein, preventing 
apoptosis [211].  
 
Further research has linked 14-3-3ε to cell cycle progression, as it has been shown that 14-3-3ε 
interacts with cdc25 phosphatases, which activate cyclin-dependent kinases, promoting the 
continuation of the cell cycle [257]. Furthermore, it also been shown to compete with importin 
α5, which is involved in its transport to the nucleus, sequestering it in the cytoplasm, 
preventing inhibition of the cell cycle [258].  
 
All these data combine to suggest mechanisms by which 14-3-3ε can promote cell cycle 
progression, acting in an anti-apoptotic manner. Furthermore, 14-3-3ε overexpression can lead 
to increased TGFβ1 signalling via the human type 1 TGFβ receptor (TβR1), a pathway which has 
been implicated in PCa progression, although the relationship between TGFβ1 and the 
prostate is complex [259]. TGFβ1 is also involved in inflammation suggesting a role for 14-3-3ε 
in BPH. In addition, 14-3-3ε has been reported as increased in PCa samples compared to BPH 
tissue [232]. 
 
 
5.4.3.6 Summary 
It is interesting that of the five proteins, three of these, HSP90β1, GRP78 and HSP70, are heat-
shock or glucose-regulated proteins. It is also interesting that the majority of these proteins 
are localized to the ER, and are involved in Ca2
+
 homeostasis, a critical factor in the balance 
between cell survival and apoptosis. 
 
Little work has been conducted investigating the effect of SF on these proteins but the effect 
of other dietary agents has been investigated. In DU145 PCa cells, resveratrol, a polyphenol 
found in red wine and grapes, was seen to reduce cell proliferation and viability, coinciding 
with an increase in HSP70 [266]. Selenium induced ER stress, increasing the expression of anti-
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apoptotic proteins including GRP78 and GRP94, as well as the expression of pro-apoptotic 
proteins in PC3 PCa cells, although they hypothesised that low doses of selenium promotes cell 
survival, whilst high doses may initiate the apoptotic process [267].  
 
Due to the importance of the apoptotic process in disease, including BPH and PCa, and data 
demonstrating induction by SF, further investigation of the proteins above may increase our 
understanding of this process. Of the proteins above, a number of papers have suggested a 
role for HSP90β1 in PCa, but none have reported a relationship with SF. However, the 
cytoplasmic homolog of HSP90β1, HSP90, is well researched and a relationship with SF 
reported. HSP90β1 will be investigated further as a possible novel target of SF to gain greater 
understanding of the relationship between the two, and also to try and discover what 
biological relevance this may have in the prostate. 
 
 
5.4.4 Conclusions 
From the results obtained, it is interesting to note that the majority of the proteins that 
naturally varied between the patients were cytoskeletal or ECM proteins, suggesting 
differences in the proliferation, adhesion and migration characteristics of the samples. That SF 
altered the expression of proteins involved in essential cell processes that are often 
dysregulated in disease, such as apoptosis, metabolism, proliferation and adhesion, suggests 
that SF may be able to modulate signalling in BPH.  
 
Furthermore, SF primarily altered the protein expression in such way that should, from our 
understanding of the proteins, have a beneficial effect in BPH. It is likely that SF can 
beneficially alter protein expression, thereby influencing processes in BPH, promoting prostate 
health. It was observed that in particular SF altered the expression of a number of molecular 
chaperones involved in apoptosis. A review of the literature regarding these proteins led to the 
decision to investigate HSP90β1 as a novel target of SF, and to try and elucidate its biological 
relevance in the prostate, the results of which are reported in the next chapter. 
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Chapter 6. Biological Relevance of HSP90β1 
6.0.1 Summary 
The previous chapter discussed the proteins whose expression was altered by SF in the ex vivo 
model. Among them SF altered a number of molecular chaperones that have been implicated 
in the control of apoptosis. From these results a single protein, HSP90β1, was selected for 
further investigation regarding the effect of SF on its expression and biological relevance, the 
results of which form this chapter. HSP90β1 was selected due to its proposed anti-apoptotic 
function, and its reported correlation with PCa. Furthermore, its cytoplasmic homologue, 
HSP90, which has been more highly researched, has been suggested as a target of SF activity.  
 
In the 2D gels, HSP90β1 was found to be significantly altered in one of the three patients.  
Analysis of a further nine samples revealed that HSP90β1 was significantly reduced by SF in 
three of the individuals, and a further two showed a reduction, but not significantly so. In 
addition, both protein and mRNA levels were analysed in healthy and cancerous prostate cell 
lines. An increase in HSP90β1 mRNA was observed in the cancerous cell line in response to SF, 
but this did not translate to an alteration in protein expression. No significant effect was 
observed on either HSP90β1 mRNA or protein after SF treatment in the healthy cell line. To 
investigate the biological relevance of HSP90β1 reduction, siRNA was used to knockdown the 
expression of HSP90β1, with a maximum reduction of 60 and 30% obtained for mRNA and 
protein levels respectively. As analysis from the previous chapter had suggested a link between 
HSP90β1 and apoptosis, the effect of this knockdown on cell viability and proliferation was 
assayed, but no effect was observed.  
 
Combined with data garnered from literature, this may indicate that a total knockout of 
HSP90β1, and additional apoptotic stimuli, are necessary to obtain a significant effect. 
Furthermore, it is hypothesised that epithelium-stroma interactions, tissue type, and disease 
state may play a role. 
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6.1 Introduction 
In the previous chapter, it was identified that 10µM SF altered the expression of a number of 
proteins in BPH tissue ex vivo, including a number of molecular chaperones involved in 
apoptosis. The control of apoptosis is a key process in tissue homeostasis and is often 
disrupted in disease [193]. To be able to understand, and manipulate, proteins involved in its 
control can provide novel targets for therapy to help prevent and treat diseases. In BPH and 
PCa where there is excess proliferation of cells, to be able to manipulate such proteins to 
increase apoptosis could help inhibit the development of these diseases [268].  
 
I had hoped to investigate a number of the molecular chaperones involved in apoptosis, 
however many were undetectable by western blotting so were not pursued in further samples.  
One of the proteins identified, endoplasmin, was detectable by western blotting and was 
selected for investigation as a possible novel target of SF, and in particular SF-induced 
apoptosis. No relationship between endoplasmin and SF has previously been reported, but a 
role in the prostate, and more specifically PCa, has been suggested. Furthermore, its 
cytoplasmic homologue, HSP90, has been suggested as an indirect target for SF activity, 
indicating that the HSP90 family of proteins may provide a novel mechanism by which SF can 
exert a beneficial effect. As such, in this chapter, further work attempts to elucidate the 
biological relevance of the effect observed in the previous chapter, with particular reference to 
its significance in apoptosis.  
 
Endoplasmin or heat shock protein 90 beta -1 (HSP90β1), is a member of both the heat shock 
and glucose-regulated families of proteins, and is also known as glucose regulated protein 94 
(GRP94) or gp96. Glucose regulated proteins (GRPs) are ubiquitously expressed molecular 
chaperones that are localized in the endoplasmic reticulum (ER) of the cell. Their expression is 
induced in conditions where there is glucose deprivation, chronic anoxia, and acidic pH, such 
as in poorly vascularised solid tumours, and they are therefore suggested to protect cells 
against adverse physiological conditions. Increased expression of GRPs is implicated in 
carcinogenesis [269], and associated with tumour size. Furthermore, they have been shown to 
protect carcinoma cells against cytotoxic T-lymphocyte-mediated cytotoxicity, and from 
treatment with drugs, such as some chemotherapeutic agents [270].  
 
Increased expression of HSP90β1 has been demonstrated in transformed cells, where it is able 
to form a stable complex with p185
erbB2
, a protein commonly expressed in many prostate, 
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breast and ovarian carcinomas, and associated with poor prognosis. Disruption of this complex 
results in degradation of existing p185
erbB2
, and an altered distribution of newly synthesized 
p185
erbB2 
protein. The expression of HSP90β1 is increased in a number of breast cancer cell 
lines compared to normal breast epithelial cells, and is also further induced in glucose deprived 
conditions [270]. In a number of human haematopoietic cell lines stably transfected with a 
wild type or mutated form of p53, a correlation between resistance to 2-deoxyglucose (a 
known inducer of GRPs)-induced apoptosis, and the cells’ ability to induce HSP90β1 was 
observed, suggesting that HSP90β1 has anti-apoptotic properties.  
 
During etoposide (an apoptotic drug) -induced apoptosis, a subpopulation of HSP90β1 
associated with the ER membrane co-localizes with calpain, an apoptosis associated Ca2
+
 
activated neutral protease, in the perinuclear region. This subpopulation is then specifically 
cleaved by calpain in a Ca2
+
 dependent manner, resulting in a 80kDa carboxyl peptide, 
concurrent with the progression  of apoptosis induced by DNA damage mediated by etoposide 
[216].  
 
The expression of HSP90β1 has also been noted as increased in malignant prostate epithelium 
compared to benign. In addition, it has been correlated with increased metastatic potential in 
prostate cell lines, both androgen-sensitive and androgen-independent [182, 250].  
 
The expression of HSP90β1 is increased by androgen-stimulation, and it is expressed at much 
lower levels in PCa cell lines lacking a functional AR, suggesting it to be an androgen-response 
gene [248]. Androgen, acting via the AR, down-regulates the expression of 
trichorhinophalangeal syndrome I (TRPS1), a transcription factor that inhibits the secretion of 
PSA. As a result, the expression of TRPS1 is higher in comparison in androgen-independent 
cells. Using the androgen-independent cell line DU145, which does not express TRPS1, artificial 
expression of TRPS1 reduced HSP90β1 expression, and was hypothesized to induce apoptosis. 
Therefore, increased TRPS1 may inhibit the secretion of PSA, a key marker of PCa progression, 
reduce HSP90β1, and induce apoptosis in PCa cells [271].  Androgen may inhibit TRPS1 
expression, thereby preventing TRPS1-mediated reduction of HSP90β1. Further to this, 
androgen induces the expression of the N-myc downstream regulated gene 1 (NDRG1) gene, 
which is implicated in differentiation, and can thereby inhibit tumour growth and metastasis. 
NDRG1, in turn, increases HSP90β1, suggesting a mechanism by which androgen can up-
regulate HSP90β1 expression [249].  
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In contradiction of the results indicating HSP90β1 is increased in PCa, Howard and colleagues 
reported HSP90β1 expression to be decreased in malignant tissue compared to BPH, and was 
further reduced in circulating tumour cells (CTCs) [183]. It may be hypothesised that this 
apparent discrepancy may be due to androgen-response status, as this may differ between the 
two sets of patients tested. Although HSP90β1 expression is altered by androgen, increased 
HSP90β1 has been correlated to metastatic potential in both androgen-sensitive and 
independent cells, so this is unlikely to explain the difference. However, as HSP90β1 has been 
implicated in tumour immunogenicity, it may be that reduced expression may be beneficial for 
CTCs, allowing them to escape detection and establishing new metastatic sites.  
 
Both HSP90β1 and HSP90, its cytoplasmic homologue, are involved in ensuring the correct 
folding conformation of a number of signal transduction proteins. Disruption of this process 
results in the destabilisation of these proteins, many of which are critical for cell survival or 
proliferation, and their disruption can result in cell death or cell cycle arrest. With particular 
reference to inhibition of HSP90β1, the resulting accumulation of misfolded proteins in the ER 
causes ER stress, initiating the upregulation of GRP78, another ER chaperone, and in some 
circumstances can result in apoptosis [272].  
 
Geldanamycin (GA) and herbimycin A (HMA), inhibitors of HSP90β1 and its cytoplasmic 
homolog HSP90, have attracted interest as potential anticancer agents.  GA and HMA can 
induce apoptosis and augment sensitivity to cytotoxic drugs in chronic lymphocytic leukaemia, 
specifically targeting malignant cells, and in some cases even conferring modest cytoprotective 
effects to normal cells. In CLL cells, GA increased HSP70 and GRP78, but decreased Akt, a key 
mediator of cell survival in CLL cells, and a target of HSP90. However, the increase of HSP70 
and GRP78 could result in a decrease in cell death, as HSP70 blocks the recruitment of 
procaspase 9 to the Apaf-1 apoptosome, and GRP78 may inhibit caspase activation directly 
[273]. In a small cell lung cancer cell line, inhibition of HSP90 by 0.1µM GA decreases cell 
viability by 40%, an effect which reached a plateau up to 3µM, and it took 4µM to decrease cell 
viability to zero. During the first phase of the response, the number of live cells was similar to 
the total number of cells, but during the second phase, the number of dead cells greatly 
increased. This indicated that the initial response was due to inhibition of cell proliferation, 
followed by increased cell death during the second phase of the response. Up to 
concentrations of 50nM GA, the effect on cell proliferation was reversible, but at higher 
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concentrations there remained a population of viable cells that did not recover. The 
experiment was repeated with a human glioblastoma cell line in which cell proliferation arrest 
was observed, but the effect was not sustained after removal of the drug [274]. 
 
Further to its proposed anti-apoptotic effects, HSP90β1 has been shown to induce anti-tumour 
immune responses to pre-existing cancers. HSP90β1 has an amino-terminal signal sequence 
and a carboxyterminal ER retention/retrieval signal, targeting it to the ER, but a small fraction 
has been seen to localise to the cell surface in transformed cells [275]. At the cell surface 
HSP90β1 interacts with antigen presenting cells (APCs) in two separate events, first by 
interacting with toll-like receptors (TLRs) 2 and 4, activating the APC and leading to secretion 
of pro-inflammatory cytokines, and secondly by interaction with CD91 and scavenger receptor-
A leading to internalization of the HSP90β1-peptide complex, and cross-presentation of the 
HSP90β1-associated peptide, eliciting a peptide-specific TC immune response [276]. The 
specificity of the response was demonstrated by Srivastava and colleagues, who were the first 
to identify HSP90β1 as a possible tumour rejection antigen (TRA). They noted that injection of 
HSP90β1 isolated from a chemically induced tumour into mice provided protective immunity 
to transplantation of cells from the parent tumour. Tumour rejection antigens (TRAs) induce 
resistance to tumour transplants in specifically immunized syngeneic recipients. Each sarcoma 
appears to have its own unique antigen, or set of antigens, because immunisation against any 
one tumour provides no protection against any other syngeneic sarcoma. [277].  
 
More recently, it has been suggested that the post-translation glycosylation of HSP90β1 is 
crucial in its function. In particular, the sialic acid content of HSP90β1 affects its interactions 
with APCs, and differences in glycosylation patterns have been observed in normal and 
cancerous tissues. Thus suggesting that the glycosylation status of the protein determines its 
anti-carcinogenic activity [276, 278].   
 
With regards to previous research investigating the effect of external agents on HSP90β1, 
particularly in the prostate, its expression has been shown to be upregulated by copper. 
Copper is an essential trace element that can also cause oxidative damage, and that is often 
accumulated in cancerous tissue, corresponding with an increase in the inflammatory response 
pathway in prostate cells [279]. Dietary agents have also been shown to modulate HSP90β1 
expression. Diindolylmethane, a derivative of the dietary phytochemical indole-3-carbinol, is, 
like SF, is derived from cruciferous vegetables.  Diindolylmethane has been suggested to have 
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protective effects against cervical cancer, and can induce apoptosis in tumour cells. 
Confusingly, it increased HSP90β1 expression in both cervical and prostate cancer cell lines 
[280]. Furthermore, HSP90β1 expression was induced in PCa cells, by methylseleninic acid, a 
selenium metabolite, which triggers ER stress and can lead to apoptosis [267].  
 
Up until now SF has not been reported to alter HSP90β1 expression, although data has 
suggested a link between SF and HSP90. It has been shown that SF increases HSP90 acetylation 
by inhibiting the enzymatic function of HDAC6, a cytoplasmic non-histone protein deacetylase. 
The increased acetylation causes dissociation of HSP90 from the androgen receptor (AR), 
resulting in a reduction of AR protein levels and reduced expression of AR targets [117]. 
 
The data above provides evidence of a role for HSP90β1 in disease, especially cancer, and 
more specifically in the prostate. It has also been seen that HSP90β1 can be altered by dietary 
agents, and that its cytoplasmic homolog has been shown to be altered by SF. The above 
evidence also highlights the dual function for HSP90β1 in disease, by firstly modulating 
apoptosis, and secondly by its immunogenic properties. This indicates the importance of the 
reduction of HSP90β1 observed in BPH tissue ex vivo, and highlights the relevance of 
investigating the effect of SF on HSP90β1 expression in the prostate in this chapter. 
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6.2 Materials & Methods 
6.2.1 Tissue culture and sample collection 
BPH tissue samples were collected, processed and cultured with four biological replicates with 
or without10µM SF as previously described in Chapter 3.2.1-3. Three biological replicates were 
washed in PBS and immediately frozen on dry ice and stored at -80
o
C for subsequent protein 
extraction and western blotting. The final biological replicate samples were placed in 
Accustain® Formalin Solution 10% Neutral Buffered (Sigma-Aldrich) for 24 hours and then 
transferred to 70% ethanol, both at 4
o
C prior to transfer to the Cotman Centre (Norwich, UK) 
for paraffin wax-embedding and sectioning using standard methods for subsequent 
immunohistochemical staining. Tissue sections were mounted on Probe-On Plus Slides (Fisher 
Scientific). 
 
Dependent on the tissue sample size received, some samples were unable to be used for both 
western blotting and immunohistochemistry (IHC). The samples received, and whether they 
were used for western blotting and/or IHC, are listed in the Annex. 
 
6.2.1.1 Protein Extraction 
Protein was extracted and quantified as described in Chapter 4.2.2-3. Protein was run by 
western blot for immunodetection of HSP90β1 as described in Chapter 6.2.3.  
  
 
6.2.1.2 Immunohistochemistry 
BPH samples that had been fixed and wax-embedded were sectioned for 
immunohistochemical staining for the detection of HSP90β1 following the protocol in Figure 
6.1.  Where a specific temperature is stated, sections were warmed using a slide warmer (Cole-
Parmer). Xylene, ethanol and 3% H2O2 were obtained from Sigma Aldrich. Citric acid buffer 
from Dako. Tris-buffered saline (TBS) was made as followed: 50 mM Tris, pH 7.4; 200 mM NaCl, 
all Sigma Aldrich. Supplemented with 0.1% Tween 20 (Sigma-Aldrich) to produce TBST. 
Incubation buffer: 1% bovine serum albumin (BSA) (Sigma-Aldrich) and 10% horse serum 
(Vector) in TBST. Primary antibody solution: HSP901 antibody (ab53075, Abcam) 1:100 in 1% 
BSA TBST. Secondary antibody solution: Elite ABC Anti-Rabbit Kit (3 drops serum and 1 drop Ab 
in 10ml TBST; Vector Laboratories). Vectastain Elite ABC Reagent prepared as follows: 2 drops 
Reagent A and 2 drops Reagent B in 5ml TBST pre-equilibrated at room temperature for 30 
minute, and DAB Peroxidase Substrate Solution: 2 drops buffer, 4 drops DAB, 2 drops H2O2 in 
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5ml distilled H2O (both Vector Laboratories). Haematoxilin from SurgiPath Europe Ltd, 
Vectamount from Vector Laboratories and coverslips from VWR International.  
 
 
Figure 6.1. Immunohistochemistry Protocol.  
Method for the immunohistochemical detection of HSP90B1 expression in wax-embedded 
tissue sections.  
Warm slides for 10 mins at 70oC
Deparaffinise and hydrate tissue with the following washes: xylene: 3 x 3 mins, 100% 
ethanol: 2 x 3 mins, 95, 75 and 50% ethanol: 1 x 3 mins in each, distilled water: 2 mins
Incubate in citric acid buffer for 20 mins at 95oC to retrieve antigens. 
Allow to cool for 5 mins and then wash for 5 mins in TBS.
Soak slides in 3% H2O2 for 30 mins to quench endogenous peroxidases.
Wash three times and then soak for 5 mins in TBST
Block with incubation buffer for 2 hrs.
Apply primary antibody and incubate at 37oC for 1 hr.
Wash two times and then soak for 5 mins in TBST.
Incubate with secondary antibody for 30 mins.
Wash two times and then soak for 5 mins in TBST.
Incubate with Vectastain Elite ABC Reagent  for 30 mins.
Wash two times and then soak for 5 mins in TBST.
Incubate withDAB Peroxidase Substrate Solution until stain starts to develop (~1 min) .
Wash in distilled water for 5 mins to stop the staining process..
Counterstain in haematoxilin for 10 secs and rinsing under running water for 10 mins.
Dehydrate slides with the following washes: 50, 75 and 95% ethanol: 1 x 2 mins in each; 
100% ethanol: 2 x 2 mins
Apply vectamount and a coverslip and allow to dry overnight.
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6.2.2 Cell Line Culture 
6.2.2.1 Cell Lines 
Human healthy prostate PNT1a cells were obtained from European Collection of Cell Cultures 
(ECACC), and human prostate cancer DU145 were obtained from American Type Culture 
Collection (ATCC). PNT1a cells were maintained in RPMI and DU145 in EMEM media, both 
supplemented with 2mM L-glutamine (Sigma-Aldrich), 5mg/ml penicillin/streptomycin 
antibiotics, 1X non-essential amino acids (Invitrogen) and 10% (v/v) foetal bovine serum 
(Sigma). 
 
 
6.2.2.2 Cell Culture 
All cells were maintained in an incubator at 37
o
C with 5% CO2. Cells were sub-cultured when 
reaching 70% confluency in 10cm dishes and experiments were performed in 6- and 96-well 
plates as appropriate. Cell treatments occurred in complete media with less than 0.1% 
dimethyl sulphoxide (DMSO, Sigma-Aldrich). Unless specified, cells were treated when at 70% 
confluency. Sulforaphane (LKT Laboratories) diluted in DMSO to 100mM and then diluted to 
1mM in PBS. SF was added to media at final concentration of 10 or 25µM as applicable. 
 
 
6.2.2.3 siRNA 
Non-targeting (NT), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and HSP90β1 siRNA, 
DharmaFECT transfection reagent 2, 5x siRNA Buffer and RNAse-Free Water were all obtained 
from ThermoScientific. siRNA was reconstituted to approximately 100µM as per instructions: 
5nmol siRNA was reconstituted in 40µl RNAse-Free Water and RNA concentration determined 
using the NanoDrop, 5x siRNA buffer was added to give a final concentration of 1x buffer, and 
the concentration calculated and noted. NT and GAPDH siRNA were used as negative and 
positive controls respectively. The NT siRNA used consisted of a pool of four NT siRNAs which 
were all confirmed to have at least 4 mismatches with all known human genes by BLAST 
analysis, and to have minimum off-target effects. Untreated cells and cells treated with 
transfection reagent but no siRNA were also used as controls. All experiments with siRNA were 
performed in antibiotic-free RPMI media, complete media is antibiotic-free RPMI 
supplemented with 10% FCS. Experiments were performed in 6-well plates (Greiner Bio-One), 
for protein and RNA extraction, and black-sided clear-bottomed 96-well plates (Perkin-Elmer), 
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for the cell viability and proliferation assays, as appropriate, and cultured for up to 7 days post-
transfection. siRNA transfection was carried out as per Figure 6.2. 
 
 
 
 
Figure 6.2. siRNA Transfection Protocol.  
Method for the transfection of PNT1a using siRNA. Adapted from protocol provided by Thermo 
Scientific. 
  
Culture PNT1a cells to 70% confluency.
Trypsinise, count, and seed in 96- or 6-well plates at correct 
density.
Incubate for 24 hours.
Dilute siRNA to 5µM in 1x siRNA buffer.
Dilute siRNA 1:20 and DharmaFECT Reagent 2 1:200 in serum-
free medium. Incubate for 5 minutes.
Mix equal volumes diluted siRNA and DharmaFECT reagent and 
incubate for 20 minutes.
Dilute 1:5 with antibiotic-free complete medium to a final siRNA 
concentration of 25nM.
Remove culture medium from cells and add the appropriate 
volume of siRNA treatment to each well: 100µl/2ml per well of a 
96-/6-well plate. 
Incubate at 37oC as per experimental requirements.
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6.2.2.4 Protein Extraction 
Cells were sub-cultured in 6 well plates and treated as per experimental design. Media was 
removed and the cells washed with ice-cold 10% phosphate buffered saline (PBS, Sigma-
Aldrich). 100µl RIPA buffer (50μl of 50mM Tris-Hcl, pH7.4; 150mM NaCl; 1% Triton X-100; 0.5% 
sodium deoxycholate; 0.2% SDS; 200mM sodium orthovanadate; plus one Roche complete 
protease inhibitor cocktail tablet and 37.5 units/ml Benzonase (Novagen)) added to each well 
and the plate placed on ice for 2 minutes. Cells were removed from the plate using a cell 
scraper (SPL Lifesciences, Korea), collected and vortexed. Lysates were placed on ice for 5 
minutes and vortexed, repeated 3 times for a total of 15 minutes, and then spun at 13,000 g 
for 10 minutes at 4
o
C to remove cell debris. Supernatants were stored at -20
o
C. 
 
 
6.2.2.5 Protein Quantification 
Protein collected from cells was quantified using the bicinchoninic acid (BCA) assay (Sigma-
Aldrich). A standard curve was prepared using BSA (range: 100 – 1200µg/ml) diluted in NaPi 
buffer (50mM sodium phosphate pH 6 plus 5mM EDTA) and samples diluted 1:3 in NaPi buffer 
prior to quantification. 25µl of each standard and sample were pipetted in duplicates into a 96-
well plate and 200µl BCA working reagent (Reagent B diluted 1:50 in Reagent A) added to each 
well. The plate was then incubated at 37
o
C for 30 minutes and the absorbance read at 550nm 
using the MRXII plate reader with Revelation 3.2 software (both Dynex Technologies). The BSA 
standards were used to prepare a standard curve which was then used to calculate the 
concentration of the samples. 
 
 
6.2.2.6 RNA Extraction 
Cells were sub-cultured in 6 well plates and treated as per experimental design. Media was 
removed and the cells washed with warm 10% PBS (Sigma-Aldrich). 350µl buffer RLT (Qiagen) 
supplemented with 1% β-Mercaptoethanol (Sigma) was added to each well. Cells were 
removed by scraping and collected in a QIAshredder tube (Qiagen), centrifuged at 13,000 rpm 
for 2 minutes and the filter disposed of. RNA was extracted from lysate using RNeasy kit 
(Qiagen) following the manufacturers’ protocol for ‘Purification of Total RNA from Animal Cells 
Using Spin Technology’. Store at -20
o
C 
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6.2.2.7 RNA Quantification 
RNA samples kept on ice were quantified using a NanoDrop ND-1000 Spectrophotometer 
(Thermo Scientific) using ND-1000 v3.7.1 software. 1µl RNA sample was placed on the pedestal 
and absorbance was measured at 260nm to calculate concentration. Duplicate readings were 
performed per sample and average was calculated. Samples with a 260/280nm ratio of 
approximately 2.0 were considered acceptable for further use in experiments.  
 
 
6.2.2.8  Cell Viability Assay 
PNT1a cells were seeded in 96-well plates and transfected with siRNA. They were then 
incubated for up to 7 days post-transfection. At the time-point at which cell viability was to be 
measured 10µl alamarBlue (Invitrogen) was added to each well and cells were incubated for 3 
hours. Fluorescence was measured every hour using a fluorescence excitation wavelength of 
540nm and fluorescence emission was read at 590nm using the FLUOstar OPTIMA plate reader 
(BMG Labtech). Viability of all treatments was calculated as a percentage of the viability of the 
untreated cells. 
 
 
6.2.2.9 Cell Proliferation Assay 
Cell proliferation assay was performed over a period of 7 days on PNT1a cells cultured in 96-
well plates with siRNA (see section 6.2.2.3). At the selected time-point cell proliferation was 
measured using the BrdU Assay (Roche) as per the kit protocol: 10µl/well BrdU labelling 
solution was added and incubated overnight at 37
o
C. Media was removed, 200µl/well FixDenat 
added, and incubated for 30 minutes at room temperature. FixDenat was removed and 
100µl/well Anti-BrdU-POD working solution was added, and incubated for a further 90 minutes 
at room temperature. Solution was removed and washed three times with 300µl/well Washing 
Solution leaving the wash solution on for up to 5 minutes each time. Washing solution was 
removed and the bottom of the plate sealed using a black adhesive foil. 100µl/well Substrate 
Solution was added and luminescence measured immediately using the Luminoskan Ascent 
plate reader (Thermo Labsystems). 
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6.2.3 Western Blotting 
6.2.3.1 SDS-Page Gel 
20µg protein samples, extracted from either cell or tissue samples, were prepared by the 
addition of NuPAGE LDS Sample Buffer (Invitrogen) and dithiothreitol (DTT; Sigma) and 
denatured at 70
o
C for 10 minutes. Samples were loaded onto a 10% NUpage Bis-Tris gel in 
MOPS running buffer supplemented with NuPAGE Antioxidant (all Invitrogen) to maintain 
reducing conditions. 2µl of the protein ladder MagicMark XP (Invitrogen) was also loaded. Gels 
were run for 50 minutes at 200V using the XCell SureLock system (Invitrogen). 
 
 
6.2.3.2 Western Transfer 
Proteins run on gel were transferred to nitrocellulose membrane (BioRad) by western blotting. 
Three sponges were placed in the XCell II Blot Module (Invitrogen) followed by one piece 
blotting paper (Whatman), the protein gel, nitrocellulose membrane (Biorad), a further layer of 
blotting paper and three more sponges. The blot module was placed in the XCell SureLock 
system and the running chamber filled with NuPAGE Transfer Buffer (Invitrogen), with 10% 
methanol (Sigma) and 0.1% antioxidant. The outer chamber of the running system was filled 
with water. The transfer was run at 30V for 60 minutes.   
 
 
6.2.3.3 Western Blot 
The nitrocellulose membrane was checked for successful protein transfer using reversible 
Ponceau S staining (Sigma-Aldrich). Membranes were blocked in 10ml 5% milk in Tris-Buffered 
Saline Tween-20 (TBST) (50mM Tris, pH 7.4; 200mM NaCl and 0.1% Tween 20; all Sigma) for 1 
hour at room temperature with rocking, and washed 3 x for 5 minutes in TBST. All primary 
antibodies were diluted in 10ml 5% milk TBST and incubated with the membrane overnight 
with rocking at 4
o
C, apart from β-Actin which was incubated for 1 hour at room temperature 
with rocking. The blot was washed as before and then incubated for 1 hour at room 
temperature with rocking with the secondary antibody in 5% milk TBST. The membrane was 
washed once more as previously described. Primary antibodies were both obtained from 
Abcam and diluted as follows; HSP90Β1 1:500 (ab53075), and β-actin 1:10,000 (ab8227). The 
secondary antibody anti-rabbit IgG (Sigma-Aldrich) diluted 1:10,000 was used for both primary 
antibodies. 
 
Biological Relevance of HSP90β1 
 
 
173 
 
6.2.3.4 Immunodetection 
The membrane was incubated with 4ml working reagent from SuperSignal West Pico 
Chemiluminescent Substrate (2ml Reagent A, 2 ml Reagent B; Thermo Scientific) for 5 minutes 
in the dark. The fluorescence intensity was measured using the BioRad Fluor-S MultiImager. 
For re-probing of the membranes, the previous antibodies were stripped for 40 min at room 
temperature using Restore
TM
 Western blot stripping buffer (Pierce). 
 
 
6.2.4 Taqman 
RNA samples extracted from cells were prepared for Taqman analysis using the CAS-1200 
robot and Robotics 4 software (both Corbett Life Science). Briefly MicroAmp Optical 96-well 
Reaction Plates (Applied Biosystems) were prepared including a standard curve with 20µl/well 
containing TaqMan RNA-to-CT 1-Step Kit (Applied Biosystems), 4ng RNA and either 1x Pre-
Developed TaqMan Assay Reagents (PDAR) mix (HSP90β1, assay ID: Hs00427665_g1; and 
GAPDH, assay ID: Hs03929097_g1, both Applied Biosystems) or 400 nM forward and reverse 
primers and 200 nM probe dye labelled with 5’-FAM™ (6-carboxyfluorescein) and 3’-TAMRA 
(6-carboxytetramethylrhodamine) for 18S detection (Table 6.1; Sigma Genosys, UK). Plates 
were analysed using the 7500 Real Time PCR System (Applied Biosystems) and reaction 
conditions consisted of 48
o
C for 30 minutes, 95
o
C for 10 minutes, followed by 40 PCR cycles of 
95
o
C for 15 seconds and 60
o
C for 1 minute. Transcript levels were calculated from the standard 
curve.  
 
Table 6.1. 18S Primers and probe sequences. 
 
 Sequence 
Forward primer 5' GGC TCA TTA AAT CAG TTA TGG TTC CT 3' 
Reverse primer 5' GTA TTA GCT CTA GAA TTA CCA CAG TTA TCC A 3' 
Probe 5' TGG TCG CTC GCT CCT CTC CCA C 3' 
 
Where possible biological triplicates were performed, and technical triplicates run, for Taqman 
analysis. However, for the optimization of the siRNA delivery (Figure 6.6), due to the number 
of conditions to be tested, only a single biological replicate, and two technical replicates were 
performed. This was due to the preference to perform all treatments simultaneously, and so 
that Taqman analysis could be ran on a single plate, to reduce technical variation for better 
comparison of results.  
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6.2.5 Statistics 
Statistical analysis performed in Minitab 15 (LEAD Technologies, Ltd), GraphPad Prism 
(GraphPad Software) and R as necessary. Analysis in R was performed by Dr Jack Dainty. Data 
for the effect of SF on HSP90β1 expression (Figure 6.3) was log-transformed to ensure normal 
distribution of residuals. Data was analysed in R using repeated measures ANOVA, with 
subsequent 1-way ANOVA of each patient. Minitab was used to perform Student’s paired t-
tests to compare treatment to control for both protein and mRNA in the two cell lines (Figure 
6.5). Student’s paired t-tests were also performed to compare each time point to time 0 for 
mRNA and protein (Figure 6.8). Data for the effect of HSP90β1 siRNA on cell viability and 
proliferation (Figure 6.9 and 6.10) was analysed in GraphPad Prism. 1-way ANOVA was 
performed for each day with subsequent Tukey post hoc tests to control each treatment to 
control.  
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6.3 Results 
6.3.1 The effect of SF on HSP90β1 in BPH tissue 
In the previous chapter, 24 hour treatment of 10µM SF significantly reduced HSP90β1 protein 
expression in one of the three patients. To investigate whether this effect was prevalent 
throughout the population, BPH tissue from nine independent patients was cultured with or 
without 10µM SF for 24 hours with in triplicate. The protein was extracted and run on western 
blots to detect HSP90β1 protein levels. The results were normalised by the housekeeping gene 
β-actin, and the results log-transformed so that the residuals were normally distributed (Figure 
6.3). Repeated measures ANOVA revealed that both patient (p-value ≤0.001) and treatment (p-
value = 0.025) had a statistically significant effect. Comparison of the means showed an 
average reduction of 22% in HSP90β1 expression as a result of 10µM SF treatment. Individual 
analysis of each patient using 1-way ANOVA revealed HSP90β1 expression was significantly 
reduced in patients 31, 32 and 38 by an average of 62% (p-values = 0.003, 0.019 and 0.021 
respectively). Although there was a reduction in a further two patients, 29 and 34, these were 
not statistically significant. 
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Figure 6.3. The effect of SF on HSP90β1.  
BPH tissue from nine independent patients was cultured with or without 10µM SF for 24 hours 
in triplicate. Protein was extracted, run by western blot and quantified. Results were 
normalised by the house-keeping gene β-actin. Data was log-transformed and analysed by 
repeated measures ANOVA, revealing that both patient and treatment had a statistically 
significant effect (p-values ≤0.001 and 0.025 respectively).  Biological triplicates for each 
patient plotted, mean value for all patients also plotted (black line through each group). 
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The expression of HSP90β1 in the BPH tissue cultured with or without 10µM SF was also 
investigated using immunohistochemical staining. Tissue samples from six patients were 
examined in this manner and representative images shown (Figure 6.4). HSP90β1 was seen to 
be expressed throughout the tissue, but most strongly in the epithelium. It is difficult to 
quantify any effect of SF due to heterogeneity between the samples, but in some samples, 
particularly 38, 42 and 43, staining of the epithelium appears to be less pronounced in the 
samples treated with 10µM SF. 
 
Of the patients examined using IHC, HSP90β1 expression was also examined by western in 
patients 38, 39 and 44 (See Figure 6.3). HSP90β1 expression was noted to be signficantly 
reduced in patient 38 analysed by western blot, which corresponds with the IHC results in that 
staining for HSP90β1 appeared less pronounced in the epithelium of the 10µM SF treated 
sample compared to the control. No significant effect was seen on HSP90β1 expression by 
western blot in samples 39 and 44, correlating with the IHC results in which no clear change in 
staining was observed as a result of SF treatment.  
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Figure 6.4. HSP90β1 expression in BPH tissue.  
BPH tissue from six patients was incubated with or without 10µM SF for 24 hours, fixed in 
formalin, wax-embedded and sectioned. Tissue was probed for HSP90β1 expression by 
immunohistochemistry. Representative images shown, all images x10 magnification. *HSP90β1 
expression was also examined by western in patients 38, 39 and 44 (See Figure 6.3).  
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6.3.2 Modulation of HSP90Β1  by SF in cell lines 
To further investigate the effect of SF on HSP90β1, prostate cell lines were used, and the 
expression of both HSP90β1 mRNA and protein measured (Figure 6.5). In the PNT1a cells, a 
healthy prostate cell line, no effect on mRNA expression was observed with either 10 or 25µM 
SF, but protein expression was reduced with the 10µM SF (p-value = 0.051). In the cancerous 
cell line, DU145, mRNA expression was seen to be significantly increased by 25µM SF 
treatment (p-value <0.05), but this did not translate into a significant effect on protein levels. 
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Figure 6.5. The effect of SF on HSP90β1 in cell lines.  
Cells were cultured with 0, 10 or 25µM SF for either 24 or 48 hours. At 24 hours, (a) mRNA was 
extracted and at 48 hours, (b) protein was extracted (triplicates performed for all and the 
experiment performed twice). HSP90β1 mRNA was measured by Taqman and protein by 
western blot. (c) Representative  western blots shown. Results were normalised for 18S and β-
actin respectively. Means ± standard deviation are shown.  *p ≤0.05 
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6.3.3 siRNA Method Optimization 
HSP90β1 protein expression was reduced by 10µM SF in BPH prostate tissue, but SF had no 
signficant effect on protein expression in both healthy and cancerous prostate cell lines. Little 
research has been conducted regarding the biological activity of HSP90β1, and in particular its 
role in the prostate. To understand the biological significance of the reduction in HSP90β1 
protein expression seen in BPH tissue ex vivo in response to 10µM SF, expression of HSP90β1 
was artificially knocked down using siRNA in PNT1a cells. 
 
Initially, the method for siRNA delivery had to be optimized to determine the most effective 
cell plating density, and which concentration of transfection reagent was the most efficient. 
Cell viability was measured to ensure the transfection did not reduce cell viability by more 
than 20%, and GAPDH gene expression was assayed, as GAPDH siRNA was used as a positive 
control to ensure successful transfection. Non-targeting siRNA was used as a negative control 
to confirm the specificity of any effect observed.  
 
Increasing the concentration of the transfection reagent decreased the viability of the cells, 
but as cell plating density increased the effect was less pronounced (Figure 6.6).  Due to the 
necessity that cell viability remained above 80%, the lowest cell seeding density, 1.5 x 10
4
 
cells/cm
2
, was found to be unsuitable, as all conditions reduced viability to below this level.  
 
Expression of GAPDH was measured in all samples, and a minimum of 80% knockdown was set 
as the threshold of efficient transfection. At all conditions, excluding the lowest transfection 
reagent dilution with the highest cell seeding density, this was achieved (Figure 6.6). The non-
targeting siRNA had no effect on GAPDH expression, confirming this was a specific targeted 
effect of the GAPDH siRNA.  
 
As the transfection reagent did have an effect on cell viability, but was essential for good 
transfection, it was decided to use the lowest possible dilution at which no more than a 20% 
reduction in cell viability was seen, but that still displayed good GAPDH knockdown. 
Comparison between all the conditions resulted in the selection of a dilution of 1:666.66 of the 
transfection reagent, with the cell seeding density of 3 x 10
4
cells/cm
2 
for all subsequent 
experiments. 
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Figure 6.6. Optimisation of siRNA delivery.  
To optimize the siRNA delivery conditions in PNT1a cells two conditions were altered: cell 
seeding density, and transfection reagent concentration. (a) Cell viability was measured by 
alamarBlue (4 biological replicates), and (b) GAPDH expression assayed by RT-PCR (2 technical 
replicates). Means ± standard deviation are shown. Increasing transfection reagent 
concentration reduced cell viability, although the loss in cell viability became less notable the 
higher the seeding density. GAPDH siRNA successfully knocked down GAPDH expression, with 
a higher knock down noted at the higher transfection reagent concentrations. The transfection 
reagent dilution of 1:666.66 and seeding density of 3 x 10
4
 cells/cm
2
 were selected for all 
further experiments.(Untreated contained transfection reagent but no siRNA). 
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6.3.4 Optimising HSP90β1 knockdown 
Subsequent to the optimization of the transfection conditions, the concentration of HSP90β1 
siRNA for the most effective knockdown needed to be assessed. Knockdown using 
concentrations of between 5-50nM HSP90β1 siRNA revealed no variation between the 
effectiveness of the different concentrations, and a 40% knockdown was achieved (Figure 6.7). 
Both the GAPDH and non-targeting siRNA were used at the concentration of 25nM, so in line 
with this, 25nM HSP90β1 siRNA was selected for all further HSP90β1 knockdown experiments. 
 
 
 
Figure 6.7. HSP90Β1 siRNA dose effect.  
PNT1a cells were seeded in 6 well plates and treated with siRNA to knockdown either GAPDH 
or HSP90β1 at different concentrations. After 24 hours mRNA was extracted and HSP90β1 and 
GAPDH measured using Taqman. Means ± standard deviation (three biological replicates). (TR 
= transfection reagent, NT = non-targeting) 
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mRNA from the siRNA experiments had been routinely collected after 24 hours, so a time 
course was performed to determine the knockdown over time for both mRNA and protein 
HSP90β1 expression (Figure 6.8).  
 
HSP90β1 knockdown was apparent from 12 hours after transfection with a 35% decrease, 
reducing further until at 48 hours, a 60% knockdown was recorded. At 72 hours, the last point 
measured, HSP90β1 expression was at a highly similar level to that seen after 24 hours, at just 
below 50% of the expression at time zero.  
 
As expected, the subsequent reduction in HSP90β1 protein levels was delayed, with no 
noticeable reduction observed until a 20% reduction at 48 hours, further reducing at 72 hours 
to 70% of the original protein level.  
 
A greater reduction of protein levels than that achieved here may make it easier to observe 
any effect on the biological phenotype of the cells, as it is expected that the greater the 
reduction of the protein, the more pronounced any behavioural changes would be. However, 
the reduction in protein recorded, no more than 30%, is comparable to the 22% reduction that 
was on average seen in the tissue, so any results may more accurately represent the biological 
relevance of HSP90β1 reduction by SF in the tissue.  
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Figure 6.8. Time course for HSP90β1 knockdown.  
PNT1a cells were seeded in 6 well plates and treated with HSP90Β1 siRNA. RNA and protein 
were extracted at different time points. mRNA was measured by Taqman and protein by 
western blotting. Mean ± standard deviation (biological triplicates) shown. N.S. = non-
significant. Protein was not significantly reduced at any time point compared to 0 hours (p-
values not shown). NT = non-targeting. 
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6.3.5 The effect of HSP90β1 knockdown on the cell 
As HSP90β1 was originally selected for further investigation due to its proposed role in 
apoptosis, it was decided to measure the effect of HSP90β1 knockdown on cell viability, as any 
effect on apoptosis would alter cellular viability. Cells were cultured for up to 7 days after 
transfection, and viability measured using AlamarBLUE (see Chapter 6.2.2.8). Over the time 
period measured, no effect was observed on viability as a result of HSP90β1 knockdown 
(Figure 6.9).  
 
 
 
 
Figure 6.9. Effect of HSP90β1 siRNA on cell viability.  
PNT1a cells were seeded on 96-well plates and treated with HSP90β1 siRNA. Cell proliferation 
was measured by alamarBlue. Values normalised to untreated cells with no siRNA or 
transfection reagent. Means ± standard deviation (9 biological replicates). 
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As no effect was observed on viability, it was then decided to measure whether the 
knockdown had any influence on cell proliferation. Cells were once again cultured for up to 7 
days after transfection and cell proliferation determined using the BrdU Cell Proliferation assay 
(see Chapter 6.2.2.9). No effect on cell proliferation was observed (Figure 6.10).   
 
 
 
 
Figure 6.10. Effect of HSP90β1 siRNA on cell proliferation.  
PNT1a cells were seeded on 96-well plates and treated with HSP90β1 siRNA. Cell viability was 
measured by BrdU Assay. Values normalised to untreated cells with no siRNA or transfection 
reagent. Means ± standard deviation (9 biological replicates). 
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6.4 Discussion 
6.4.1 Modulation of HSP90Ββ1 by SF 
6.4.1.1 Ex Vivo Model 
In the previous chapter, it was reported that HSP90β1 was significantly reduced by 10µM SF in 
one of the BPH samples from three patients analysed by 2D gel electrophoresis. To investigate 
whether this result could be observed in further patients, further BPH tissue samples were 
obtained and treated as before, and analysed using western blotting for the immunodetection 
of HSP90β1.  
 
Analysis of the results from the nine patients, using repeated measures ANOVA, showed that 
both patient and treatment had a statistically significant effect (p-values <0.001 and 0.025 
respectively) (Figure 6.3). On average, a significant reduction of 22% was observed after SF 
treatment, indicating that the effect observed in the 2D gels was repeatable and applicable to 
a larger population. Individual assessment of each patient by 1-way ANOVA, indicated 
HSP90β1 was significantly reduced by SF by an average of 62% in three patients (patients 31, 
32 and 38). Visual assessment showed a non significant reduction in a further two patients 
(patients 29 and 34), whilst two showed a possible increase (patients 35 and 44), and the final 
two remained unaltered (patients 36 and 39).  
 
The different response of the patients demonstrates once again the variation that exists 
between individuals, and the necessity for large sample numbers in order to observe trends in 
a population. Despite the individual nature of the responses, the reduction seen in five of the 
nine patients and the statistically significant reduction seen in the group as a whole, suggests 
that the modulation of HSP90β1 by SF, may be of importance to the larger population. As such, 
this effect is worth investigating further in the hope that it may help us to understand more 
about SF activity, and how SF can be beneficial to prostate health.  
 
 
6.4.1.2 Immunohistochemistry 
To further investigate the expression of HSP90β1 in BPH, samples were fixed and wax-
embedded, and immunohistochemically examined for HSP90β1 staining (Figure 6.4). From the 
sections, it is clear that HSP90β1 is expressed throughout the epithelium and stroma of the 
tissue, but with darker staining in the epithelium, suggesting higher expression in this region. 
Due to the heterogeneous nature of the tissue samples it is difficult to determine the effect of 
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SF on the expression of HSP90β1, but in a number of the samples the epithelial staining 
appears less pronounced in the samples cultured with SF, suggesting that SF may reduce the 
expression of HSP90β1 in the epithelium. This effect was observed in a select number of 
patients, and would correlate with results from the western, where some patients showed no 
effect of SF on HSP90β1 expression, whilst others did.  
 
This result is also interesting as it suggests that SF only alters HSP90β1 in epithelial, but not 
stromal cells. This observation may help explain the limited reduction in HSP90β1 seen, as 
stroma typically constitutes a greater percentage of the samples compared to epithelium. If SF 
only reduces HSP90β1 in epithelial cells, and not stromal cells, there is a lower percentage of 
cells on which SF can act. Therefore, any effect in HSP90β1 expression in epithelial cells may be 
hidden when looking at reduction in the whole sample. For example, if 80% of the sample is 
comprised of stroma, and the remaining 20% is epithelium, and they both express HSP90β1 at 
the same level, then the stroma and epithelium will contribute 80 and 20% of the total 
HSP90β1 expression respectively. If SF reduces HSP90β1 expression by 50% in the epithelium, 
but has no effect on the stroma, then the 80% of HSP90β1 expression contributed by the 
stroma is unchanged, but the 20% from the epithelium is reduced by half to only 10%. In turn, 
this would therefore lead to an observation of only a 10% reduction in total HSP90β1. As such, 
if HSP90B1 expression was assessed in the stroma and epithelium independently, it would 
then be revealed that SF had a significant effect on HSP90β1 expression in epithelial cells, but 
no effect in the stroma.  
 
However, in the control tissue HSP90β1 expression is greater in the epithelium compared to 
the stroma.  As a result, you may expect an effect on HSP90β1 in the epithelium to be more 
noticeable when examining total expression than in the example given above. However, it is 
still likely that this reduction would be partially obscured by the prevalence of stroma in the 
tissue, which may help explain why a significant reduction was seen in so few samples. It 
would also be more likely that the samples which had a higher percentage of epithelium 
compared to stroma would show a greater reduction of HSP90β1 expression in response to SF.   
 
 
6.4.1.3 Cell Lines 
The variation between tissue samples from different patients and the differing degrees to 
which SF can reduce HSP90β1 in each sample, makes the use of tissue very difficult and 
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complex in further investigating this relationship. Therefore, it was decided to use prostate cell 
lines for further experiments, as this less complex system allows greater reproducibility of 
results. The two cell lines selected were PNT1a, a healthy prostate cell line, and DU145, a 
cancerous prostatic cell line, to see whether there was any variation in the effect of SF on 
HSP90β1 in the different diseases states, due to the suggested relationship between HSP90β1 
and cancer.  
 
In the cells, the only significant effect observed was on the mRNA in DU145 cells treated with 
25µM SF. However, despite this, the effect on protein expression was not significant (Figure 
6.5). It has previously been reported that  HSP90β1 mRNA and protein levels do not always 
correlate  [270], so this is not unprecedented. That the effect seen ex vivo can not be 
replicated in vitro, may be due to a number of factors.  
 
As the immunohistochemistry (IHC) results suggest that SF reduced HSP90β1 in the epithelial 
cells, and not the stroma, it was expected that a reduction of HSP90β1 in response to SF would 
be seem in vitro, as the cell lines used were both of epithelial origin. That an effect was not 
seen, suggests that the interactions between the epithelium and stroma play a crucial role in 
the result seen ex vivo. 
 
The importance of epithelial-stromal interactions in the normal prostate is well established, 
and is known to be mediated by growth factors including FGF, IGF and EGF [3]. Epithelial cells 
secrete factors that alter the behaviour of stromal cells, which in turn secrete factors to 
modulate epithelial cell proliferation and differentiation. The expression of these growth 
factors is often altered in BPH, altering the behaviour of both the stroma and epithelial cells 
[173]. For example, FGF-2 secretion by basal cells is increased in BPH and can promote stromal 
cell proliferation. In addition, TGFB1, which has a complex role in prostate regulation, is also 
secreted by basal cells and can, at low concentrations, increase cell proliferation, but at higher 
concentration, inhibits stromal cell proliferation [219, 281]. Therefore, the interactions 
between the two cell types play a crucial role in the development of BPH. 
 
 In culture, cell lines lack the signals that in vivo are crucial to their function and behaviour, and 
may therefore respond differently to outside stimuli. As such, it may be suggested that 
reduction of HSP90β1 by SF is dependent on cross-talk between the stromal and epithelial 
cells.  
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Further to this, the reduction of HSP90β1 by SF was only seen in a select number of the tissue 
samples analysed, indicating variation in how each individual responds. In the same way that 
not all tissue samples responded in the same way, not all cell lines will, as each cell line is 
established from a different patient, so variation will exist between cell lines in the same 
manner it exists between tissue samples. Therefore, if tissue samples were taken from the 
patients from which the cell lines were initially established, it may be that SF would not reduce 
HSP90β1 expression in these samples, explaining why HSP90β1 was not reduced in the cell 
lines.  
 
Cell lines are typically well documented and major mutations characterised, so careful 
selection of cell lines can help elucidate and understand the mechanisms by which stimuli can 
elicit a response. The knowledge of specific mutations in cell lines was implemented to great 
success in a study by Traka and colleagues who sought to investigate the effect of PTEN-
deletion on SF activity. PTEN is a major tumour suppressor which is commonly mutated or 
deleted in PCa. Using the PC3 PCa cell line, in which PTEN is not expressed, and the healthy 
PNT1a cell line, in which PTEN is expressed, it was observed that the PC3 cells were more 
sensitive to growth inhibition by SF. These results suggested that the mechanism by which SF 
reduced growth was via altering the PTEN pathway. As there are other unspecified genetic 
differences between the two cell lines, a mouse model in which PTEN was specifically deleted 
was used, and confirmed that PTEN-deficient cells were more sensitive to SF. Thus suggesting 
that SF can specifically target cells in which PTEN is deleted, helping protect against 
carcinogenesis [160].  
 
In addition, in the current study the tissue was taken from patients with BPH, whilst the cell 
lines used were representative of healthy and carcinogenic prostate, so it may be that the 
result observed is disease state specific. For example, TGFβ1 is able to inhibit the growth and 
proliferation of non-malignant cells, but conversely promotes survival and proliferation of 
tumour cells [36]. In BPH, stromal cells proliferate in response to  IFN-γ, IL-2 and IL-7 and are 
not affected by IL-4, but in healthy stromal cell the opposite is true [19]. These examples 
provide evidence that the response to stimuli can vary in relation to prostate disease.   
 
It must therefore be considered that the reduction of HSP90β1 by SF may be BPH specific. If 
this is the case, then it would be expected that treatment of an established cell line, isolated 
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from BPH, with SF, would result in a reduction of HSP90β1. Furthermore, if tissue samples 
taken from healthy or cancerous prostate were treated and analysed in the same way as the 
BPH tissue, then a reduction in HSP90β1 would not be expected.  
 
If the reduction of HSP90β1 by SF is disease state specific, and occurs in BPH cell lines but not 
those representative of other disease states, then understanding the differences between the 
cell lines may help discover the mechanism by which SF reduces HSP90β1 expression. It would 
therefore be likely, that this mechanism is dependent on a pathway or protein which is 
specifically altered in BPH, and identification of this difference would help elucidate the 
mechanism by which SF alters HSP90β1. 
 
From these results, it is apparent to see that the reduction of HSP90β1 by SF in the prostate is 
a complex process in which it is likely that stroma-epithelium interactions, inter-individual 
variation and disease state play a crucial role.  
 
 
6.4.2 Artificial knockdown of HSP90β1  
As SF did not reduce the expression of HSP90β1 in vitro, to investigate the biological relevance 
of the effect seen ex vivo, HSP90β1 had to be suppressed artificially. To this end, siRNA 
targeted to the HSP90β1 gene was used. Although the siRNA was pre-designed (DharmaFECT, 
ThermoScientific), the delivery method had to be optimised for the cell line used, and the 
specificity of the siRNA knockdown confirmed (Figure 6.6).  
 
A number of controls were used for the experiment, including: no treatment, as a complete 
blank for all conditions; transfection reagent only, to determine whether transfection reagent 
alone altered the cells; non-targeting siRNA, a negative control to demonstrate the specificity 
of the siRNA effect; and GAPDH siRNA, a positive control to show whether the transfection was 
successful. Using these controls, the concentration of transfection reagent, and density of 
cells, was determined for optimum transfection of PNT1a cells. Successful transfection was 
determined as >80% GAPDH knockdown and <20% reduction in cell viability.  
 
It was apparent from the results that increased transfection reagent concentration decreased 
cell viability, with a greater effect seen on cells with a lower seeding density. However, a 
greater concentration of transfection reagent allowed for a greater knockdown of GAPDH due 
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to increased siRNA uptake by the cells. A balance between these two observations had to be 
reached, so a transfection reagent dilution of 1:666.66, and seeding density of 3 x 10
4
cells/cm
2
, 
was selected for all further experiments. 
 
Increasing concentrations of HSP90β1 siRNA did not induce a greater knockdown of gene 
expression. Therefore, a concentration of 25nM was selected to correspond with the 
concentrations used of the control siRNA (Figure 6.7). In comparison to GAPDH, with which 
>80% knockdown was achieved, the maximum knockdown of HSP90β1 observed was 60%. 
Commonly the main sources of insufficient knockdown are siRNA degradation, poor delivery 
and inappropriate detection methods [282]. However, as both the GAPDH and HSP90β1 siRNA 
were stored, handled and delivered in the same manner, with GAPDH being reduced by >80%, 
it is unlikely that degradation or delivery are the reason why only a 60% knockdown of 
HSP90β1 could be achieved. The final common cause is incorrect detection of the knockdown, 
which here was measured using real-time RT-PCR and western blotting to quantify mRNA and 
protein respectively. Methods with poor sensitivity may produce false results, which may be a 
factor in western blotting, but Taqman is highly sensitive [283], and it is therefore unlikely that 
this was the source of the insufficient reduction. 
 
A time course revealed that mRNA levels decreased from 12 hours post-transfection 
decreasing steadily until 48 hours although at 24, 48 and 72 hours the level of HSP90β1 was 
highly comparable. As expected there was a time delay for this to translate to protein 
expression, with a reduction first seen at 48 hours reducing further at 72 hours (Figure 6.8).  
 
Both mRNA and protein were measured, as although siRNA exerts its effect at the mRNA level, 
it is the protein level which dictates the biological phenotype of the cell. As such, it is essential 
to determine that the mRNA knockdown translates into a reduction in protein.  As protein and 
mRNA levels were only measured up to 72 hours post transfection, at which point protein 
levels were still decreasing, it would be interesting to see if studied over a longer time period 
whether protein levels carried on reducing, and what the ultimate reduction would be. 
Alongside this, it would then be interesting to note the mRNA levels to discover the longevity 
of this knockdown, and at what time point the levels started to recover, if at all. Typically 
siRNA-mediated silencing lasts between 5-7 days [282], and taking into account the delay 
between mRNA and protein reduction, a behavioural change may therefore be expected to be 
observed from days 2-9. Here, the mRNA and protein expression were measured up to three 
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days post-transfection, but it would be expected that the reduction of mRNA would last twice 
as long. Therefore, the reduction in protein may become more pronounced if measured over a 
longer time period. 
 
 
6.4.3 The effect of HSP90β1 reduction on cell function  
In the previous chapter, HSP90β1 was chosen for investigation due to its reduction by SF in 
BPH, and its postulated role in apoptosis, a process essential to normal tissue homeostasis, 
and which SF has previously been reported to induce.   
 
To investigate its biological relevance, it was hypothesised that a reduction of HSP90β1 would 
lead to a decrease in cell viability as a result of increased apoptosis. However, here, the 
reduction of HSP90β1 by siRNA had no effect on cell viability (Figure 6.9). As no effect was 
seen on cell viability it was decided to investigate whether a reduction of HSP90β1 would 
reduce cell proliferation, a process of critical importance in BPH. A previous paper had also 
reported that inhibition of HSP90β1 by geldanamycin (GA) resulted in reduced cell 
proliferation at low concentrations, whilst inducing apoptosis at higher doses, leading to the 
hypothesis that this may have been what was happening in this study [274]. However, no 
significant effect was observed on cell proliferation (Figure 6.10).  
 
It is intriguing that no effect on either viability or proliferation was observed when previous 
data reports a link. However, in previous research they have often measured HSP90β1 
expression after apoptosis has been induced, so it may be that a reduction in HSP90β1 alone 
does not trigger apoptosis, but sensitizes the cell to apoptotic stimuli.  It would of great 
interest to repeat the experiment with some external apoptotic stimulus, such as the apoptotic 
drug etoposide, to see whether the reduction of HSP90β1 leads to greater induction of 
apoptosis than etoposide alone. Although no effect was observed on HSP90β1 expression in 
vitro by SF, it would also be interesting to see whether artificial HSP90β1 knockdown would 
sensitize the cells to SF-induced apoptosis.  
 
Pan and colleagues [284] performed a similar experiment to the one here, and found that 
HSP90β1 knockdown promoted apoptosis. However, there were three major differences 
between the two experiments. Firstly, they were working with a pancreatic cancer cell line, 
secondly they were able to achieve a greater knockdown (70% at 48 hours increasing to 90% at 
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72 and 96 hours and reaching 98% at 120 hours), and lastly they treated the cells with 
actinomycin D to stimulate apoptosis. All these differences may be the reason that they 
reported an increase in apoptosis, whilst here none was seen.  
 
It may be that the induction of apoptosis is cell type specific, so may not occur in prostate cells, 
or may be dependent on disease state, as the cells used here were healthy, whilst Pan and 
colleagues were working with a cancerous cell line. With regards to tissue type specificity, very 
few studies have looked directly at HSP90β1 silencing and apoptosis as Pan and colleagues 
have done, but the reduced expression of HSP90β1 has been correlated with apoptosis in a 
number of cell lines, including prostate. This suggests that the effect Pan and colleagues 
observed is unlikely to be unique to pancreatic cells, and that it is probable the same effect 
would occur in prostate cells.  
 
A second possible explanation could be the disease state of the cells, as the prostate cells used 
were healthy, whilst the pancreatic cells were cancerous. This suggestion is not without 
precedence as GA and HMA, inhibitors of HSP90β1 and HSP90, have been seen to induce 
apoptosis and sensitivity to cytotoxic drugs in CLL cells whilst conferring cytoprotective effects 
to normal cells [273]. Thus, suggesting that whilst the silencing of HSP90β1 may lead to 
increased apoptosis in cancerous cells, it may actually protect healthy cells. This may explain 
why no effect in the prostate cells was seen. To test this, it would be necessary to perform the 
experiment in both healthy and cancerous prostate cell lines to discover whether there is any 
difference in the level of apoptosis as a result of HSP90β1 siRNA.  
 
It may also be that the knockdown achieved here was not sufficient to observe an effect, as 
the maximum knockdown observed was 60% at 48 hours, compared to 70% at the same time 
point in the experiment by Pan and colleagues. At 72 hours, the knockdown had not increased 
further, whilst theirs had reached to 90%. However, we did not measure mRNA at any later 
time points, whilst they measured it again at 96 and 120 hours, so it would be interesting to 
see whether the reduction of HSP90β1 mRNA further increases over a longer period.  
 
Using a mouse model, null mutation of HSP90β1 results in embryonic lethality, but in 
embryonic stem cells (ESCs), HSP90β1 -/- prevents cells from differentiating into muscle cells 
due to lack of insulin-like growth factor II. Complete knockout of HSP90β1 also resulted in 
upregulation of other ER chaperones, including GRP78 and calreticulin (see Chapter 5.3.3 and 
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5.4.3), but not protein disulfide isomerase, suggesting some form of compensatory 
mechanism, but this effect was only observed in the HSP90β1 heterozygotes [272]. As this 
effect was only seen in the HSP90β1 null ESCs, this suggests that total knockdown of HSP90β1 
may be necessary to see any effect, which may be why the 60% knockdown we achieved did 
not elicit a response. However, the compensatory mechanism seen may result in other 
chaperones being upregulated, taking on the functions of HSP90β1, and may therefore allow 
the cell to function as normal. It would be interesting to investigate whether any ER 
chaperones were upregulated as a result of the knockdown in the PNT1a cells.  
 
Finally, the last difference noted was that they used actinomycin D to induce apoptosis, so it 
may be, that as discussed above, the knockdown on HSP90β1 alone is not sufficient to increase 
apoptosis, but sensitizes the cell to apoptotic stimuli. Therefore, repeating the experiment but 
with the addition of a pro-apoptotic drug, such as actinomycin D or etoposide, could 
determine whether the knockdown of HSP90β1 sensitizes the cell to apoptotic stimuli.    
 
Due to time constraints further investigations were not possible. As well as the suggestions 
made above regarding apoptotic stimuli, disease state, and knockdown status, there are other 
possible experiments that could be performed. Cell viability was measured as an indicator of 
apoptosis as HSP90β1 is suggested to have anti-apoptotic properties. However, the cell 
viability assay was not specific for apoptotic cell death, and could also measure different types 
of cell death, such as necrosis. Instead, there are other more specific markers of apoptosis that 
could be investigated. These include annexin V, DNA fragmentation, and caspase 3 activity. 
 
Annexin V binds to phosphatidylserine (PS) on the cell surface, the amount of which increases 
in apoptotic cells. As such, annexin V binds to cells with PS exposed on their surface, acting as a 
marker of apoptosis. Annexin V can be coupled with a fluorescent dye and added to the cells 
under investigation before being analysed by flow cytometry. The number of cells to which the 
annexin V has bound is then detected, indicating the level of apoptosis within a sample [207-
208]. Furthermore, DNA fragmentation is a hallmark of apoptosis, and assays can detect either 
low molecular weight DNA which increases in apoptosis, or high molecular weight DNA that 
decreases in apoptosis. DNA fragmentation can be measured in the nuclei of lysed cells by 
ELISA, or using extracted DNA can be analysed by gel electrophoresis [285]. A further marker 
of the apoptosis is caspase 3 activity, which plays a key role in initiating cellular events during 
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the early stages of the process. As with DNA fragmentation, caspase 3 activity can be assayed 
by ELISA but it is also detectable by western blotting [125]. 
 
 
6.4.4 Conclusions 
In conclusion, the results reported in the previous chapter that SF can reduce HSP90β1 protein 
expression ex vivo has been confirmed in tissue from further patients, although the variation in 
responses obtained, once again highlights natural variation between individuals, and therefore 
the need for a large sample number. However, SF was not seen to significantly alter HSP90β1 
expression in vitro, suggesting the effect was dependent on interactions between cell types or 
was specific to BPH. Despite research suggesting a role for HSP90β1 in apoptosis, artificial 
reduction of HSP90β1 using siRNA did not reduce cell viability or inhibit cell proliferation. 
Further research is needed to investigate the role of HSP90β1 in apoptosis, its biological 
relevance in BPH and prostate health in general, and to clarify its relationship with SF. 
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Chapter 7. Final Discussion 
7.1 Contributions to thesis aims  
The rationale behind this thesis was strongly influenced by previous work, which has primarily 
focussed on investigating the bioactivity of SF with the use of in vitro cell models. However, 
such models have limitations, as discussed in Chapter 1, notably poor replication of conditions 
in vivo. To address this issue, this current study developed an ex vivo BPH tissue culture 
method to more closely replicate in vivo conditions. The majority of BPH samples exhibit 
inflammatory infiltrates, so this system was used as a model of inflammation, which is also 
suggested to have a role in the aetiology of PCa. To investigate the effect of SF on this system, 
two approaches were used. Initially, a targeted approach was used to measure the effect of SF 
on inflammatory cytokine secretion. Following on from this, an untargeted approach was then 
employed to investigate the effect of SF on global protein expression. Further work was then 
conducted to investigate the biological relevance of HSP90β1, a protein found to be reduced 
by SF ex vivo. 
 
In this chapter I will discuss the results of the five results chapters, their contributions to my 
original thesis aims, and also their context within the wider field of research. The original aims 
of my thesis as stated out the end of Chapter 1 were: 
 
1. Develop a method for the culture of BPH tissue to replicate in vivo conditions using an 
ex vivo model. 
 
2. Establish whether SF is able to reduce inflammation in the ex vivo model as has been 
previously demonstrated using in vitro models. 
 
3. Determine what effect SF has on global protein expression in BPH tissue ex vivo. 
 
4. Confirm the effect of SF on a selected protein, as identified from aim 3, using a greater 
sample number, and investigate further to determine whether this effect may have 
any biological significance for prostate health. 
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7.1.1 Ex vivo model of prostate inflammation 
The first aim of my thesis was to establish an ex vivo tissue culture method in order to replicate 
in vivo conditions in the prostate. Previously, the use of tissue culture as a model has been 
limited, with researchers instead favouring the use of established cell lines. These cell lines 
provide a good starting point for investigating biological mechanisms, but do not provide as 
close a model to in vivo conditions as ex vivo tissue culture can offer.  
 
Established immortalised cell lines are easy to grow and manipulate, but due to the single cell 
type, are a lot less complex than, and therefore a poor model, for conditions in vivo. Using a 
tissue culture method still allows for targeted treatment, as with cell culture models, but due 
to the complexity of the system, there is interaction between different cell types, resulting in a 
response which is more representative of what happens in vivo. However, as this system is 
more complex and the cells have not been immortalized, establishing a viable culture method 
is difficult.  
 
Although culture of prostate tissue has been performed previously [136, 139, 141-144], a 
standard method has not yet been established. A review of previous protocols (see Chapter 2), 
was used as a starting point for my own method, influencing the types of media tested, and 
whether the addition of DHT was necessary, as well as the assays used to determine the 
success of the procedure. Of all the conditions tested, and the markers of viability and function 
measured, there was seen to be no significant difference between them. It was, however, 
obvious in all conditions that sections of the tissue, in particular the epithelium, rapidly died 
(see Chapter 2). Other studies noted that the tissue adjusted to the conditions after time in 
culture [138-139], but due to this rapid loss of the epithelium, which was felt to be of 
importance for the biological relevance of this model, the tissue was not cultured for longer 
than 24 hours.  
 
One issue that may have affected the success of the culture may be the size of the culture 
pieces, which were ~2mm
3
. It is known that the size of a tumour without new vascularisation is 
limited to about 200nm due to the oxygen diffusion limit [193]. If this work were repeated, it 
may be of interest to investigate the effect the size of tissue piece has on viability, and 
therefore the success of the culture.  
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The use of an ex vivo tissue culture model may be a promising technique that can, and should, 
be expanded due to its closer representation of in vivo conditions compared to in vitro 
established cell lines. However, work still needs to be done to establish a standard culture 
procedure, and to improve viability. In addition, factors such as the availability of tissue, 
natural variation, and ethical issues, will most likely always limit the use of ex vivo models. 
  
 
7.1.2 Reduction of inflammation by sulforaphane 
It has been previously suggested that SF can reduce inflammation [103, 111, 113-114], but this 
work has been primarily performed using in vitro models. The current study is novel, as it 
investigates whether this still holds true in an ex vivo model.  
 
In in vitro models it is often necessary to induce an inflammatory response before measuring 
any effect of treatment, but, in correspondence with literature, the BPH samples used here all 
secreted inflammatory cytokines, so no induction of inflammation was necessary.  
 
Inflammatory cytokines were measured as a marker of inflammation and were selected due to 
their reported importance in BPH. Six cytokines were selected for investigation, but only three 
were detectable in the media by ELISA. Of the three cytokines detected, it was observed that 
IL-6 and IL-8 were secreted at similar concentrations, but FGF-2 levels were 4-fold lower 
(Figure 3.3).  
 
Tissue was initially treated with 25µM SF, in line with previous studies [117, 132-133, 135, 
162]. At this concentration, SF was seen to significantly reduce the secretion of IL-6 and IL-8, 
but had no effect on FGF-2 (Figure 3.4). In terms of physiologically relevant levels, 25µM SF is 
greater than has been recorded in vivo, but possible through the use of supplements. A dose-
dependent experiment was then performed using lower, more physiologically relevant 
concentrations, and IL-6 secretion measured. Using SF concentrations ranging from 2-25µM, 
the lowest concentration at which a significant effect on IL-6 secretion was seen was 10µM 
(Figure 3.5). In comparison to 25µM SF, 10µM is physiologically achievable through diet. This 
was demonstrated by Gasper and colleagues who recorded SF at 7.4µM ± 3.08 after high-
glucosinolate broccoli consumption [100].  
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In the experiment performed with 25µM SF, a greater reduction was seen on IL-8 secretion 
than IL-6. IL-6 was chosen for the dose-dependent experiment as evidence commonly 
correlates IL-6 levels with inflammation and disease risk [163, 170-171]. However, it may have 
been interesting to see whether the secretion of IL-8 was also more sensitive at lower SF 
concentrations than IL-6.  
 
When evaluating the results obtained, the biological relevance must be considered. Although 
previous work has suggested 10µM SF to be physiologically achievable, this level was 
measured in the plasma, not the tissue. In this experiment, 10µM SF was directly added to the 
tissue, but it may be that even if plasma levels are this high, the concentration which reaches 
the tissue in vivo is much lower. Studies in which subjects have consumed either broccoli or SF 
have observed changes in the prostate, providing evidence that SF does reach the prostate at 
biologically active levels in vivo [95, 160]. In the plasma, the concentration of SF after broccoli 
consumption is transient, peaking at two hours, after which it rapidly reduces [100]. In 
addition, repeated consumption of broccoli, every day for 10 days, does not result in an 
accumulation of SF in plasma [286]. As such, it would be interesting to investigate the 
concentration of SF in the prostate, and also whether there is accumulation of SF in tissue if 
broccoli is regularly consumed. This would provide further evidence for the biological 
relevance of the SF concentrations used in this study, and the results obtained from this.  
 
One of the aims of this work was to investigate whether the previous results observed in in 
vitro studies could be replicated ex vivo. In agreement with previous work [103, 158-159], SF 
was seen to reduce IL-6 concentrations. Also, previous work in prostate cancer cell lines, has 
demonstrated that SF can inhibit IL-6-induced activation of oncogenic signalling pathways 
involved in PCa progression, highlighting the relevance of the result observed here [177]. It is 
also of note that a significant effect was observed with 10µM SF, which is at the upper limit of 
levels achieved in plasma, demonstrating that these results are therefore biologically relevant 
[100]. 
 
Although not investigated in this study, the mechanism by which SF can reduce the secretion 
of IL-6 has been previously described. Therefore, it may be possible that such mechanisms 
(Figure 7.1) can explain how SF reduced IL-6 secretion in the ex vivo model.  
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One mechanism by which SF is proposed to reduce IL-6 secretion is by inhibiting the TLR4 
pathway. TLR4, a membrane-spanning receptor protein, is activated by LPS, increasing the 
production of cytokines, including IL-6, and inducing inflammation. Youn and colleagues 
demonstrated that SF binds to cysteine residues in the extracellular domain of TLR4, inhibiting 
its oligomerization, an essential step in its activation [112]. Furthermore, SF was found to 
inhibit NFκB activation induced by the overexpression of myeloid differentiation primary 
response gene 88 (MyD88) or IκB kinase (IKKβ), both downstream signalling components of 
TLR4 activation. Coupled with previous evidence, Youn and colleagues suggested that SF 
directly inhibited the activity of IKKβ and NFκB. Using a mouse model, injection of LPS was 
observed to significantly increase levels of circulating cytokines, including IL-6, an effect which 
was strongly inhibited by oral administration of SF [112].  
 
Xu and colleagues further demonstrated inhibition of NFκB transcriptional activity by SF, 
subsequently reducing the expression of NFκB-regulated genes. Their results suggested that SF 
primarily acted by inhibiting IKK phosphorylation, and preventing p65 nuclear translocation. 
Thus, this prevented IKK from catalysing the phosphorylation, ubiquitination and degradation 
of IKβ, which sequesters NFκB in the cytoplasm. As a result, NFκB, which is formed from a 
heterodimer of p50 and p65, is not phosphorylated, and does not translocate to the nucleus 
[287].  
 
In a number of previous studies, other isothiocyanates have been shown to have similar 
biological activity to SF, including the study by Xu and colleagues who showed PEITC to be 
biologically active at lower concentrations than SF [287]. Furthermore, it has been shown that 
a range of other phytochemicals, such as resveratrol, epigallocatechin-3-gallate and curcumin, 
which are derived from red grapes, green tea, and tumeric, respectively, can act through 
similar mechanisms [288], demonstrating how a range of dietary components can reduce 
inflammation. However, this work was conducted in cell line models, and as such, it remains to 
be seen whether the same effect would occur in humans. 
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Figure 7.1. Inhibition of IL-6 production by sulforaphane. 
Diagram demonstrating the induction of IL-6 via TLR4. Blue arrows represent the normal 
pathway of activation following TLR4 oligomerization. Red arrows indicate components of the 
pathway which SF can exert an inhibitory effect, thereby inhibiting IL-6 production. The red 
cross indicates degradation of IKβ. The dotted lines indicate translocation to the nucleus. 
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7.1.3 Sulforaphane and protein expression in BPH tissue ex vivo 
Once it was established that SF was able to alter the secretion of inflammatory markers from 
BPH tissue using a targeted method, it was decided to investigate the effect of SF on BPH 
tissue using an untargeted approach to look at changes in global protein expression.  
 
The method decided upon was 2D gel electrophoresis which allows the separation of proteins 
extracted from the BPH tissue using both iso-electric focussing point and mass. Subsequent 
overlay and comparison of gels allowed the selection of spots that altered between gels for 
protein identification. Biological triplicates were performed for tissue from three patients, with 
and without SF treatment, and showed little replicate variation demonstrating the 
homogeneity of the sample replicates (Table 4.2). Technical replicates were not performed 
due to the quantity of protein required per gel, and the limitation of the amount of protein 
that could be extracted from each sample. Collecting a larger sample from each patient would 
have allowed a greater amount of protein to be recovered, allowing technical replicates, which 
would have acted as a further control for the reliability of the results obtained. However, the 
size of the sample obtained was itself limited.  
 
From comparison of the gels, it was evident that variation exists between individuals, as there 
were significant differences in protein expression between the patients at baseline (Table 4.2). 
Further variation was observed when treated with 10µM SF, as only two of the three patients 
exhibited a significant effect on global protein expression in response to SF (Table 4.2 and 
Table 4.3). Of the two that did alter, there was very little overlap between the spots that had 
changed in each patient (Figure 4.6). This highlighted the natural variation that exists, not only 
in the baseline protein expression in human tissue, but in the varying ways in which our bodies 
can respond to the same stimulus. In order to elucidate the relevance of any data to the 
general population, it would be beneficial to use as large a number of patients as possible.  
 
From the data, 70 spots were selected as significantly altered and chosen for identification, 
although only 55 spots were positively identified, of which there were only 37 unique proteins. 
Analysis of the proteins using the Gene Ontology website, indicated five main processes that 
the proteins were involved in: apoptosis; metabolism; muscle development and contraction; 
cell proliferation, adhesion and angiogenesis; and cytoskeleton organization (Table 5.4). In 
addition, the majority of proteins could be sorted into three functional groups; enzymes, 
molecular chaperones, and structural and adhesion proteins (Table 5.6). The two lists of 
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groups, function and process, were compared, and the greatest overlap observed was the 
involvement of molecular chaperones in the apoptotic process. The spots of these proteins, 
HSP90β1, calreticulin, 14-3-3ε, GRP78 and HSP70-1, from the 2D gels were then more closely 
examined (Figure 5.1-5), and HSP90β1 selected for further investigation.  
 
In summary, it is apparent that SF can alter a wide range of proteins in BPH tissue ex vivo, 
including proteins involved in cell processes critical for normal tissue homeostasis, such as 
apoptosis, cell adhesion, and transcription and translation. Dysregulation of both molecular 
chaperones and apoptosis has been implicated in disease, including cancer, so it is interesting 
that SF can alter these proteins. These results highlight the variation that exists between 
individuals, as well as the diverse activity of SF, and the many pathways by which it may exert a 
beneficial effect on prostate health. 
 
 
7.1.4 Novel target for sulforaphane activity  
The final aim of the thesis was to identify and investigate a possible novel target for SF activity. 
From the 2D gel work, it was discovered that SF modulated a number of molecular chaperones 
involved in apoptosis, so it was decided to investigate one of these further, the protein 
selected was HSP90β1.  
 
In the tissue samples analysed by 2D gel electrophoresis, HSP90β1 was found to be reduced by 
SF in one of the three patients. A further nine independent tissue samples were then analysed 
to investigate whether this result could be repeated in other patients. In these samples it was 
apparent that the effect of SF on HSP90β1 varied between patients, but overall a reduction in 
HSP90β1 expression was seen.  
 
HSP90β1 was selected due to its proposed anti-apoptotic function, along with its correlation 
with cancer progression. Furthermore, no work has previously been published with regard to 
SF activity, although, it has been suggested that SF is capable of modulating HSP90, the 
cytoplasmic homologue of HSP90β1 [117, 289].  
 
The biological function of HSP90β1 was discussed in detail in Chapter 6, but briefly, its anti-
apoptotic properties are suggested to be due to its calcium-binding properties [216] (Figure 
7.2).  
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Figure 7.2. HSP90β1 and apoptosis. 
Diagram outlining the proposed anti-apoptotic functions of HSP90β1. Briefly, HSP90β1 binds to 
calcium (Ca
2+
) in the endoplasmic reticulum preventing apoptosis. If the cell is overloaded with 
Ca
2+
, beyond the binding capacity of HSP90β1 (and other Ca
2+
-binding proteins), the free Ca
2+
 
can activate calpain, subsequently triggering the caspase cascade. In addition, calpain can 
cleave HSP90β1, preventing it from binding Ca
2+
, thereby promoting apoptosis. In contrast, 
androgen can promote the expression of HSP90β1 inhibiting the apoptotic process. The dotted 
lines represent translocation, and the red cross indicates degradation. 
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By binding calcium, HSP90β1 can modulate calcium homeostasis, preventing calcium overload-
induced apoptosis. In the absence of HSP90β1, calcium levels within the cell can promote 
apoptosis by activating calpain, triggering the caspase cascade [127]. Calpain, in turn, can 
cleave HSP90β1, which has been seen to coincide with DNA damage, thus further promoting 
apoptosis [216]. In addition, its expression can be induced by androgen [271], suggesting a 
mechanism by which HSP90β1 expression can be specifically modulated in the prostate. 
Furthermore, HSP90β1 can form a stable complex with p185
erbB2
, a protein often upregulated 
in PCa, and associated with poor prognosis. Disruption of this complex leads to degradation of 
p185
erbB2 
[270], demonstrating how reduction of HSP90β1 expression could be beneficial to 
prostate health. As such, the reduction of HSP90β1 by SF, may contribute to the pro-apoptotic 
activity of SF.  
 
As no previous work has investigated a relationship between HSP90β1 and SF, the mechanism 
of action is unknown. However, using previous knowledge of SF activity, a possible pathway 
can be hypothesised. Previously, SF has been shown to increase intracellular free Ca
2+
, 
activating calpain [127], which in turn cleaves HSP90β1. The cleaved HSP90β1 may then be 
degraded, or if not degraded, when run on a 2D gel, the two fragments would run at a 
different position, explaining the reduction observed ex vivo. This reduction of HSP90β1 within 
the cell would therefore reduce the calcium binding capacity of the cell, further increasing 
intracellular free Ca
2+
, driving apoptosis. As such, this indicates a possible mechanism by which 
SF may be able to reduce HSP90β1 expression. 
 
Up until this point all experiments had been performed using the ex vivo tissue culture model, 
due to its closer replication of in vivo conditions, but to further investigate the relationship 
between SF and HSP90β1, it was decided to use in vitro established prostate cell lines. This 
approach was used as the simpler model allows for better manipulation, and greater 
reproducibility of results. It also allowed the investigation of the effect of SF in different states 
of prostate dysregulation by using both healthy, PNT1a, and carcinogenic, DU145, cell lines.  
 
In contrast to the results from the tissue, very little effect was seen in the cells, with no effect 
seen on mRNA or protein levels in the healthy PNT1a cells with either 10 or 25µM SF. 25µM SF 
significantly increased mRNA levels in the DU145 cells, but this did not translate into any effect 
on protein levels. It is interesting that no effect was seen on protein expression in the cell lines, 
but this could be due to a number of factors.  
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The cell lines were all epithelial in origin, but it may be that in the tissue, SF has more effect on 
the stromal cells than the epithelium, or that the effect is due to some interaction between the 
cell types that does not occur in the less complex in vitro model. It may also be related to the 
disease state of the prostate as the tissue was from those diagnosed with BPH, whilst the cell 
lines were established from healthy and cancerous prostate respectively, so it may be that SF 
only reduces HSP90β1 in BPH.  
 
Although no effect was observed on the cell lines treated with SF, the relevance of the effect 
seen ex vivo still needed to be investigated. As the reduction of HSP90β1 in tissue cannot be 
guaranteed in each patient, and due to culture viability issues, the use of the ex vivo model 
was not appropriate to investigate this question. Established cell lines remove issues 
associated with variability and viability, but as HSP90β1 was not reduced by SF in vitro, it was 
decided to artificially reduce HSP90β1 using siRNA.  
 
Using the healthy PNT1a cells, a maximal reduction of 60% in HSP90β1 protein expression was 
observed. As HSP90β1 had been selected due to its role in the apoptotic process, the effect on 
cell viability was initially investigated, but no effect was seen. Further investigation measuring 
the effect on cell proliferation also revealed no effect. Therefore, the biological relevance of 
the reduction of HSP90β1 by SF as seen ex vivo is undetermined.  
 
Given further time, it would be interesting to try and determine what role HSP90β1 plays in 
the cell (see Chapter 7.4), and whether its reduction by SF, is relevant to the mechanism by 
which SF can promote a beneficial effect on health. The reduction of HSP90β1 expression by SF 
in BPH tissue, which was originally observed in one of the three patients analysed by 2D gel 
electrophoresis, was further confirmed in three out of nine independent BPH tissue samples. 
However, further investigation into its biological relevance and possible impact on prostate 
health was inconclusive, as no effect on cell behaviour was observed. 
 
 
  
Final Discussion 
 
 
209 
 
7.2 Further Contributions 
7.2.1 Ex Vivo models versus In Vitro Models 
In this thesis the use of an ex vivo prostate model has been described as a viable alternative to 
in vitro models. However, in the final results chapter of the thesis, in vitro models were also 
employed. Such a shift was necessary due to limitations and disadvantages intrinsic to both 
models, an understanding of which is essential in selecting the correct model to best answer 
the question being asked (Table 7.1).  
 
Initially, the ex vivo model was used, as this provides greater replication of conditions in viv,o 
due to the complexity of the system. Of particular relevance are the epithelial-stromal 
interactions, which, as discussed previously, are of great importance in the prostate. In 
comparison, cell lines are established from a single cell type, and are therefore a far simpler 
model, and much less representative of conditions in vivo. 
 
However, due to the complexity, and the variation present between patients, reproducibility of 
results is low, so to obtain statistically significant results, larger numbers of patients must be 
analysed. In contrast, established cell lines are genetically identical, providing greater 
reproducibility of results, and reducing the need for larger numbers of replicates.  
 
Cell lines are often well described, with any mutations or deletions documented, allowing 
greater understanding of the cell response to external conditions. Due to the genetic variation 
that exists between patients, samples are genetically uncharacterised, and any differences 
unidentified, leading to unexplained variations in sample responses.  
 
As ex vivo models are infrequently used, there are no standard methods for the culture of 
tissue, so method optimisation must be performed prior to starting experimental 
investigations. However, protocols for the culture and experimental use of cell lines are well 
established. Furthermore, due to the simplicity of the system, cell lines are easier to 
manipulate, and collection of the necessary measurements simpler. For example, techniques 
such as the delivery of siRNA have been optimized in cells, and whilst delivery to tissue is 
possible, it is much more complex [290]. To further complicate matters, whilst the extraction 
of protein and RNA from cells is straightforward, the extraction of these from tissue is less 
routine. Procedures have been established for the collection of mRNA from fresh tissue, 
however, mRNA could not be successfully extracted from the cultured tissue (data not shown), 
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limiting the investigative techniques that could be used on this model. The reason as to why 
mRNA was not successfully extracted was undetermined despite multiple attempts, suggesting 
that the mRNA in the culture samples had degraded.  
 
A further advantage of cell lines is the ease of availability, and the number of cell lines 
available that are representative of the different disease states of the prostate. These range 
from healthy cells to cancerous cells, including those which are androgen-dependent or 
independent, or poorly or highly metastatic, thus allowing investigation and comparison of the 
different stages of prostate dysregulation.  
 
In contrast to this, prostate tissue is less readily available with tight regulation in place to 
ensure its ethical use. Tissue is often removed as part of routine clinical care in prostate 
diseases, including BPH and PCa, so can be obtained without the need for patients to undergo 
non-essential surgery. However, obtaining healthy tissue is more complex as this would most 
likely require volunteers to undergo elective surgery for this to be collected, which obviously 
has associated health, cost, and ethical issues. Thus, it is common for studies analysing tissue 
samples to use BPH samples as a healthy comparison to PCa tissue, although normal prostate 
samples can be obtained from cadavers [291]. However, studies in which normal, BPH and PCa 
samples have been used, have often demonstrated the variation between normal and BPH 
tissue, providing evidence that BPH tissue should not be used as a ‘normal’ control. Although 
the use of BPH as a healthy control for PCa is not ideal, due to the issues associated with the 
collection of healthy tissue, its use is understandable and almost unavoidable. It is therefore 
apparent that the use of cell lines can be of great value when comparing disease states.  
 
The use of the two models in this study provides evidence for the complementary nature of 
the results obtained from each, and the benefits of using the two models in combination. 
Unfortunately, within the time constraints of this study, the biological relevance of results 
obtained ex vivo were unable to be determined in vitro. However, using a similar combination 
of techniques, a global approach followed by a targeted in vitro approach, Sreekumar and 
colleagues were able to identify the metabolite sarcosine as elevated in PCa, and using cell 
lines demonstrated its role in the development of an invasive phenotype [292]. A similar 
metabolomic approach in the ex vivo BPH model may therefore be successful in identifying 
novel targets of SF activity. 
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In summary, the use of both ex vivo and in vitro models can complement each other by taking 
advantage of the strengths, and considering the weaknesses, of each technique. Together the 
two models can be used to further our knowledge of cellular processes, and the behaviour of 
tissue as a complex whole, providing greater understanding of biological systems than either 
model alone. 
 
 
Table 7.1. Advantages and limitations of ex vivo and in vitro models 
 
Ex Vivo Models In Vitro Models 
 High genetic variability Genetically identical  
Complex system (interactions between cell 
types) 
 
Simple system 
Closer replication of conditions in vivo Poor replication of in vivo conditions 
Novel Well documented 
Ethical issues No ethical approval needed 
Not freely available Readily available 
Difficult to obtain healthy tissue Numerous cell lines representative of 
different disease states 
 
Summary of the major advantages and limitations in the use of ex vivo tissue culture compared 
to in vitro established cell lines. 
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7.2.2 Targeted versus Untargeted Approaches 
Along with the use of both ex vivo and in vitro models to investigate the thesis aims, two major 
approaches were used: targeted and untargeted. The targeted methods included ELISA, 
western blotting and RT-PCR (Chapter 3 and 6), whilst the untargeted approach chosen was 2D 
gel electrophoresis (Chapter 4).  
 
BPH tissue was selected as a model of inflammation, as although the aetiology of BPH is yet to 
be determined, inflammation is proposed to play a crucial role [10]. More recently 
inflammation has been implicated in the development of some cancers, including PCa [29], 
highlighting the impact inflammation can have on health. Furthermore, inflammation is a 
critical component in the aetiology of a wide range of other diseases, such as cardiovascular 
disease and arthritis, the treatment of which places a huge burden on healthcare budgets. 
Moreover, the occurrence of these diseases increase with age which, in an aging population, 
means that in the future, the burden from these diseases is only likely to increase. Therefore, 
finding ways in which changes in our diet could help prevent the onset or slow development of 
these diseases is a major challenge.  
 
Previous research has suggested that the consumption of cruciferous vegetables can have a 
beneficial effect on health [72, 75], and in particular broccoli has been shown to positively 
impact the prostate [52, 73-74]. Furthermore, SF, which is believed to be the main bio-active 
compound derived from broccoli, has been proposed to have anti-inflammatory properties.  
 
To build on this previous research, BPH tissue was used as a model of prostate inflammation. A 
number of inflammatory cytokines were selected for targeted analysis based on previous data 
regarding the expression of inflammatory cytokines in BPH, some of which SF has previously 
been reported to alter. Using a targeted analysis allows the investigation of specific molecules, 
in this case inflammatory cytokines, but this means you must know what you are looking for.  
 
Initially, this answered the question as to whether SF can alter the secretion of inflammatory 
cytokines ex vivo. However, targeted methods have limitations in that they require previous 
knowledge of the system being investigated, whereas untargeted methods allow multiple 
measurements to be made without specificity. The most commonly used example of this 
method are microarrays, in which changes in gene expression throughout the genome can be 
detected. Further techniques include the fields of metabolomics and proteomics.  
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As it is proteins which determine the biological response of a cell, the global protein expression 
in the tissue was investigated using 2D gel electrophoresis. This allowed protein extracted 
from BPH tissue to be separated by both isoelectric focussing point and mass on 2-dimensional 
gels, which can then be overlaid to identify differences in the protein spots. Selected spots are 
then analysed using mass spectrometry to identify the protein. This allows all proteins that are 
altered in a system to be detected without any bias or previous decisions as to what to look 
for.  
 
However, 2D gel electrophoresis is not without its limitations. Although 2D gels are considered 
to be of high resolution and can separate many proteins, the resolution is still not great 
enough to separate all proteins, due to the huge diversity that exists. The use of reduced-range 
pH gradient gels partially combats this issue, allowing better separation of proteins within this 
range, but obviously leads to poorer resolution outside this range. Furthermore, it is not 
uncommon for proteins to migrate together, leading to multiple proteins within a spot, as seen 
in some spots in Chapters 4 and 5, reducing the clarity of the results.  
 
2D gels, however, do allow for the recognition of different isoforms and post-translational 
modifications of proteins.  Identification is based on sequence recognition, and the peptides 
derived from modified and unmodified proteins rarely differ, therefore allowing correct 
identification by mass spec.  Whereas the use of a targeted approach such as antibodies may 
produce false results, as the antibody may not recognise that particular isoform, or post-
translational modification, depending on the specificity of the antibody, and where on the 
protein it binds. Antibodies that are specific for particular post-translation modifications, such 
as phosphorylation, are available, but to test for all possible modifications would require 
numerous antibodies which are not necessary in 2D gel electrophoresis.  
 
A further limitation of 2D gels, results from the differing abundance of proteins in the sample, 
so low abundance proteins are not detected, as 2D gels have a 10
4
 dynamic range. Therefore, 
if some proteins are expressed at 10
8
 molecules per cell, and some at 10
2
 molecules per cell, 
the proteins expressed below 10
4
 molecules per cell will not be detected. Proteins with certain 
properties are also poorly separated by 2D gel electophoresis, especially poorly soluble 
hydrophobic proteins, such as many membrane and nuclear proteins [293]. Due to the 
limitations in the proteins that can be detected by 2D gel electrophoresis inflammatory 
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cytokines, such as interleukins, are not measurable by this method, so for investigating 
inflammatory markers another method may be more appropriate. 
 
The analysis of 2D gel data can be complicated due to the volume of data generated, and the 
multiple sources of error. These sources were discussed in detail in Chapter 4 but briefly 
resulted from technical, replication, patient and treatment variation. Although software used 
to analyse the 2D gels is highly sensitive and can detect low volume spots, it is also necessary 
to manually assess the spots identified by the software, which is time-consuming. Statistical 
analysis of the data needs to be dealt with carefully, as correction for multiple-testing due to 
the volume of data produced is often impractical because it removes all statistical significance.  
 
When dealing with human data, large sample numbers are required due to the vast amount of 
natural variation that exists.  2D gel electrophoresis is not high throughput so is not suited to 
dealing with the necessary sample numbers. As such, once proteins of interest are identified, 
the use of targeted methods is often more practical for further investigations. 
 
Despite the limitations associated with 2D gel electrophoresis it is currently the best technique 
available for unbiased analysis of complex protein mixtures, and can be successfully used to 
identify novel changes in protein expression. Results from 2D gel electrophoresis can then be 
built on using targeted methods, so, in the same way that in vitro and ex vivo models can be 
used to provide complementary information, so may targeted and untargeted approaches. 
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7.3 Summary 
In line with the first aim of the thesis, a method for the culture of BPH tissue ex vivo was 
successfully established, and it is shown that the use of an ex vivo model is a novel but viable 
method for the investigation of the response of human tissues.  
 
This model has been used to show that SF is able to reduce the secretion of known pro-
inflammatory cytokines by BPH tissue, which confirms data obtained from in vitro models, 
fulfilling the second aim of this work.  
 
Furthermore, as set out for investigation in the third aim, this model also demonstrated that 
global protein expression naturally varies between individuals, and that SF at a biologically 
relevant concentration can alter global protein expression, although the nature of the 
response differs between individuals.  
 
The proteins altered were seen to fall into three main functional groups: enzymes, molecular 
chaperones, and structural and adhesion proteins. These were involved in apoptosis, muscle 
development and contraction, cell adhesion, cellular component moving, glycolysis, 
transcription and translation, metabolism, cell redox homeostasis, proliferation and 
angiogenesis. The greatest overlap between function and process resulted from the molecular 
chaperones involved in apoptosis, which were HSP90β1, calreticulin, 14-3-3ε, GRP78 and 
HSP70-1.  
 
In accordance with the fourth aim, a single protein, HSP90β1, was selected for further 
investigation as a novel target of SF activity, due to its correlation in the literature with disease 
progression. However, its biological relevance, and therefore possible influence on prostate 
health, was not ascertained.  
 
The reduction of HSP90β1 protein expression by SF observed in the one of the three initial 
patients was confirmed in further patients, although once again the effect varied between 
individuals. Interestingly, SF did not alter HSP90β1 protein expression in established healthy 
and carcinogenic prostate cell lines, suggesting the effect may be due to disease state, cell 
type, or may rely on interactions between cell types within the tissue sample. Transfection of a 
healthy prostate cell line with HSP90β1 siRNA resulted in a maximum reduction of 60%, but did 
not affect cell viability or proliferation.  
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This study demonstrated that the use of an ex vivo model is a viable approach for the 
investigation of the effects of dietary agents on prostate health. Further to this, it showed that 
the use of an untargeted approach, such as the 2D gel electrophoresis, is a suitable method for 
the identification of novel targets of SF. Further investigation is required to better understand 
the biological role of HSP90β1, and thereby what effect the reduction by SF may have on the 
prostate, and any relevance there may be to the beneficial effects of SF on prostate health. 
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7.4 Future Work 
There a number of areas on which future work could build and investigate further, including 
the tissue culture method, the biological effect of HSP90β1 reduction, and its biological 
relevance in the prostate.     
 
 
7.4.1 Further Ex Vivo Tissue Culture Optimization 
The initial experimental work focussed on the development of an ex vivo tissue culture method 
which extra work could further optimise. Possible factors for investigation include sample 
piece size and the viable culture period length. In this study, the sample piece size was not 
investigated and the size selected based on previous studies. However, other studies have 
investigated different sectioning methods, and considering the diffusion limit of oxygen, it may 
be that the centre of the pieces were starved of oxygen and other nutrients which may have 
impacted the results. Therefore, culturing smaller pieces or using precision cut slices may 
positively impact the success of the culture.  
 
Furthermore, the viability of the tissue rapidly decreased, with little epithelium remaining after 
24 hours. If it were possible to extend the viable culture period this would allow investigation 
of the model over longer time periods, providing greater understanding of the system. 
Alteration of the sample piece size may possibly impact this, but other factors such as culture 
medium, including the possible addition of DHT, may further improve viability.   
 
 
7.4.2 HSP90β1 
Using the ex vivo model, it was discovered that SF could reduce the expression of HSP90β1, a 
previously unidentified target for SF activity. However, this result was not replicated in 
established cell lines, as no significant effect was seen on HSP90β1 protein expression in 
response to SF treatment. In order to investigate the biological effect in vitro, HSP90β1 
expression was artificially reduced using siRNA. Using this approach, a maximum reduction of 
60 and 30% was seen in RNA and protein expression respectively. As HSP90β1 is suggested to 
play a role in apoptosis, the effect of HSP90β1 siRNA on cell viability and proliferation was 
investigated, but no effect found. To further this work, there are two major areas that can be 
addressed: the knockdown of HSP90β1, and the biological relevance of this reduction. 
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7.4.2.1 Knockdown of HSP90β1 
In this study, siRNA was used to knockdown the expression of HSP90β1 from which a 
maximum reduction of 60 and 30% was seen in RNA and protein expression respectively. 
Previous work suggests that a total knockout of HSP90β1 may be necessary to observe a 
response [272, 294], which may explain no effect was seen here. Therefore, if HSP90β1 can not 
be knocked down to a greater degree using siRNA, an alternative approach may be more 
appropriate. Two possible methods may be the creation of a cell line or mouse model in which 
HSP90β1 is permanently deleted. 
 
To investigate the effect of HSP90β1 knockout in vitro, a transgenic cell line could be created in 
which HSP90β1 is permanently deleted. This would facilitate the investigation of the biological 
relevance of HSP90β1, and whether HSP90β1 deletion reduces cell viability or proliferation. 
 
Using a conventional mouse model, null mutation of HSP90β1 results in embryonic lethality 
[272]. To create a mouse model in which HSP90β1 knockout can be investigated, the Cre/loxP 
system could be used to create a conditional model in which HSP90β1 expression is specifically 
knocked-out in the prostate. This would then allow the investigation of the effect of the 
specific knockout of HSP90β1 in the prostate in a whole organism.  
 
 
7.4.2.2 Biological Relevance of HSP90β1 
As SF was observed to reduce HSP90β1 expression ex vivo, using siRNA HSP90β1 was reduced 
in vitro. The biological relevance of this reduction was investigated by measuring the effect on 
cell viability and proliferation, due to the suggested anti-apoptotic properties of HSP90β1 but 
no difference was observed. To understand the biological function of HSP90β1 in the prostate, 
and the importance of the reduction by SF observed ex vivo, further work is necessary.  
 
Previous work has correlated increased HSP90β1 expression with cancer progression, whilst 
another paper reported it as reduced in circulating tumour cells suggesting a negative 
correlation. To try and clarify the relationship between HSP90β1 and prostate disease, two 
approaches could be used. Firstly, public databases, such as The Human Protein Atlas and the 
Gene Expression Atlas, could be used to gather information regarding the expression of 
HSP90β1 protein and RNA in different prostate disease states. However, often these databases 
only sort data as being from either normal or cancerous tissue so it may be necessary to gather 
fresh data. Tissue samples representative for normal, BPH, PIN and PCa prostate could be 
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analysed for HSP90β1 protein expression, providing greater understanding of the correlation 
of HSP90β1 with prostate dysregulation. 
 
To begin to understand the mechanism by which SF reduces HSP90β1, it would be beneficial to 
know whether it acts at a transcriptional or translational level. To accomplish this it would be 
necessary to extract RNA from the tissue in which a reduction in protein level is observed, but 
unfortunately it was not possible to achieve this. However, it has been reported that HSP90β1 
mRNA and protein levels do not always correlate, so even if RNA could be successfully 
extracted from the cultured tissue the results may be inconclusive.  
 
The reduction of HSP90β1 was initially investigated for its effect on cell viability due to its 
proposed anti-apoptotic function, but no significant effect was observed. However, it may be 
that a reduction in HSP90β1 does not induce apoptosis, but instead sensitizes the cell to 
apoptotic stimuli. Further work may be to induce apoptosis using a chemical such as 
etoposide, which has previously been shown to sensitize cells to SF induced apoptosis. Cells 
treated with both etoposide and HSP90β1 siRNA in combination may therefore have reduced 
viability compared to cells treated with either etoposide or HSP90β1 siRNA alone. 
 
The use of siRNA to knockdown HSP90β1 was necessary as SF had no effect on HSP90β1 
expression in vitro, despite the effect seen ex vivo. There were four main hypothesis that were 
suggested to explain this result; cell type, stroma-epithelial interactions, inter-individual 
variation and disease state.  
 
The first explanation as to why the effect seen ex vivo was not replicated in vitro was due to 
the cell type. The cell lines were of epithelial origin, but it may be that SF reduces HSP90β1 
expression in stromal cells in the tissue. However, IHC suggested that it was the epithelial cells 
in which HSP90β1 was reduced. As a result, it was suggested that the reason for the 
discrepancy between the cell lines and tissue was due to stromal-epithelial interactions which 
are essential in normal prostate development in function. In which case, SF may be more likely 
to reduce SF expression in a co-culture of stromal and epithelial cells, or epithelial cells grown 
in Matrigel which acts as an extracellular matrix. This may then more closely replicate the ex 
vivo model and if the stroma-epithelial interactions are key to the reduction of HSP90β1 by SF, 
then an effect may be observed.  
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The reduction of HSP90β1 by SF was only seen in a select number of the tissue samples 
analysed, indicating variation in how each individual responds. The cell lines used were each 
established from a single patient, so it may be that in the same way HSP90β1 expression was 
not altered in the tissue samples from all patients that the cell lines used were established 
from patients who do not respond in this way. It would be interesting to isolate primary 
epithelial and stromal cells from a number of BPH samples and to culture these alongside 
tissue from the same patients and to compare if whether HSP90β1 expression is reduced in the 
primary epithelial cells obtained from tissue samples in which a reduction is observed. If no 
effect is seen in the cells isolated from tissue samples in which a reduction is observed, this 
would be further evidence for the importance of stromal-epithelial interactions.  
 
Finally, the last reason suggested for SF not reducing HSP90β1 expression in vitro may be 
related to disease state. The ex vivo model used was BPH tissue whilst the established cell lines 
investigated were PNT1a, a healthy cell line, and DU145, a PCa cell line. It may be that the 
reduction of HSP90β1 by SF only occurs in BPH through BPH-specific mechanisms and does not 
occur in other disease states. To investigate this hypothesis, healthy and PCa tissue samples 
may be cultured to see whether the reduction of HSP90β1 expression by SF can be observed in 
samples other than BPH tissue. This would provide further evidence for whether baseline 
HSP90β1 expression alters in correlation with prostate dysregulation as current evidence is 
inconclusive. 
 
 
7.4.3 In Vivo Models 
The aim of studies concerning the role of diet in health is to understand the impact 
consumption of particular dietary components can have on a whole organism. To investigate 
this there are two options, animal models and human studies.  
 
The use of an animal model has already been suggested in investigating the importance of 
HSP90β1 knockdown. Here an animal model can be used to answer the question as to whether 
SF can reduce HSP90β1 expression in vivo. There are a wide range of mouse models available, 
including a number of PCa models [295], such as TRAMP mice [296], but to investigate 
whether SF reduces HSP90β1 expression a healthy mouse model, such as C57BL/6, may be 
more appropriate. The diet of the mice could be supplemented with SF, and the prostates 
collected for analysis of HSP90β1 expression in comparison to mice on a control diet.  
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The ultimate aim to investigate the relationship between SF and HSP90β1 expression in the 
prostate is a human study. To follow-on from the work performed in this thesis, volunteers 
with BPH could be recruited to a study, in which they would consume broccoli, as a vehicle for 
SF delivery, for 6 months. Prostate samples could be collected at the beginning and end of the 
study period, and analysed for HSP90β1 expression. 
 
 As the BPH tissue was originally cultured ex vivo as a model of prostate inflammation, it may 
also be of interest to look at the effect of broccoli consumption on inflammatory markers.  This 
could be achieved either by measuring the levels of cytokines in the blood to assess the effect 
on systemic inflammation, or by quantifying cytokines in seminal plasma [167] to investigate 
prostate inflammation. 
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Annex 
BPH Tissue Patients 
 
No. Tissue Bank Code Culture Conditions Thesis 
1 
2 
3 
4 
8 
9 
10 
12 
13 
14 
15 
16 
29 
31 
32 
34 
35 
36 
37* 
38 
39 
41 
42 
43 
44 
- 
- 
- 
- 
09TB00041 
09TB00043 
09TB00044 
09TB00050 
09TB00051 
09TB00061 
09TB00062 
09TB00063 
09TB00233 
10TB0002 
10TB0007 
10TB0013 
10TB0015 
10TB0016  
10TB0033 
10TB0034 
10TB0051 
10TB0058 
10TB0088 
10TB0089 
10TB0090 
KGM/RPMI 
+/- DHT 
+/- DHT 
+/- DHT 
+/- 25µM SF 
+/- 25µM SF 
+/- 25µM SF 
2/5/10/25µM SF 
2/5/10/25µM SF 
2/5/10/25µM SF 
2/5/10/25µM SF 
2/5/10/25µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF (and 24 hr TC.) 
+/- 10µM SF (and 24 hr TC.) 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF 
+/- 10µM SF (and 5 day TC.) 
+/- 10µM SF (and 5 day TC.) 
Figure 2.3 
Figure 2.4 
Figure 2.4 
Figure 2.4 
Figure 3.3-4  
Figure 3.3-4 
Figure 3.3-4 
Figure 3.5 
Figure 3.5 + Chapters 4-5 
Figure 3.5 + Chapters 4-5 
Figure 3.5 
Figure 3.5 + Chapters 4-5 
Figure 6.3 
Figure 6.3 
Figure 6.3 
Figure 6.3 
Figure 6.3 
Figure 6.3 
- 
Figure 2.8 + 6.3-4 
Figure 6.3-4 
Figure 6.4 
Figure 6.4 
Figure 2.6 + 6.4 
Figure 2.6 + 6.3-4 
 
TC = Time Course 
*Patient 37 was later identified as high grade cancer so excluded from analysis and data not 
shown. 
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